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Abstract 
 
Schizophrenia is a debilitating psychiatric disorder with a prevalence of around 
1% worldwide. It is an extraordinarily complex syndrome, which encompasses 
multiple psychological domains leading to the impairment of a range of 
symptoms. These symptoms are categorised as positive symptoms, negative 
symptoms and cognitive deficits.  The profile of cognitive deficits is broad and 
severe, and is likely to be present in most, if not all patients. Despite cognitive 
enhancement being recognised as an important treatment target in 
schizophrenia, the discovery of an effective treatment has been met with 
difficulty. 
The degree of psychosis is subject to numerous genetic and environmental 
factors. Family, twin and adoption studies show schizophrenia is unequivocally a 
genetic disorder, however the genetics behind schizophrenia are indisputably 
complex as it is not characterised by a single causative gene. A number of 
candidate genes have been implicated in schizophrenia. Recent genetic 
association studies have found an association for two genes, FXYD6 and MAP2K7, 
as risk factors in the susceptibility to schizophrenia. However the roles of these 
genes in the underlying mechanisms of the symptoms of schizophrenia are 
unknown.  To address this I utilise two mouse models, one containing 
homozygous disruption of Fxyd6 (Fxyd6-/-) and one heterozygous for Map2k7 
(Map2k7+/-). I employ a range of molecular and behavioural tests to investigate 
the roles FXYD6 and MAP2K7 in schizophrenia- like phenotypes in these mice.  
 
FXYD proteins are a family of seven single-span transmembrane proteins, all 
thought to be regulators of the Na+ K+ ATPase pump in a tissue-specific fashion. 
Up until now, FXYD6 function and its role in the risk to schizophrenia remain 
unclear. To address this I firstly investigated the association between FXYD6 and 
schizophrenia in a Northern European population using a genetic association 
study. However from this study I was unable to confirm an allelic or haplotypic 
association between FXYD6 and schizophrenia. Furthermore there was also no 
evidence for a role of epistatic interactions between FXYD6 and MAP2K7 in the 
risk of schizophrenia.  
 
III 
A putative functional link for FXYD6 in schizophrenia was explored further using 
Fxyd6-/- mice. The in situ hybridisation technique was utilised to reveal the 
expression of Fxyd6 in the mouse brain. Fxyd6 is interestingly expressed in the 
prefrontal cortex and hippocampus, two brain regions associated with 
schizophrenia and learning and memory. In addition, I have shown for the first 
time that disruption of Fxyd6 results in a significant deficit in Na+ K+ ATPase 
activity in the forebrain, confirming that FXYD6 is a modulator of mouse brain 
Na+ K+ ATPase activity. Anxiety- like behaviours and hyperlocomotion were 
explored Fxyd6-/- mice. However activity in plus maze and open field tests, and 
response to amphetamine or ketamine was not altered in comparison to wildtype 
mice. Nonetheless subtle deficits observed in prepulse inhibition suggest 
potential deficits in neurotransmission in Fxyd6-/- mice may be present. 
Interestingly, Fxyd6-/- mice displayed deficits in working memory at delays of 5 
seconds, indicating cognitive deficits. The molecular characterisation and insight 
into the phenotype of Fxyd6-/- mice are encouraging to investigate the role of 
FXYD6 in underlying mechanisms of schizophrenia-like symptoms further.   
 
MAP2K7 belongs to the family of Map Kinases which have key roles in the 
regulation of a diverse range of cellular processes such as gene expression, 
apoptosis and synaptic plasticity. The brain expression of Map2k7 was previously 
unknown, however this study utilised the in situ hybridisation technique to show 
expression in regions associated with schizophrenia, including the PFC and the 
hippocampus.  
For the reason that the homozygous disruption of Map2k7 is embryonically 
lethal, mice heterozygous for the disruption Map2k7 were used to explore the 
role of MAP2K7 in the susceptibility to schizophrenia. RTqPCR confirmed a 
modest but significant reduction of Map2k7 in these mice. The heterozygous 
deletion of Map2k7 results in alteration of glutamate receptor Grin1 expression, 
a receptor reported to have altered expression in schizophrenia. Furthermore, 
Map2k7+/- mice display cognitive deficits, as observed by increased perseverative 
responding in the working memory task.  Despite not exhibiting deficits in PPI, 
social behaviours or neurochemical deficits in GABAergic markers, Map2k7+/- 
mice revealed altered sensitivity to amphetamine, suggesting alterations in 
dopaminergic circuitry. 
IV 
In conclusion, this study provides an insight in to the functional roles of FXYD6 
and MAP2K7. Although the roles of FXYD6 and MAP2K7 as risk factors in 
schizophrenia still requires further elucidation, these results provide evidence of 
a putative role for both genes in some areas of the underlying neuronal activity 
associated with schizophrenia-associated symptoms. Furthermore, results from 
this study suggest both strains of mice are potential rodent models of cognitive 
impairments.  
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1.1 General Introduction 
Schizophrenia is an extraordinarily complex syndrome, which encompasses 
multiple psychological domains leading to the impairment of a range of positive 
symptoms, negative symptoms and cognitive deficits. The schizophrenic 
phenotype is subject to numerous genetic and environmental factors however 
the genetics behind schizophrenia are indisputably complex as it is not 
characterised by a single causative gene. Recently, genetic association studies 
have found an association for two genes, FXYD6 and MAP2K7, as risk factors in 
the susceptibility to schizophrenia. However the roles of these genes in the 
underlying mechanisms of the symptoms of schizophrenia are unknown.   
 
We set out to investigate the roles of these genes in schizophrenia by firstly 
investigating the association between FXYD6 and schizophrenia in a Northern 
European population using a genetic association study. Epistatic interactions 
between FXYD6 and MAP2K7 were also explored within these samples. The 
functional roles of FXYD6 and MAP2K7 in cognitive and schizophrenia- related 
molecular pathways and behaviours were further investigated using two separate 
mouse models; one homozygous for disrupted Fxyd6 (Fxyd6-/-) and one 
heterozygous for Map2k7 (Map2k7+/-).  
 
1.2 Background 
Schizophrenia is a debilitating psychiatric disorder with a prevalence of around 
1% worldwide (Andreasen., 2000). It is an extraordinarily complex syndrome, 
which encompasses multiple psychological domains leading to the impairment of 
a range of cognitive and emotional functions, such as social interaction and the 
ability to form close relationships, executive function, imaginative thought, 
cognition and the expression of emotions (American Psychiatric Association., 
2000). The course and outcome of schizophrenia present great variability from 
patient to patient however symptoms generally begin in late adolescence or 
early adulthood and usually progress throughout life, with males being at a 
slightly higher risk compared to females (risk ratio 1.3:1) (Aleman et al., 
2003;McGrath et al., 2004). A huge economic burden is associated with 
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schizophrenia; this was estimated to be £6.7 billion in 2004/05, covering costs 
for treatment and care, lost productivity from employment, costs to the criminal 
justice system and benefit payments (Mangalore and Knapp., 2007).  
1.3 Clinical Diagnosis 
Schizophrenia has been described in the DSM-IV as a “disturbance that lasts for 
at least 6 months and includes at least 1 month of active phase-symptoms” 
(American Psychiatric Association., 2000). Due to the vast heterogeneity of 
schizophrenia, several criterions have been introduced to distinguish between 
the symptomology of this disorder, allowing standardised clinical diagnosis; 
criterions are based on both type and duration of symptoms and include the 
concurrent presence of 2 symptoms from the following list: Delusions, 
hallucinations, disorganised speech, grossly disorganised or catatonic behaviour 
and negative symptoms (American Psychiatric Association., 2000). The types of 
symptoms are as follows: 
1.3.1 Positive Symptoms 
Positive symptoms are additional to normal experiences and are usually absent 
in the general population. Positive symptoms can be classified under two 
dimensions: the “psychotic dimension” which includes hallucinations, the most 
prevalent being auditory (‘hearing voices’) and visual, however, frequent 
occurrences of tactile, gustatory and olfactory delusions are also known to occur  
and also the “disorganisation dimension” which includes disorganised speech and 
grossly disorganised or catatonic behaviour (American Psychiatric Association., 
2000).  
1.3.2 Negative Symptoms 
Negative symptoms include those that could be seen as a diminution of normal 
functioning and are largely responsible for the morbidity associated with 
schizophrenia.  Affective flattening (reduced emotional expression), alogia 
(reduced ability in fluency of thought and speech) and avolition (reduced 
motivation in goal-directed behaviour) are listed as negative symptoms of 
schizophrenia. However anhedonia (reduced ability to experience pleasure) and 
social withdrawal are associated with negative symptoms. These symptoms are 
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generally the first to arise in schizophrenic patients, followed by cognitive 
deficits and positive symptoms. 
1.3.3 Cognitive Dysfunction 
The profile of cognitive deficits is broad and severe, and is likely to be present 
in most, if not all patients. Marked cognitive deficits can be detected in first 
episode schizophrenia and include attention deficits, impairments in normal use 
of language and impairments in  memory (Mohamed et al., 1999;Gold et al., 
1999;Addington and Addington., 2002). The most prominent cognitive deficits 
occur in the domains of memory, attention, working memory, executive 
function, speed of processing, and social cognition (Nuechterlein et al., 
2004;Fioravanti et al., 2005). Despite cognitive enhancement being recognised 
as an important treatment target in schizophrenia, the discovery of an effective 
treatment has met with difficulty.  
1.4 Treatment 
There are two main classifications of medication associated with the treatment 
of schizophrenia; the first generation typical antipsychotics (chlorpromazine, 
loxapine, haloperidol), and the newer atypical antipsychotics (clozapine, 
olanzapine, sertindole, asenapine). Administration of early typical antipsychotics 
at clinically effective doses were found to elicit severe side effects such as 
seizures, agranulocytosis, and long term administration induced extrapyramidal 
symptoms (EPS) akin to parkinsonian-like behaviour. The mechanism of action of 
typical antipsychotics was subsequently found to be inhibition of the DA D2 
receptor (Burt et al., 1976;Creese et al., 1976), inducing undesirable EPS 
symptoms as the result of attenuated DA transmission in the nigrostriatal 
pathway (Bunney et al., 1973;Clement-Cormier et al., 1974). 
Soon after, atypical antipsychotics were developed and favoured. Positive, 
negative and some cognitive symptoms were found to respond following 
treatment with atypical antipsychotics, compared to the treatment of only 
positive symptoms with typical antipsychotics. Atypical antipsychotics often 
have a strong affinity for 5-HT receptors as well as the DA D1 and D2 receptors 
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(Leysen et al., 1994;Meller et al., 1985), resulting in low EPS at clinically 
effective doses (Leucht et al., 1999). 
1.5 Neuropathology of Schizophrenia 
Though the neuropathology of schizophrenia is somewhat elusive, there is 
considerable evidence suggesting it is fundamentally a disorder of subtle 
aberrations of brain development and plasticity. Despite some remaining 
inconsistencies, which may be a result of factors such as poor controls in early 
studies, differences in diagnostic criteria and changes caused by long term use 
of antipsychotics, technologies such as computer axial tomography (CAT) scans 
and magnetic resonance imaging (MRI) scans have revealed morphological and 
structural abnormalities in brains of patients with schizophrenia (Sigmundsson et 
al., 2001;Shenton et al., 1992). Key findings include enlarged lateral and third 
ventricles, decreased brain size, decreased cortical volume (temporal lobes) and 
decreased hippocampal volume (Daniel et al., 1991;Degreef et al., 1992;Lawrie 
and Abukmeil., 1998;Vita et al., 2006;Lawrie et al., 1999;Jeste and Lohr., 1989). 
One of the initial studies associating structural abnormalities with schizophrenia 
was carried out by (Johnstone et al., 1976), who observed a dilation of 
ventricles in chronic schizophrenics through the implementation of CAT scans. A 
number of studies have since followed and a comprehensive review estimates an 
average increase of 40% in ventricular size from MRI studies with a loss of around 
3% brain tissue (Lawrie and Abukmeil., 1998) however a  correlation has not 
been found between ventricular size and brain loss (Harrison., 1999).    
Early evidence of gliosis (Stevens., 1982), a marker of neural scarring and 
inflammation, suggested schizophrenia was a neurodegenerative disorder, 
however subsequent studies failed to support this (Falkai et al., 1999;Roberts et 
al., 1986). A range of studies further dissociate schizophrenia from a 
neurodegenerative disorder; the failure to find discrete lesions such as amyloid 
plaques and neurofibrillary tangles has now led to the prevailing idea of 
schizophrenia being a neurodevelopmental disorder (Arnold et al., 1998;Falkai et 
al., 1999;Casanova et al., 1993). 
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It has been suggested structural abnormalities may be a result from medication. 
However first-episode patients show ventricular enlargement and cortical 
volume reduction, and brain pathology in young adults at high risk of developing 
schizophrenia shows ventricular enlargement and smaller medial temporal lobes 
(Lawrie et al., 1999;Shihabuddin et al., 1998;Cannon et al., 1993;Szeszko et al., 
2003). Following the start of symptoms, abnormalities correlate with disease 
progression (Ho et al., 2003;Giedd et al., 1999). MRI studies of monozygotic 
twins discordant for schizophrenia reveal the affected twin has larger ventricles, 
smaller cortical size and smaller hippocampal size (McNeil et al., 2000;Thomas 
et al., 1996;Goldman et al., 2008;Thomann et al., 2009), suggesting ventricle 
size is not only associated with schizophrenia phenotype, but is also subject to 
factors other than genetics, such as environmental factors (refer to section 1.7).  
1.6 Neurochemical hypotheses of schizophrenia 
Prominent aberrations of the neurotransmission systems in brain circuitry have 
been associated with the aetiology behind schizophrenia. In particular, 
dopaminergic, glutamatergic and serotoninergic systems have been postulated to 
contribute to the neurobiology of this disorder.   
1.6.1 Dopamine (DA) hypothesis of schizophrenia:  
The DA hypothesis is the preeminent hypothesis of schizophrenia; proposing that 
the dysfunction of the DA system underlies the behavioural and cognitive 
abnormalities that are associated with this disorder (Howes and Kapur., 2009). 
Dopaminergic receptors can be categorised into two main subtypes; the D1-like 
receptor family (D1 and D5 receptors) and the D2-like receptor family (D2, D3, and 
D4 receptors). The DA hypothesis originated from correlations between the 
clinical potency and affinity of antipsychotics for the DA D2 receptor (Seeman 
and Lee., 1975;Creese et al., 1976). Studies also found hyperfunction of D2 
receptors (Abi-Dargham et al., 2000) and increased D2 receptor densities in 
mesolimbic regions of schizophrenia brains and post mortem schizophrenia 
brains (Abi-Dargham et al., 2000;Seeman., 1987;Cross et al., 1981;Laruelle., 
1998). Positive symptoms of schizophrenia can be successfully controlled with D2 
antagonists, however, these typical antipsychotics prove less effective in the 
treatment of negative and cognitive symptoms (Meltzer and McGurk., 
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1999;Harvey et al., 2005). This suggests D2 receptors have a role in the 
underlying mechanisms of positive but not negative or cognitive symptoms.  
D1 receptors are the most abundant DA receptors in the neocortex (Meador-
Woodruff et al., 1996;Lidow et al., 1991;Hurd et al., 2001), a brain region 
associated with cognition. It has been hypothesised that abnormalities in the 
activity of these receptors may be responsible for cognitive deficits associated 
with schizophrenia. Decreased densities of D1 receptors have been observed in 
brains from non-medicated schizophrenia patients (Okubo et al., 1997;Hess et 
al., 1987). D1 and D2 receptors have been shown to have impaired molecular 
interaction in schizophrenia (Seeman et al., 1989), the reduction in D1 activity 
may therefore contribute to hyperfunction of D2 receptors. Together the 
abnormal activity of D1 and D2 receptors may be responsible for a wide range of 
schizophrenia symptoms. Thus the DA hypothesis was reformed to encompass 
both the hyperfunction of D2 receptors in the underlying mechanisms of positive 
symptoms, and the hypofunction of D1 receptors with the onset of negative and 
cognitive symptoms (Howes and Kapur., 2009). 
Supporting the DA hypothesis, it is well known that administration of the DA-
transmission enhancer, amphetamine, induces schizophrenic-like behaviour in 
both healthy volunteers and animals (Breier et al., 1997;Angrist and Gershon., 
1970;Bell., 1965;Gambill and Kornetsky., 1976) and many of these behaviours 
can be reversed via the administration of anti-psychotics clozapine and 
haloperidol (Arnt., 1995;Warburton et al., 1994). Often genetic animal models of 
psychiatric disorders, such as schizophrenia, will be tested with amphetamine in 
order to investigate impairments to the Dopaminergic circuitry. 
Glutamate hypothesis of schizophrenia: 
 
The glutamate hypothesis of schizophrenia arose primarily from the observation 
that abuse of ‘angel dust’ (phencyclidine (PCP)) led to a psychosis similar to that 
observed in schizophrenia (Allen and Young., 1978). When PCP or ketamine, both 
NMDA receptor antagonists, are given to healthy subjects, positive symptoms, 
negative symptoms and cognitive deficits are induced (Adler et al., 1999;Lahti et 
al., 2001;Bakker and Amini., 1961), whereas administration of PCP to 
schizophrenia patients exacerbates the symptoms (Lahti et al., 2001;Allen and 
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Young., 1978). The ability of these compounds to transiently reproduce key 
features of schizophrenia led to the assumption that glutamatergic dysfunction 
has an underlying role in the onset of some of the symptoms associated with 
schizophrenia.  
Glutamate receptors can be categorised into either ionotropic ligand-gated ion 
channels or metabotropic G-protein coupled glutamate receptors (mGluRs). The 
ionotropic glutamate receptors include N-methyl-D-aspartic acid (NMDA), alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite 
receptors, named due to their selective responses to the respective agonists 
(reviewed by Traynelis et al., 2010).  
NMDA receptors are responsible for the mediation of the vast majority of 
excitatory neurotransmission in the brain, hypofunction of these receptors form 
the basis of the glutamate hypothesis of schizophrenia. Three subunits, termed 
NR1 (GRIN1), NR2 (GRIN2) and NR3 (GRIN3) make up the NMDA receptor, and 
these subunits and splice variants have been identified and associated with 
schizophrenia. For example, decreased expression of NMDA subunit splice variant 
NR2A has been observed in the PFC of schizophrenia brains (Bitanihirwe et al., 
2009). In further support of the glutamate hypothesis, clinical studies have found 
an association between the NR1 subunit and schizophrenia (Georgi et al., 
2007;Galehdari., 2009;Qin et al., 2005). This link is further supported by the 
behavioural characterisation of a mouse model expressing 5% of normal levels of 
the NR1 subunit. These mice display behavioural abnormalities reflective of 
those associated with schizophrenia symptoms, such as elevated motor activity 
and stereotypy and deficiencies in social and sexual interactions, furthermore, 
these behaviours are reversed with haloperidol or clozapine (Mohn et al., 1999).  
Despite studies focussing mainly on the role of NMDA receptors in schizophrenia, 
AMPA receptors have also been implicated in the aetiology of schizophrenia. The 
AMPA receptor subunits are derived from a family of four genes termed gluR1–
gluR4. Analysis of post mortem brains of schizophrenic patients revealed 
decreased expression of a range of AMPA receptors Glur1 and Glur2 in the medial 
temporal lobe and prefrontal cortex (PFC) (Eastwood et al., 1995;Beneyto et al., 
2007;Mirnics et al., 2000), whilst mouse models haplosufficient for AMPA 
receptor subunits display behaviours similar to those associated with 
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schizophrenia, some of which are be reversed following antipsychotic 
administration (Chourbaji et al., 2008;Gray et al., 2009; Wiedholz et al., 2006)  
Due to their role in the mediation of molecular correlates of neuroplasticity, 
such as long-term potentiation, via the modulation of the release and reuptake 
of synaptic glutamate, it is not surprising that mGluRs have also been implicated 
in schizophrenia. mGluRs are seven transmembrane domain, G-protein coupled 
receptors that can be categorised into group I, group and group III subtypes. 
Group I are responsible for increasing presynaptic glutamate release and consists 
of mGlur1 and mGlur5, and group II, which is responsible for the inhibition of 
presynaptic glutamate release, consists of mGlur2 and mGlur3 and group III 
consist of mGlur4, mGlur6, mGlur7, mGlur8 (reviewed by Traynelis et al., 2010). 
mGluRs show strong expression in the prefrontal cortex and striatum, two 
regions associated with schizophrenia. Interestingly, altered immunoreactivity 
for receptors belonging to both mGluR group I and II have been observed in 
schizophrenia brains (Gupta et al., 2004; Volk et al., 2010) whilst animal studies 
and genetic association studies further support a role of mGluRs in schizophrenia 
(Bolanna et al., 2007; Devon et al., 2001; Moghaddam et al., 1998; Profaci et 
al., 2011).  
1.6.2 GABAergic hypothesis of schizophrenia 
The role of NMDA receptors in schizophrenia has also led to the implication of 
GABAergic dysfunction. Excitatory input derived from NMDA receptors acts as a 
mediator of the inhibitory activity of parvalbumin GABA (γ-amino-butyric acid) 
interneurons (Kinney et al., 2006). Studies have shown pharmacologically-
induced impairments in NMDA receptor activity results in a dose-dependent 
decrease in the density of neurons immunoreactive for parvalbumin (Kinney et 
al., 2006;Abekawa et al., 2007). The impact of NMDA dysfunction on 
parvalbumin neurons is further observed in mice homozygous for the disrupted 
expression of the NMDA receptor NR1 subunit in parvalbumin-positive 
interneurons, these mice exhibit abnormal gamma oscillations and deficits in 
working memory and associative learning (Korotkova et al., 2010;Carlen et al., 
2011). These studies, in addition to evidence of reduced expression of 
messenger ribonucleic acid (mRNA) for PVALB in schizophrenia brains (Beasley et 
al., 2002;Lewis et al., 1999), supports the use of parvalbumin as a marker of 
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potential molecular aberrations associated with schizophrenia pathophysiology. 
For this reason, Pvalb expression is explored in the molecular characterisation of 
two potential mouse models of schizophrenia (Fxyd6 and Map2k7) later in these 
thesis (refer to Chapter 4 & Chapter 6).   
Further evidence of GABAergic dysfunction in schizophrenia comes from 
decreased expression of mRNA for glutamic acid decarboxylase (GAD), the enzyme 
responsible for the conversion of glutamate to GABA (Beasley et al., 2002;Lewis 
et al., 1999).  Furthermore, a decrease in the expression of the GABA 
transporter 1 (GAT1), is also observed in post mortem schizophrenia brain (Woo 
et al., 1998), which may be reflective of decreased GABA transmission due to 
altered GAD expression.  
1.6.3 Serotoninergic hypothesis of schizophrenia  
The serotoninergic hypothesis of schizophrenia proposes that hyperfunction of 
serotonin (5HT) receptors has a role in the symptoms of schizophrenia (Breier., 
1995). The induction of psychosis-like symptoms following administration of the 
potent 5HT agonist D-lysergic acid diethylamide (LSD) (Woolley and Shaw., 1954) 
lead to the initial suggestion of a role of 5HT in the pathology of schizophrenia. 
Despite recent positron emission tomography studies failing to find alterations in 
5-HT receptor expressions (Trichard et al., 1998;Lewis et al., 1999), evidence of 
a serotoninergic dysfunction in schizophrenia comes from reports that 5-HT1A and 
5-HT2A receptor expressions are increased by up to 80% in the PFC (Lopez-
Figueroa et al., 2004;Burnet et al., 1996;Sumiyoshi et al., 1996;Hashimoto et 
al., 1991) and atypical antipsychotics such as clozapine, olanzapine, and 
risperidone, have a stronger affinity for the 5-HT2a receptor in comparison to DA 
D2 antagonists (Leysen et al., 1994). It has been suggested these antipsychotics 
may elicit their effects through a DA-5HT interaction and accounts for the 
reduction in EPS observed in atypical antipsychotics (Meltzer., 1989;Meltzer., 
1992;Leysen et al., 1994).  
1.7 Risk factors for Schizophrenia  
Family, twin and adoption studies show schizophrenia is unequivocally a genetic 
disorder, with studies estimating around 80% chance of heritability (Riley and 
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Kendler., 2006;Cardno and Gottesman., 2000;Gottesman et al., 1987). Despite 
running in families, schizophrenia is also sporadic. In the general population, the 
risk of developing schizophrenia is 1%, increasing to 2% if a first cousin or sibling 
has schizophrenia (Gottesman et al., 1987). This risk rises further to 15% in 
dizygotic twins and reaches 50% in monozygotic twins (Gottesman et al., 1987). 
Despite a high degree of genetic risk, genetic factors alone do not determine risk 
to schizophrenia; otherwise a 100% concordance rate would be observed 
between monozygotic twins. Instead schizophrenia is a multifaceted disorder 
subject to complex interactions of numerous risk factors. 
 
Factors early on in life, such as intrauterine complications, viral infections 
during early childhood and/or parental loss all appear to be factors in the 
development of schizophrenia (Hultman et al., 1999;Dalman et al., 
2001;Rantakallio et al., 1997).  Environmental factors such as winter births or 
urban living are also thought to attribute to the risk (Mortensen et al., 1999). 
The recreational use of illicit substances such as cannabis has also been given 
much attention.  
Studies have shown adolescence abuse of cannabis can result in an increased 
incidence of psychiatric diagnosis later in life (Arseneault et al., 
2002;Andreasson et al., 1987;Arendt et al., 2005). Despite this, the association 
between cannabis and the development of schizophrenia remains controversial. 
It has been suggested that cannabis use hastens the development of 
schizophrenia in individuals predisposed to the disorder, or worsens the course 
and outcome of the disorder, rather than being a causal factor (Degenhardt et 
al., 2003). Furthermore, some studies have shown the association between 
cannabis and schizophrenia can also be influenced by a genetic interaction 
dependent on the allelic composition of the catechol-O-methyltransferase 
(COMT) gene, however this association has not been observed in all studies 
(Caspi et al., 2005;Henquet et al., 2009). COMT catabolism is the primary 
mechanism for catecholamine signal deactivation, such as with DA transmission, 
and COMT and has been genetically associated with schizophrenia by a single 
nucleotide polymorphism (SNP) located in exon 4 at codon 158. This results in a 
shift of methionine (Met) to valine (Val), resulting in increased enzymatic 
activity, and therefore decreased DA transmission (Chen et al., 2004; Lotta et 
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al., 1995). Carriers of the COMT Val158/Met alleles had shown an increased risk 
of developing schizophrenia symptoms following cannabis use, unlike carriers 
homozygous for met158 alleles (Caspi et al., 2005;Henquet et al., 2009); 
suggesting a modulating effect of COMT on the risk of developing schizophrenia. 
These studies show that not only is the risk of developing schizophrenia 
influenced by genetic and environmental risk factors, but it is also potentially 
susceptible to genetic and environmental interactions.   
1.8 Genetic risk factors 
The high heritability rate of schizophrenia has led to a search for genes that 
confer risk. However, the genetic architecture and mode of inheritance of 
schizophrenia is indisputably complex as it is not characterised by a single 
causative gene. Risk genes are likely to vary from case to case and models 
predict individual genes only confer a small risk which is mediated further by 
genetic and environmental interactions (refer to section 1.7).  
It has been thought that in the general population, schizophrenia arose from the 
accumulation of modest effects from inherited common polymorphisms (the 
common disease, common alleles model (CDCA model) (Chakravarti., 
1999;Gottesman and Shields., 1982). Genome wide association studies (GWAS) 
and candidate gene association studies have provided some evidence suggesting 
a role of common variants in the genetic architecture of schizophrenia in 
unrelated schizophrenia patients, (McClellan et al., 2007;Owen., 2010). Despite 
these variants being limited in number, these studies along with the increasingly 
high prevalence rate of schizophrenia and the lack of Mendelian inheritance 
associated with schizophrenia and linkage studies, has lead to the polygenic 
CDCA model receiving wide acceptance. However, this model does not explain 
why mutations are often specific to families, or why schizophrenia, an illness 
associated with reduced fertility, has not had reduced frequency over a long 
period of time (McGrath et al., 1999;Nimgaonkar et al., 1997). It is now being 
argued schizophrenia is likely to derive from rare but highly penetrant highly 
penetrant mutations (McClellan et al., 2007;Mitchell and Porteous., 2011).  
Several features of schizophrenia support the view that it is a ‘common disease 
caused by multiple rare alleles’. For example, mutations are often specific to a 
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subset of families or an individual. This may explain why only a small fraction of 
genetic risk factors have been identified and consistently replicated in 
association and linkage studies (McGrath et al., 1999;Nimgaonkar et al., 1997). 
These studies assume unaffected individuals sharing the same SNP-defined 
haplotypes will share common risk variants and present a common phenotype, 
however rare but highly penetrant mutations causing schizophrenia may vary 
within the same haplotype block resulting in a lack, or reduced association 
which could be worsened with high sample numbers (reviewed by McClellan et 
al., 2007;Mitchell and Porteous., 2011).  
The genetic variants are also subject to effects from other genetic and 
environmental factors (refer to section 1.7). Many processes such as gene 
regulation, signal transduction and biochemical networks are influenced and 
regulated by the interaction of multiple genes (Moore., 2003). The modification 
of a gene’s output by the actions of another gene (known as epistatic 
interactions) results in differences in phenotype and has implications in disease 
phenotype (Cloninger., 1997;Moore., 2003). Epistatic interactions in combination 
with influencing risk factors make the identification of putative susceptibility 
genes in schizophrenia complex and very few methods have been developed to 
model epistasis.  
Epigenetic mechanisms, which regulate chromatin structure and gene expression 
including deoxyribonucleic acid (DNA) methylation and histone modification, 
without changing the genetic code, have been suggested to be responsible for 
some of the genetic anomalies associated with schizophrenia (Matrisciano et al., 
2012). A recent study conducted in monozygotic twins discordant for 
schizophrenia revealed numerous loci demonstrating differences in disease- 
associated DNA methylation (Dempster et al., 2011) suggesting environmental 
factors may exert their effects by influencing epigenetic mechanisms. Further 
support for a role of DNA methylation in modifying schizophrenia risk comes 
from studies that have observed increased expression of methylation enzymes in 
GABAergic neurons in the PFC of schizophrenia brains (Veldic et al., 
2007;Ruzicka et al., 2007;Matrisciano et al., 2012). 
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1.9 Investigating the genetic basis of schizophrenia 
1.9.1 Types of variants 
Different types of DNA variants are associated with the risk of schizophrenia. 
CNVs are the submicroscopic deletion or duplication of segments of DNA, ranging 
from kilobases (kb) to megabases (Mb) (Redon et al., 2006;Sebat et al., 2004). 
Genes present in this segment will therefore have a lower or higher copy number 
than the standard two copies per genome, and may be present in one, three or 
more copies. CNVs associated with schizophrenia are not just used as markers 
but are risk variants. Despite the majority of CNVs not contributing towards an 
altered phenotype, genome-wide SNP arrays have shown aberrations in CNVs are 
a risk factor in schizophrenia (Nuechterlein et al., 2004;Fioravanti et al., 
2005;Stefansson et al., 2008).  
Microsatellites are di-, tri- or tetra- tandem repeats in short sequences of DNA 
e.g. GTGTGT. They are often referred to as simple sequence tandem repeats 
(SSTRs) and tend to occur in non-coding DNA. Microsatellites have been useful in 
associating genes as risk factors of schizophrenia, such as Neuroregulin 1 
(Stefansson et al., 2003;Stefansson et al., 2002;Li et al., 2006;Allen et al., 
2008).  
SNPs are DNA sequence variations occurring when a single nucleotide base is 
altered at a specific locus between members of the same species. This alteration 
is usually a substitution of one nucleotide with another, deletions or insertions 
may occur. In a polymorphic locus, the frequency of the least commonly 
occurring allele (DNA variant) is termed the minor allele frequency (MAF), and 
must occur in at least 1% of the population to be classified a SNP. If a suspected 
DNA variant occurs more frequently in cases than healthy controls, this 
constitutes evidence of genetic association. SNPs can occur throughout the gene, 
with the majority occurring within non-coding introns; these SNPs are generally 
phenotypically silent (silent mutation) however some mutations can result in 
splice site mutation and lead to errors in intron splicing, protein formation and 
also the binding of transcription factors. Silent mutations in the coding regions 
of the gene (exons) are termed synonymous mutations; however mutations in 
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exons are often non-synonymous and can result in the alteration of a codon 
leading to a different amino acid and subsequent protein (missense mutation).  
SNPs are thought to occur as often as once every 600 bp (Lander et al., 2001), 
implying there could be as many as 10 to 30 million potential SNPs. A 
combination of SNPs with high linkage disequilibrium (LD) are inherited together 
and is regarded as a haplotype block (Gabriel et al., 2002). Many haplotype 
blocks can be transmitted through generations with little or no recombination, 
making it possible to track a mutation (Gabriel et al., 2002).  
 
1.9.2 Linkage disequilibrium (LD) 
LD also known as gamete phase equilibrium or allelic association, reflects the 
non-random association of two or more alleles at different loci on the same 
chromosome (Cardon and Bell., 2001).  Identification of a candidate region using 
LD is dependent on the association between the causal mutation and the marker 
allele (Cardon and Bell., 2001;Carlson et al., 2004;Li and Li., 2008).  
1.9.3 Linkage studies 
Linkage studies assess genetic loci in familial- based samples; providing the 
ability to investigate a trait with different alleles in different families (Cordell 
and Clayton., 2005). Linkage studies are effective for the detection of small but 
powerful causative polymorphisms and thereby support the concept that 
schizophrenia is a common disease with rare but highly penetrant alleles. Many 
loci have been associated with schizophrenia following linkage studies, however 
very few of those fulfilled criteria for statistical significance and subsequent 
studies often failed to repeat positive findings (Jurewicz et al., 2001). Linkage 
studies found an association between Disrupted-in-Schizophrenia-1 (DISC1) and 
cognitive disruption and psychosis in a Scottish pedigree (Millar et al., 2001), 
however, mixed results were found in several independent studies in multiple 
populations (Millar et al., 2001;Ekelund et al., 2004;Sachs et al., 2005), 
providing further evidence that schizophrenia is a disorder of rare but highly 
penetrant alleles. Due to the lack of recombination, linkage studies are a great 
way of analysing the interaction of environmental and lifestyle factors with 
genetic risk factors in the induction of a disease, however, they hold less power 
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than a genetic association study (Cordell and Clayton., 2005).  Unlike linkage 
studies, genetic association studies aim to assess correlations between a genetic 
polymorphism and a disease phenotype across the whole population.  
1.9.4 Genetic association studies 
Genetic association studies aim to investigate links between DNA variance and 
the general population, and include genome wide association studies (GWAS) and 
candidate gene association studies.  
Association between a phenotype and a haplotype of SNPs can be determined by 
identifying and genotyping a SNP which is representative of the whole set of 
polymorphisms belonging to the haplotype. These SNPs are called ‘Tag SNPs’. 
Haplotype analysis exposed significant associations between dystrobrevin-binding 
protein 1 (dysbindin or DTNBP1) and schizophrenia, but despite further evidence 
such as reduced DTNBP1 mRNA expression in frontal brain areas of schizophrenia 
patients, implicating DTNBP1 in schizophrenia a single susceptibility marker is 
yet to be found (Straub et al., 2002). Associations can also exist between 
markers which do not share the same chromosome, this is called epistatic 
interaction. 
An association study requires the genotyping of many SNPs located throughout 
the gene to ensure the indirect association is captured. As associations are 
generally not directly linked to the disease, they can hold low power and can 
present difficulty in analysis (Cordell and Clayton., 2005). Population 
stratification can also be a problem in association studies. Common markers for 
a certain phenotype may be more common in certain populations despite there 
being no true causal relationship. If present it can be responsible for concealed 
associations or the generation of false-positive results. Control subjects need to 
be carefully matched to the cases by ethnicity to avoid population stratification. 
It may be required to select samples from mixed populations or match 
geographical location and ethnicity of cases and controls (Cardon and Bell., 
2001;Carlson et al., 2004;Cordell and Clayton., 2005) and in complex disorders, 
such as schizophrenia, the accuracy of diagnostic criteria is important if 
diagnosis is performed by different medical practitioners. 
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1.9.5 Genome-wide association studies (GWAS) 
GWAS are pivotal in the discovery of genetic components implicated in the 
susceptibility of disease. With the ability to scan hundreds of thousands of SNPs 
per sample, GWAS prove to be an efficient process for associating common DNA 
variations in the population with a phenotype. Since the introduction of GWAS in 
genetic studies for a range of disorders, over 1 million causative SNPs have now 
been discovered (szgene.org). A further advantage of GWAS is that no 
assumption is required about the location or function of a causal SNP prior to the 
study, providing unbiased results. However, GWAS is an expensive process to 
run, hindering the quantity of studies performed, also the SNPs have to be 
present on the chip for them to be genotyped in samples, so the sampling of 
genetic variation may not be complete. Furthermore, despite the large sample 
numbers, only a few risk loci have reached statistical significance (reviewed by 
Mitchell and Porteous., 2011). 
1.9.6 Candidate gene association studies  
Genetic association studies aim to identify polymorphisms within genes that vary 
between individuals with different disease states such as schizophrenia cases 
and healthy controls. Similar to GWAS, candidate gene association studies 
involve the genotyping of SNPs that are generally not causative but are located 
in a region inherited with a causative SNP.  
1.9.7 Candidate gene criteria  
Biological evidence is required to identify good candidate genes for genetic 
association studies. For example, confirmation of the gene’s role in pathways 
associated with the disease, positional information or positive association from a 
previous association study is often required to consider the gene for a study 
(Hattersley and McCarthy., 2005). A number of candidate genes have been 
implicated in schizophrenia, a comprehensive database of these genes can be 
accessed at SZgene (http://www.szgene.org/). Though many putative 
susceptibility genes, such as COMT, DISC1 and Dysbindin, have been implicated 
in schizophrenia, biological evidence of their role and association is still required 
to implicate a gene as a definitive risk factor of schizophrenia.  
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One of the most extensive and readily available sources of such evidence is 
provided by rodent models. Almost all mouse genes have orthologs in humans 
and further genetic manipulation provides an effective model to elucidate the 
roles and functions of putative candidate genes identified in association studies. 
1.10 Animal Models of Schizophrenia  
Animal models provide a unique way of analysing and understanding genetic, 
molecular and environmental influences implicated in the pathophysiology of 
schizophrenia. In vitro manipulation of cell biology can elucidate information 
surrounding the biochemical and molecular interactions involved in 
schizophrenia, yet it does not take into consideration the complex networks, 
interactions and potential regulatory and compensatory mechanisms which only 
an animal model can provide. However, schizophrenia is evidently a divergent 
multifactoral disorder with a wide range of symptoms and therefore difficulty 
arises in reaching a coherent animal model.  
The generation of an animal model which fully encompasses all symptoms of 
schizophrenia has been met with failure and as a result, animal models are 
focussed on one subset of features of schizophrenia. These models will possess a 
convergence of a variety of domains; behavioural, neurochemical and genetics 
and allow investigation into the impact of environmental factors and 
pharmacological interventions. Behavioural tests alone cannot be used to 
validate an animal model, as phenotypes such as deficits in sensorimotor gating 
or impaired learning cannot be said to be solely indicative of schizophrenia as 
they are often present in other psychiatric disorders (Perry et al., 2007;Perry et 
al., 2001;Bennetto et al., 1996). Therefore it is important animal models are 
tested for analogy to symptoms of schizophrenia through a variety of molecular, 
biochemical and behavioural measures. Animal models of schizophrenia have 
been generated through a number of methods. 
1.10.1 Pharmacological Models 
Alterations in neurotransmitters and neuropeptides are a major factor in 
schizophrenia, and attempts to replicate this in an animal model have been 
made using pharmacological intervention. The use of pharmacological agents to 
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create animal models generally aim to explore the neurotransmission hypotheses 
of schizophrenia. NMDA receptor antagonists provide a model to explore the 
glutamatergic hypofunction hypothesis of schizophrenia (reviewed by Morris et 
al., 2005). In healthy human volunteers, administration of non-competitive 
NMDA receptor antagonists phencyclidine (PCP, also known as angel dust) or its 
analogue ketamine induces positive, negative and cognitive symptoms of 
schizophrenia, whereas administration to schizophrenia patients exacerbates 
symptoms (Lahti et al., 2001;Malhotra et al., 1997). Animal models of symptoms 
derived from glutamate dysfunction can be achieved via the administration of 
PCP or ketamine, and generally result in a phenotype reminiscent of the 
negative and cognitive symptoms associated with schizophrenia, such as 
impairments in cognitive flexibility and sensorimotor gating (Egerton et al., 
2008;Sams-Dodd., 1996). Administration of ketamine and PCP in rats also 
reduces glucose utilisation in the PFC (hypofrontality) and network connectivity, 
providing evidence for a model of not only the symptoms of schizophrenia but 
also to investigate the underlying mechanisms and neural circuitry of 
schizophrenia (Cochran et al., 2003;Dawson et al., 2010;Dawson et al., 2011). 
The effectiveness with which ketamine and PCP models schizophrenia in rodents 
differs dependent of treatment regime, dose and testing end point. 
Administration of high doses of PCP results in neurotoxic effects; therefore low 
doses are generally administered to ensure any effects are reflective of 
schizophrenic pathology (Egerton et al., 2008).  
Another highly documented animal model of schizophrenia is based on the DA 
hypothesis (refer to 1.6.1); this is replicated in animal models via the 
administration of amphetamine and amphetamine-like compounds such as 3,4-
methylenedioxymethamphetamine (MDMA). Amphetamine and its analogs 
increase synaptic DA levels through a number of different mechanisms. These 
compounds act on transporters located in the plasma membrane, including the 
DA transporter (DAT), serotonin (5-hydroxytryptamine, 5HT) and norepinephrine 
transporter. Interaction with the DAT inhibits the reuptake of DA from the 
synapse into the nerve terminal. Amphetamine also can also induce the release 
of DA from synaptic vesicles back into the synaptic cleft, further increasing DA 
levels (reviewed by: (Fleckenstein et al., 2007;McMillen., 1983). Excess DA levels 
result in increased activation of DA D1 and D2 receptors, and administration of 
20 
 
 
 
amphetamine and its analogs consistently results in behaviour stereotypic of 
schizophrenia, such as hyperlocomotion and deficits in sensorimotor gating in 
rodents (Sharp et al., 1987;Tenn et al., 2003;Mansbach et al., 1988;Pijnenburg 
et al., 1975). Administration of amphetamine and MDMA act as psychostimulants 
in healthy volunteers and exacerbate psychotic symptoms in schizophrenic 
patients, even at doses which are sub-psychotic in healthy volunteers, these 
symptoms are reversed by the administration of antipsychotics (Angrist et al., 
1985;Angrist et al., 1980;Angrist and Gershon., 1970;Harris and Batki., 2000)  
In addition to animal models based on the glutamate and DA hypotheses of 
schizophrenia, models also exist based on the 5HT hypothesis (refer to 0). LSD 
induces sensory distortions, such as hallucinations and euphoria. Despite the 
mechanisms of action being unclear, LSD is structurally similar to 5HT and has 
been suggested to exert its actions through the 5HT receptor (5-HT2A) (Titeler et 
al., 1988;Marek and Aghajanian, 1996). Following administration of LSD to rats, 
sensorimotor deficits are induced, (Geyer and Braff., 1987;Braff and Geyer., 
1990;Farid et al., 2000) however using LSD to model symptoms of schizophrenia 
in rodents has been met with controversy due to lack of evidence for prominent 
aberrations in the serotoninergic system in schizophrenia. 
 
1.10.2 Developmental Models 
The induction of a lesion via a toxin or an environmental insult at an early stage 
of development provides valuable animal models of the neurodevelopmental 
hypothesis of schizophrenia. 
Lesion models are useful in evaluating and modelling the long term pathological 
changes associated with schizophrenia, which pharmacological models may not 
represent. Lesion models, usually created by the introduction of a toxin during 
early development, may not reflect the aetiology of schizophrenia. However 
they provide a model encapsulating the neurodevelopmental and circuitry 
disruption associated with schizophrenia (Lipska., 2004). A robust lesion model 
involves neonatal exocitoxic lesions of the rat ventral hippocampus, which 
results in deficits in spatial alternation learning, recognition memory, locomotor 
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activity, social interaction and sensitivity to amphetamine (Lipska., 2004;Lipska 
et al., 1995;Kruger et al., 2012;Wilkinson et al., 1993;Lipska et al., 1995). 
The introduction of environmental insults at an early stage of development 
provides a non-invasive animal model of schizophrenia-related behaviours. Rats 
are highly social animals, and studies have shown that in social isolation models, 
where pups are removed from their home cages into an isolated cage following 
weaning, results in altered neural development and behavioural changes 
reminiscent to those associated with schizophrenia, such as sensitivity to 
amphetamine and deficits in sensorimotor gating (Geyer et al., 1993, Wilkinson 
et al., 1994). However, it must be noted that these effects are strain-specific 
and can be observed in hooded Listar rats but not Wistar rats (Geyer et al., 
1993;Hall et al., 1997; Wilkinson et al., 1994). 
The loss of a parent during childhood has been associated with the increased risk 
of depression and psychosis (Kendler et al., 2002; Morgan et al., 2007). The 
disruption of usual mother–infant interactions (maternal deprivation model), 
where a pup is removed from it’s mother often for a short period of time (either 
a single 24 hours episode or brief period of 3-6 hours) results in changes in brain 
neurobiology such as sensitivity to dopaminergic drugs (Ellenbroek and Cools., 
1995; Hall et al., 1999) and behavioural changes associated with psychosis, 
including deficits in sensorimotor gating and latent inhibition (Geyer and Braff., 
1987). For these reasons, animal models of maternal deprivation are often used 
to investigate the neurodevelopmental hypothesis of schizophrenia. 
1.10.3 Genetic Models of schizophrenia 
Despite genetic association studies linking numerous genes to the pathology of 
schizophrenia, biological evidence is still required to explore and confirm the 
involvement of a candidate gene. Genetic animal models allow characterisation 
of genes of biological importance that are often implicated in disease-
susceptibility and provide several advantages over lesion and pharmacological 
models, such as exploring gene x environment and gene x drug interactions.  
The mouse genome can be altered by several different methods, such as random 
integration of transgenes or homologous recombination to change the 
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endogenous gene. Using the ‘cre/ loxp system’ allows tissue specific knockout or 
mutation of a gene in response to an external stimulus, and can therefore be 
induced at a specific time (Nagy., 2000). This is a particularly useful method to 
investigate the knockout of genes required for embryo development. Genes of 
interest can also be ‘knocked in’ and ‘knocked out’ via the insertion of DNA 
constructs, such as a ‘gene trap vectors’, which are accepted into the desired 
locus through homologous recombination (Evans and Kaufman., 1981). The 
insertion of a gene trap vector disrupts the gene of interest and will generally 
result in an inactivated (null) allele. Gene targeting and insertion of DNA 
constructs are predominately carried out in 129 mice, which are a proven 
germline competent embryonic stem cell strain, and have an impressive record 
of success in generation of knockouts (Melton., 1994;Simpson et al.,1997). 
Embryonic stem cells containing the inserted/recombined DNA locus are injected 
into mouse blastocysts and transferred into a pseudopregnant surrogate mother, 
however due to the poor phenotype of 129 mice, litters are often backcrossed 
onto a mouse strain expressing a more desired behavioural phenotype. The 
resultant phenotype of a mouse containing a targeted gene disruption is not only 
derived from the disruption created from the insert, but also from the 
cumulative effects and interactions elicited from background genes. It is 
therefore important that experimental mice are fully backcrossed onto one 
strain to eliminate variations in phenotype resulting from a mixed genetic 
background. 
The background strains must be carefully considered due to variations in areas 
such as locomotor activity, anxiety and sensorimotor gating (Bouwknecht and 
Paylor., 2002;Contet et al., 2001;Paulus et al., 1999;Rodgers et al., 2002). For 
example, 129 mice have a poor phenotype which may make subtle changes 
difficult to detect, whereas C57BL/6 strain of mouse portray high levels of open 
field (OF) locomotion and low levels of anxiety-related behaviours. Therefore 
subtle changes in a mouse model of anxiety would be easier to detect in a 
C57BL/6 strain, rather than a 129 strain.  For this reason C57BL/6 are commonly 
used for backcrossing (Bouwknecht and Paylor., 2002;Contet et al., 2001;Paulus 
et al., 1999;Rodgers et al., 2002). In order to characterise a novel genetically 
modified (GM) mouse, a range of molecular, biochemical and behavioural tests 
are required. 
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1.10.4 Behavioural tests 
Phenotypes of GM mice derive from the effects of the disrupted gene or over-
expressed transgene in pathways and can therefore be influenced by a number 
of factors such as age, hormones and the background strain, in addition to 
familiarity to the testing apparatus, level of illumination in testing rooms, 
odours, housing conditions and motivation (in food restricted animals). The 
function of a gene cannot be elucidated from a single behavioural test, and in 
general a battery of tests encompassing a wide range of behaviours are utilised. 
The elevated plus maze (EPM) and OF apparatus are designed to test locomotor 
activity and anxiety levels in the mouse. These paradigms are investigated by 
exploiting the mouse’s innate conflict between their natural tendency to explore 
and the need to be cautious when exposed to a new environment (Denenberg, 
1969). The OF behavioural test is widely used to test the efficacy of anxiolytic 
treatment or antipsychotics on hyperlocomotor activity.  
Deficits in sensorimotor gating often derive from an impaired response to 
sensory information in the CNS, resulting in the inability to filter important 
information from ‘noise’. It is a complex process involving multiple interactions 
with multiple neurotransmitters including DA, 5HT and glutamate (Ojima et al., 
2004;Quednow et al., 2004;Egerton et al., 2008) and is also thought to involve 
the prefrontal cortex and the hippocampus (Swerdlow et al., 1995; Japha and 
Koch., 1999). Deficits are a core symptom of schizophrenia and can be 
investigated in rodent models through prepulse inhibition (PPI) of the startle 
response. PPI assesses the ability of the nervous system to adapt to a strong 
sensory stimulus, following a weaker signal. If the startle response is not 
attenuated in response to a preceding weaker signal, it is likely deficits in 
sensorimotor manifest (Braff et al., 2001;Powell et al., 2009).  
Much attention has been focussed on the cognitive deficits in schizophrenia and 
a number of paradigms have been designed to assess different forms of cognition 
and memory in rodents. For example, spatial learning and memory can be tested 
using the Morris water maze; visual cues are used to help a rat or mouse learn 
and navigate a route to a hidden platform in a water arena (Morris et al., 2005). 
Executive function and cognitive flexibility can also be assessed through a rodent 
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version of the Wisconsin Card Sorting Task. The rodent attentional set shifting 
task (ASST) requires rodents to solve a series of discriminations containing an 
intra-dimensional to an extra-dimensional shift (Birrell and Brown. 2000). Tasks 
such as the ‘n-back task’ or ‘delayed non-match to sample’ have been designed 
to assess working memory, which requires synchrony between the prefrontal 
cortex and hippocampus (Sigurdsson et al., 2010;Yoon et al., 2008). During these 
tasks, rodents manipulate short term memory in order to reach a goal or reward, 
and involve delayed alteration in either a T maze or 8-arm radial maze.  
1.11 Na+ K+ ATPase pump 
The sodium potassium adenosine triphospatase (Na+ K+ ATPase) pump Na+ K+ 
ATPase pump is an integral membrane-bound enzyme present in the plasma 
membrane of all mammalian cells. It belongs to a family of P-type ATPases that 
includes the gastric H+ K+ ATPase and the Ca2+ ATPase (Lutsenko and Kaplan., 
1995). The Na+ K+ ATPase pump is essential for the normal functioning of all 
excitable tissues by establishing and maintaining resting membrane potential 
following depolarisation, it is therefore imperative in neuronal functioning 
(Moseley et al., 2003).  The pump maintains low internal sodium (Na+) and high 
internal potassium (K+ ) cellular concentrations through the active transport of 3 
Na+ ions out of the cell in exchange for 2 K+ ions moving in (Figure 1.1), and is of 
paramount importance for establishing and maintaining resting membrane 
potential and cellular volume (Blanco and Mercer., 1998). This process requires 
free energy released from the hydrolysis of adenosine triphosphate (ATP) to 
adenosine diphosphate (ADP); the release of inorganic phosphate from this 
reaction is often used as a marker of pump activity (Sarkar, 2002;Esmann, 1988). 
The activity of the Na+ K+ ATPase pump consumes approximately 30% of total 
energy in the body, whilst high expression in the brain consumes about 40-50% of 
brain ATP (Erecinska et al., 2004).  
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Figure 1.1 The Na+ K+ ATPase pump creates an electrochemical gradient across cell 
membranes by maintaining low internal Na+ and high internal K+ cellular concentrations. This 
is an active process involving the following steps: 
1. In conformation E1, the pump has a high affinity for sodium. Three sodium ions bind to 
the pump from the cytoplasmic side of the phospholipid bilayer membrane, which has a low 
sodium (Na+) concentration and a high potassium (K+) concentration.  
2. ATP phosphorylates the enzyme (represented by the P attached to the cytoplasmic side of 
the pump). This results in a change in pump conformation from E1 to E2, reducing the pumps 
affinity for sodium. The three sodium ion are released. 
3. Two potassium ions enter and bind to the pump in the E2 conformation. 
4. The pump becomes dephosphorylated, returning to conformation E1 and in the process 
transporting and releasing the potassium ions into the cell. The pump is ready to start again. 
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1.11.1 Structure and isoforms of Na+ K+ ATPase 
The Na+ K+ ATPase pump is a heterodimer comprising of two essential subunits; 
the catalytic α subunit which is responsible for ATP hydrolysation and Na+ and K+ 
transportation, and the regulatory β subunit required for protein folding and 
modulation of substrate affinity (Blanco and Mercer., 1998). Very little is known 
about the specific roles of the α/β heterodimers.  
The α subunit is a multi-spanning membrane protein, with a molecular mass of 
about 112 kilo Dalton (kDa), and contains binding sites for ATP and the Na+ K+ 
ATPase pump-specific inhibitor, ouabain (Jorgensen et al., 2003;Pedemonte and 
Kaplan, 1990). Four α isoforms exist (α1, α2, α3, α4) and three are abundant in 
the brain (α1, α2, α3) (Blanco and Mercer., 1998;Urayama et al., 1989;Lingrel et 
al., 2007;Orlowski and Lingrel., 1988). All four isoforms have a high degree of 
amino acid identity, however studies have shown isoforms differ in the kinetic 
properties and affinities for sodium, with α1 and α2 showing the most similarity 
(Jewell and Lingrel., 1991;Segall et al., 2001). The α isoforms are responsible for 
the tissue specific mechanisms of the Na+ K
+ ATPase pump (Lingrel et al., 2007). 
The α1 subunit is present in neurons and glia and is thought to be essential for 
neurodevelopment as mice lacking α1 die at embryonic stage (Moseley et al., 
2007;Lingrel et al., 2003). The α2 isoform is found mainly in skeletal muscle, 
heart and brain, and may be involved in the regulation of the Na+/calcium (Ca+) 
exchanger, whilst α3 is found in neurons of the brain and central nervous system 
(CNS), and plays a role in neurotransmission (Moseley et al., 2007;James et al., 
1999;Lingrel et al., 2003;McGrail et al., 1991).  
The glycosylated β-subunit is 40-60 kDa in size and only crosses the membrane 
once. It is responsible for the normal activity of the membrane by maturation of 
the Na+ K+ ATPase pump and the transportation to the plasma membrane and 
(Lingrel et al., 2007;Noguchi et al., 1990;Geering et al., 1985). Moreover, the β-
subunit modulates the pump’s affinity for sodium and potassium (Eakle et al., 
1994;Jaisser et al., 1992). Without the β subunit, the α subunit is unable to 
adopt the conformation of the mature proteins and is quickly degraded (Geering 
et al., 1985). Three isoforms of the β subunit exist and they are all glycosylated 
27 
 
 
 
(β1, β2, β3) (Orlowski and Lingrel., 1988;Martin-Vasallo et al., 1989). The β1 
isoform is ubiquitous (in almost all tissues), whilst β2 is expressed in skeletal 
muscle and nervous tissues and β3 in the testis, retina, liver and lung (Lingrel., 
1992).   
A third, non-obligatory, small protein of around 6.5 kDa has also been identified. 
The γ subunit is thought to not be essential for Na+ K+ ATPase normal functioning 
however does have a regulatory role through the modulation of the α/β 
complexes (Mercer et al., 1993;Beguin et al., 1997;Therien et al., 1997). The γ 
subunit belongs to a family of small membrane proteins, the FXYD family 
(proline-phenylalanine-X-tyrosine-aspartate (PFXYD) refer to 1.12) (Sweadner 
and Rael., 2000;Crambert and Geering., 2003;Garty et al., 2002). 
1.11.2 Modulation of the Na+ K+ ATPase pump 
The exact mechanisms involved in the regulation and facilitation of the Na+ K+ 
ATPase pump remain largely unknown, however it is thought to be prominently 
maintained via the control of phosphorylation, after which a conformational 
transition occurs (E1 → E2). The main rate-limiting step of the Na
+ K+ ATPase 
comes from the modulation of the conformational change of the phosphorylated 
enzyme from E1 → E2, and the conformational transition of the unphosphorylated 
enzyme from E2 → E1 (Lupfert et al., 2001;Jorgensen and Andersen., 1988) 
(Figure 1.1). The γ subunit and other members of the FXYD family are not 
essential for the functioning of the Na+ K+ ATPase pump; however have a role in 
the modulation of its activity (Beguin et al., 2001;Bibert et al., 2008;Crambert 
et al., 2005;Delprat et al., 2007). With the exception of the γ subunit (FXYD2), 
FXYD proteins do not form an integral part of the Na+ K+ ATPase pump, and 
therefore interaction and modulation must take place at the molecular level. It 
is thought the pump is regulated via the interaction of FXYD protein and the α/β 
heterodimer; however the specific interactions remain elusive. Beguin et al., 
(1997) have shown the γ subunit modulates the K+ activation of Na+ K+ ATPase 
pump by associating with α/β heterodimers. 
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1.11.3 Association between Na+ K+ ATPase activity and 
psychiatric disorders 
Reduced Na+ K+ ATPase activity has been observed in various disorders affecting 
the brain (Ischemia, epilepsy, depression and bipolar disorder) (Looney and El-
Mallakh., 1997;Mintorovitch et al., 1994;Renkawek et al., 1992). Ouabain-
induced inhibition of the pump in rats has been shown to result in increased 
spontaneous locomotor activity and reduced spatial learning in the rat which 
may model some aspects of symptoms associated schizophrenia and similar 
disorders (El-Mallakh et al., 2003;Riegel et al., 2009;Zhan et al., 2004). 
However, despite studies suggesting that Na+ K+ ATPase activity modulates 
neurotransmission of DA, GABA, norepinephrine and glutamate (Levi et al., 
1976;Rose et al., 2009;Westerink et al., 1989), little is known about the exact 
functioning of Na+ K+ ATPase in these disorders and further investigations are 
required to elucidate information about the role of Na+ K+ ATPase in psychiatric 
disorders.  
1.12 FXYD Family 
FXYD proteins are a family of single-span transmembrane proteins. So far, a 
total of 7 FXYD proteins have been identified at the mammalian level, all of 
which contribute to a variety of apparently unrelated physiological processes 
(summarised in Table 1.1). They are, however, all known to interact with the 
Na+ K+ ATPase pump in a tissue-specific fashion, altering the kinetics of the 
pump to meet specific tissue requirements (Crambert and Geering., 
2003;Geering., 2006;Li et al., 2004;Cornelius and Mahmmoud., 2003;Geering et 
al., 2003;Therien et al., 1997). The most highly characterised FXYD protein is 
the γ subunit of the Na+ K+ ATPase pump (FXYD2) (Bibert et al., 2008;Crambert 
et al., 2002;Lifshitz et al., 2006). FXYD2 is expressed in the kidney and is 
thought to regulate electrolyte homeostasis (Crambert and Geering., 
2003;Goldschmidt et al., 2004;Shustin et al., 1998). Protein expression and 
physiological roles of the FXYD family are summarised in Table 1.1. 
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Protein Gene Protein expression Physiological role References
Phospholemman (PLM) FXYD1 Heart, brain, kidney Substrate for proteinase A and C , Sweadner and Rael, 2000;Crambert et al., 
suspected role in heart contractility 2002;Moshitzky et al., 2012;Chen et al., 1997
The γ subunit of the FXYD2 Kidney Regulatory role in α/β complex activity and Beguin et al., 2001;Bibert et al., 2008;
Na+ K+ ATPase pump electrolyte homeostasis Crambert et al., 2005;Delprat et al., 2007
Mat-8 FXYD3 Stomach, colon, cancer cells Role in tumorogenesis Bibert et al., 2009;Arimochi et al., 2007;
Kayed et al., 2006
CHIF FXYD4 Kidney, colon regulatory role in electrolyte homeostasis Shustin et al., 1998;Goldschmidt et al., 2004
through mediating sodium absorption
RIC, dysadherin FXYD5 Kidney, intestine, heart, Regulates E-cadherin,  promotes metastasis Lubarski et al., 2005;Ino et al., 2002
lung, spleen
Phosphohippolin FXYD6 CNS, brain, inner ear Endolymph homestasis, Delprat et al., 2007a;Delprat et al., 2007b;
role in brain currently unknown Kadowaki et al., 2004
FXYD7 Brain, cerebellum Suscepted role in neuronal excitability Beguin et al., 2002;Crambert et al., 2003  
Table 1.1 Summary of FXYD family. FXYD proteins all modulate the Na+ K+ ATPase pump in a tissue-specific manner.  
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1.12.1 Structure 
The FXYD family consists of small hydrophobic proteins. Each protein has an 
extracellular NH2 terminus and contains a marked homology in a 35 amino acid 
sequence located in the transmembrane domain, this sequence is made up of 3 
exons and contains 7 invariant amino acids located within, and surrounding, the 
membrane span (Sweadner and Rael., 2000). With the exception of the 35 amino 
acid stretch, the structure of FXYD proteins has not been well conserved, around 
11 % of the amino acids of phospholemman (PLM) and (corticosteroid-induced 
factor) CHIF vary between the rat and mouse sequence (Garty and Karlish., 
2006). The short sequence proline-phenylalanine-X-tyrosine-aspartate (PFXYD) 
gives rise to the motif and is invariant among the proteins. It has been suggested 
that it is likely these residues are involved in a function common to FXYD 
proteins, such as interaction with the Na+ K+ ATPase pump (Beguin et al., 2001). 
FXYD proteins are modulatory proteins of the Na+ K+ ATPase pump, with the 
exception of PLM activity which has been shown to be modulated by protein 
kinase (PK) A (PKA)- and PK C (PKC)- dependent phosphorylation (Mahmmoud et 
al., 2000;Fuller et al., 2004).  
1.12.2 FXYD modulation of Na+ K+ ATPase 
Association between FXYD proteins and the Na+ K+ ATPase was first noted in 1978 
when a short polypeptide (later to be identified as the γ subunit) was 
characterised and shown to be directly associated with the renal Na+ K+ ATPase 
(Forbush et al., 1978;Collins and Leszyk., 1987). Further studies confirmed co-
immunoprecipitation and co-purification of the γ subunit with the Na+ K+ ATPase 
(Mercer et al., 1993;Arystarkhova et al., 2002). Studies investigating the 
functional relationship between the γ subunit and Na+ K+ ATPase have shown the 
pump is modulated by a change in confirmation of the enzyme from E2 to E1, 
increasing the affinity for ATP and increasing K+ antagonism of cytoplasmic Na
+ 
activation (Beguin et al., 1997;Pu et al., 2002;Therien et al., 1999).   
More recently, the functional relationship between the FXYD proteins and the 
Na+ K+ ATPase pump has shown to be a non-essential association between FXYD 
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and the α/β complex (Cornelius and Mahmmoud., 2003;Crambert and Geering., 
2003;Therien et al., 1997;Crambert et al., 2005;Geering et al., 2003). FXYD 
proteins associate with the α/β complex, inducing changes in K+ and Na+ 
apparent affinity. The modulation of pump kinetics differs depending on the 
FXYD protein and the α/β complex with which it associates. This suggests FXYD 
proteins modulate the kinetics of the pump specific to each tissue requirement 
(Table 1.2, Crambert and Geering., 2003;Geering., 2006;Li et al., 2004;Cornelius 
and Mahmmoud., 2003;Geering et al., 2003;Therien et al., 1997).  
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Protein Gene Role in Na
+ K+ ATPase pump kinetics References
Phospholemman (PLM) FXYD1 Increases Na
+ 
binding affinity  by 30- 50%, Crambert et al., 2002;Cirri et al., 2011
FXYD2 Reduces apparent Na
+
  affinity, increases K
+
 affinity  during hyperpolarisation,  however Cirri et al., 2011;Li et al., 2004;
The γ subunit of the  decreases K+ affinity in high levels of Na+, it also increases ATP affinity Pu et al., 2002
Na+ K+ ATPase pump
FXYD3 Decreases apparent affinity for both Na
+ and K+ Crambert et al., 2005
Mat-8
FXYD4 Induces a two- to threefold increase in apparent affinity for Na
+ but does not affect affinity  Garty et al., 2002
for K+
CHIF FXYD5 Increases the apparent affinity for Na
+ 2-fold, and decreased the apparent affinity for K+ by 60%  Miller and Davis, 2008
FXYD6 Association of FXYD6 with Na
+
 K
+
 ATPase α1/β1 slightly decreases the apparent K
+
 affinity and  Delprat et al., 2007
RIC, dysadherin  significantly decreases the apparent Na
+ affinity. Association with the α1/β2 heterodimer  
increases their apparent K+ and Na+ affinity.
Phosphohippolin FXYD7 Association with Na
+ K+ ATPase increases K+ affinity of  α1/ß1 and  α2/ß1, but not of  α3/ß1 Beguin et al., 2002
heterodimers
 
Table 1.2 The FXYD family each modulate the kinetics of the Na+ K+ ATPase in tissue- specific ways 
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1.12.3 FXYD6 and schizophrenia  
A number of SNPs within the FXYD6 gene have been shown to be associated with 
schizophrenia in a Caucasian population, implicated this as a risk factor for 
schizophrenia (Choudhury et al., 2006;Choudhury et al., 2007). Despite the 
inability to confirm this association in Japanese and Chinese populations, several 
forms of evidence suggest a role for FXYD6 in the susceptibility to schizophrenia. 
FXYD6 is located on chromosome 11q23.3, a chromosomal region which has been 
previously linked with both schizophrenia and bipolar disorder (Grandy et al., 
1989;Egeland et al., 1987). Furthermore, in situ hybridization and western 
blotting have both reveal the expression of FXYD6 in regions of the brain 
associated with schizophrenia, in particular the PFC and hippocampus (Kadowaki 
et al., 2004). The PFC and hippocampus both have several roles in memory and 
cognition; they also share pathways to regulate working memory. It is therefore 
possible that impairments in FXYD6 may result in symptoms similar to 
schizophrenia, such as deficits in working memory.  
As of yet, FXYD6 has not been fully characterized, however, it has been revealed 
to co-localise, and associate, with the Na+ K+ ATPase pump in the inner ear, 
suggesting it has a role in the modulation of the pump (Delprat et al., 2007).  
This demonstrates a theorized mechanism of action by which FXYD6 and the Na+ 
K+ ATPase pump interact, based on the interaction of other FXYD members with 
this pump (Figure 1.2) (Geering., 2006). It is possible that aberrations in FXYD6 
may induce impairments in Na+ K+ ATPase activity. Impairments in Na+ K+ ATPase 
pump activity have been previously associated with psychiatric disorders (El-
Mallakh and Wyatt., 1995;Kurup and Kurup., 2003;Looney and El-Mallakh., 1997) 
and it would therefore be interesting to investigate further a role of Na+ K+ 
ATPase in schizophrenia. A mouse model expressing homozygous disruption of 
Fxyd6 has been created, however it has yet to be characterised and assessed for 
biochemical, molecular and phenotypic similarities to schizophrenia. 
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Figure 1.2 Proposed mechanism of the interaction between FXYD6 and Na+ K+ ATPase pump.  
Despite FXYD6 showing co-localisation and association with the Na+ K+ ATPase pump in the 
inner ear, the functional relationship between FXYD6 and the pump is currently unclear. It 
has been suggested the Na+ K+ ATPase pump is modulated by a non-essential association 
between FXYD proteins and the α/β complex, inducing changes in K+ and Na+ apparent 
affinity (Cornelius and Mahmmoud, 2003;Crambert and Geering, 2003;Therien et al., 
1997;Crambert et al., 2005;Geering et al., 2003).     Represents the potential association 
between FXYD6 and the Na+ K+  ATPase pump.  
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1.13 Mitogen activated protein kinase (MAPK) cascades 
MAPKs are serine/threonine specific protein kinases that respond to extracellular 
stimuli. They form part of the MAPK cascade; an evolutionarily conserved signal 
transduction cascade, responsible for the mediation of adaption and survival of 
eukaryotic cells’ in response to physical and chemical stress triggers (Johnson 
and Lapadat., 2002;Robinson and Cobb., 1997). Despite the majority of 
information on MAPK cascades deriving from yeast studies, more information is 
now becoming elucidated on the role of mammalian MAPKs. An important role of 
the MAPK cascades in the regulation of a diverse range of cellular processes such 
as gene expression, growth factors and hormones and cell survival/ apoptosis is 
apparent.  
MAPK cascades typically consist of a three kinase model that is activated through 
the sequential phosphorylation of MAPK by MAPK-kinases (MAP2Ks) (also known 
as MAPK/extracellular signal-regulated kinase (ERK)-kinases (MEKs), which are 
phosphorylated and activated by MAPKK-kinases (MAP3Ks) (Figure 1.3) (English et 
al., 1999). A number of distinct, but not mutually exclusive, mechanisms ensures 
specific MAPK activation in response to diverse cellular processes and 
extracellular stimuli (reviewed by (Johnson and Lapadat., 2002;Cobb and 
Goldsmith., 1995).  
1.13.1 Mammalian MAPK cascades 
In the MAPK cascades (reviewed by (Cobb., 1999), MAPKs are activated by 
MAP2Ks through common mechanisms at two regulatory phosphorylation sites 
located in the activation lip. This motif contains the sequence ‘threonine-X-
tyrosine’, both residues require phosphorylation, but can be phosphorylated 
independently of one another, and result in a conformation change. Once 
activated, MAPKs need to find their targets. Although it is necessary to limit the 
phosphorylation of irrelevant substrates, it is also important that each MAPK 
recognises a number of substrates to allow the regulation of many processes. 
Mechanisms ensuring specific MAPK cascade activations include scaffold proteins 
responsible for the organisation of specific cascades to specific activators, the 
regulation of physical interactions between members of a given cascade and the 
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indirect regulation of both ligands and inhibitors for cell-surface receptors that 
feed into MAPK cascades (Pierce et al., 2001;Su and Karin., 1996).   
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Figure 1.3 schematic diagram representing MAPK cascade. MAPK= mitogen activated protein 
kinase, MAP2K= mitogen activated protein kinase kinase, MAP3K= mitogen activated protein 
kinase kinase kinase.  
The MAPK cascades are typically initiated by the activation of MAP3Ks in response to diverse 
cellular processes and extracellular stimuli. MAP3Ks sequentially phosphorylate and activate 
MAP2Ks through common mechanisms at two regulatory phosphorylation sites. MAP2Ks 
proceed to phosphorylate and activate MAPKs in a similar manner. Once activated, MAPKs 
recognise a number of substrates to allow the regulation of many processes such as gene 
expression, cytokine production and apoptosis. 
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1.13.2 Different classes of mammalian Map kinases 
In mammalians, 4 distinct MAPK modules have been characterised (reviewed by 
(Johnson and Lapadat., 2002)). The four major MAPK members are: extracellular 
signal-regulated kinases (ERKs 1 and 2), C Jun amino- terminal Kinase (JNK1, 2, 
3), also known as stress activated protein kinases (SAPK), p38 (α, β, γ, δ) and 
the most recent to be identified, ERK5.  
ERKs 
The ERK signalling pathway was the first Mammalian MAPK pathway to be 
identified and is preferentially activated by growth- related signals. ERK1 and 
ERK2 are both activated by MKK1 (MEK1) and MKK2 (MEK2) through the 
concomitant phosphorylation of tyrosine and threonine residues, and 
subsequently undergo a conformational change. The activation of MKK1 and 
MKK2 is required for ERK activation, this occurs following phosphorylation by 
protein kinase Raf, which has in turn been activated by GTP-bound Ras.    
ERKs act to regulate cell proliferation and cell differentiation. Interestingly, it 
was found ERKs are involved in signalling pathways of mature neurons that no 
longer require differentiation (Sava et al., 2011). Further studies revealed ERKs 
are involved in long-lasting neuronal plasticity, including long-term potentiation 
and memory consolidation, controlled by excitatory glutamatergic signalling 
through AMPA and NMDA receptors (Winder et al., 1999;English and Sweatt., 
1997;Xia et al., 1996). These processes are crucial in the underlying mechanisms 
of complex behaviours in the brain such as learning and memory and a role of 
ERK in memory retention and fear conditioning has been confirmed in animal 
studies.  
JNKs 
JNK (also known as SAPKs) are important in controlling programmed cell death or 
apoptosis in response to stress stimuli such as cytokines, ultraviolet irradiation, 
heat shock, and osmotic shock. The JNK protein kinases are encoded by three 
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genes; JNK1 (also known as MAPK8), JNK2 (MAPK9) and JNK3 (MAPK10) and like 
the other map kinases, JNKs are also activated through the phosphorylation of 
tyrosine and threonine by inflammatory cytokines such as interleukin by MAP2Ks. 
Similar to ERKS, studies have revealed JNKs have a role in the mediation of 
cortical and hippocampal synaptic plasticity (Yang et al., 2011). 
P38 MAP kinase 
P38 MAP kinases have four isoforms and play an important role in the production 
of cytokines such as IL-1, tumour necrosis factor alpha (TNFa) following 
activation. Because the p38 MAPKs are key regulators of inflammatory cytokine 
expression, they appear to be involved in human diseases such as asthma and 
autoimmunity (Irusen et al., 2002;Wilms et al., 2003).  
MAP2K and MAP3K 
Unlike MAPKs which are specifically recognised by their corresponding MAP2Ks, 
each of the MAP2Ks can be phosphorylated and activated by several different 
MAP3Ks. These MAP3Ks recognise different MAP2Ks, enabling diversity in the 
activation of MAPK pathways upstream of MAP2K. JNK2 is activated by either of 
the two dual specificity kinases, MAP2K4 and MAP2K7. MAP3Ks (c-Raf, MEKK4, 
MLK3) are more complex and require multiple steps for activation. They are 
allosterically controlled enzymes residing in an inactive state. Small ligands such 
as (ras) partially activate MAP3Ks, resulting in the formation of dimers, which 
act to phosphorylate and activate one another (Cheng et al., 2005).  
1.13.3 MAPKs and schizophrenia 
Due to the pivotal role of MAPK in the integration, amplification and regulation 
of signal transduction and synaptic plasticity, it is not surprising that alterations 
in the expression and/or function of various intermediates MAP kinase cascades 
are involved in the neuropathophysiological events occurring in the brain in 
schizophrenia. Because of the role in glutamatergic signalling, many studies have 
focussed on the role of ERK in schizophrenia. However, recently, our lab found 
evidence of a putative role of the JNK2-MAP2K7 pathway in schizophrenia as a 
risk factor in schizophrenia. An expression study revealed MAP2K7 mRNA levels 
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are reduced in the PFC of post mortem schizophrenia brains. The role of MAP2K7 
as a risk factor in schizophrenia was strengthened further by a positive genetic 
association in a UK population (Winchester et al., 2012). The MAP2K7 protein is 
an upstream activator of JNK2 which mediates signal transduction and regulates 
many cellular processes such as cell growth and proliferation, transcription and 
apoptosis (Tournier et al., 2001;Holland et al., 1997;Mayer et al., 2005). JNK2 
has also been shown to have decreased expression and phosphorylation in the 
anterior cingulate cortex (Funk et al., 2011). However, further biological and 
functional evidence of a role for MAP2K7 in schizophrenia is required.  
1.14 Hypotheses and Aim 
The genetic interactions underlying the pathophysiology of schizophrenia still 
remain ambiguous. Many genes have been implicated as risk factors in this 
disorder however these genes still require biological evidence in order to 
confirm an association. Recent genetic association studies have implicated both 
FXYD6 and MAP2K7 as risk factors in the susceptibility to schizophrenia; these 
associations have been strengthened further by the expression of FXYD6 in 
schizophrenia-related brain regions, such as the PFC and the involvement of 
MAP2K7 in signalling cascades used in cognitive processes. We sought to 
investigate the functional roles of FXYD6 and MAP2K7 and explore whether these 
genes are risk factors in the susceptibility to schizophrenia.  
This study initially aims to investigate whether FXYD6 and MAP2K7 individually 
propose a risk to schizophrenia susceptibility in a north European population. 
Epistatic interactions between FXYD6 and MAP2K7 are also investigated in order 
to explore genetic interactions between these two genes in the risk to 
schizophrenia. 
The role of FXYD6 in psychiatric disorders is further explored by using mice 
homozygous for disrupted Fxyd6. FXYD proteins are known modulators of Na+ K+ 
ATPase activity and disruption of FXYD6 is hypothesised to result in altered 
activity of brain Na+ K+ ATPase. A molecular characterisation of these mice aims 
to confirm whether FXYD6 plays a modulatory role in brain Na+ K+ ATPase 
activity, and explores the role of FXYD6 in the neurochemical pathways 
associated with schizophrenia.   
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The expression of FXYD6 in the PFC and the hippocampus suggests this protein 
may be involved in the underlying mechanisms of cognition, such as working 
memory. Therefore the disruption of this gene could result in cognitive 
impairments in Fxyd6-/- mice. In order to investigate the role of FXYD6 in 
cognitive impairments, as well as behaviours associated with psychiatric 
disorders, such as sensorimotor gating, this study aims to explore a number of 
phenotypes in Fxyd6-/- mice in order to provide further insight into the 
functional role of FXYD6 in areas such as locomotor activity, cognition, 
anhedonia and in DA and glutamatergic circuitry.   
Similarly to FXYD6, the functional role of MAP2K7 is explored using mice 
haploinsufficient for Map2k7 (Map2k7+/- mice). Due to the recent association of 
MAP2K7 with schizophrenia and the role in MAPK cascades and glutamate 
signalling and synaptic plasticity, it is hypothesised the disruption of Map2k7 in 
mice will result in impairments to neurochemical circuitry associated with 
schizophrenia and psychiatric disorders, as well as impaired cognition. This aim 
is explored via the molecular and phenotypic characterisation of Map2k7+/- mice. 
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Chapter 2. Materials and Methods 
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2.1 Materials 
Routinely used chemicals and buffers are listed in Table 2.1 and Table 2.2 
respectively. Sources for chemicals not listed in these tables are detailed in the 
relevant methods section. 
Chemical Formula Source
Tris Base C4H11NO3
Potassium chloride KCl
Potassium phospate KH2PO4
Sodium chloride NaCl
Sodium hydrogen phosphate Na2HPO4
Sucrose C12H22O11
Adenosine 5′-triphosphate disodium C10H14N5Na2O13P3 
Ethanol C2H6O
Ethylenediaminetetraacetic acid (EDTA) C10H16N2O8
Imidazile.hcl C3H4N2 · HCl 
L-histidine C6H9N3O2
Magnesium Chloride MgCl2
Methanol CH4O
Ouabain octahydrate C29H44O12 · 8H2O 
Saponin C27H42O3
Sodium citrate Na3C6H5O7
Sodium phosphate dihydrate NaH2PO4.2H2O
Tween®20 C58H114O26
All oligo primers
BDH, UK
Sigma-Aldrich, 
UK
 
Table 2.1 Routinely used chemicals and their source. 
 
 
44 
 
 
Table 2.2 Recipes for routinely used buffers 
 
2.2 Genetic association study 
The genomic DNA (gDNA) sample set used for the genetic association study 
consists of The University College London (UCL) Schizophrenia Case Control 
samples (Pimm et al., 2005) and West of Scotland DNA samples.  
2.2.1 Power Calculation 
Power of sample size was calculated using G*Power 3.1.2, the study had a power 
level of 0.95. 
2.2.2 UCL schizophrenia case control samples 
The UCL schizophrenia case control gDNA samples were obtained from Professor 
Hugh Gurling (Pimm et al., 2005) and are comprised of 300 unrelated, gender 
mixed gender healthy controls (age- information unavailable) and 293 mixed 
gender schizophrenia participants (mean age 44, age range 19-91, mean age of 
onset 23) from Greater London (Pimm et al., 2005). Samples were included if 
both parents were of English, Irish, Scottish or Welsh descent and had at least 3 
grandparents of British Ancestry. Samples did not contain pedigrees. All 
schizophrenia participants have an International Classification of Diseases 
version 10 (ICD10) diagnosis of F20 Schizophrenia (World Health Organization., 
1992) and Schedule for Affective Disorders and Schizophrenia- Lifetime version 
(SADS-L) (Spitzer and Endicott., 1978) interview was completed for all case and 
control participants. Research subjects with short-term drug-induced psychoses, 
Buffer Recipe/ source
10x phosphate buffered saline 1.3M NaCl, 30mM NaH2PO4.2H2O, 
70mM Na2HPO4, pH 7.4. 
Diluted to 1x using dH20
20x Saline sodium citrate (SSC) buffer 3 M NaCl, 0.3 M Na3C6H5O7
10x TBS (forumla) 200 mM Tris base, 1.37 M NaCl, 
pH 7.6. Diluted to 1x using dH20
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learning disabilities, head injuries, and other symptomatic psychoses were 
excluded from the present study. The UCL schizophrenia Case Control samples 
have been shown not to have significant population stratification by ancestry 
(Pimm et al., 2005). The UCL samples were collected with full ethical consent, 
and the approval of the local ethical committee.  
 
2.2.3 West of Scotland samples 
The West of Scotland cohort was recruited mainly from in or around Glasgow. It 
consists of 198 healthy, unrelated mixed gender healthy controls (mean age 32) 
recruited from local higher education facilities and matched as a group for age 
and sex and DNA from 211 schizophrenia participants (mean age 44 (range 18-
78)) with an ICD10 F20 diagnosis, ascertained by a consultant psychiatrist and 
verified by researchers using structured interview and case note review; meeting 
ICD10 criteria for schizophrenia spectrum disorders. gDNA was isolated from 
blood by Demetrius Vouyouiklis and Catherine Winchester (PsyRING) using the 
DNAce Spin Blood Kit (BIOLINE., London, UK). These samples have been shown 
not to have significant population stratification. A multicentre Research Ethics 
Committee (MREC) approval letter (reference 03/0/093) was obtained for the 
West of Scotland samples. All participants gave informed consent. 
 
2.2.4 SNP selection 
Six tagging SNPs representing polymorphic loci in FXYD6 were selected using 
publicly available genetic recombination data from Utah residents with ancestry 
from northern and western Europe (CEU) ((The International HapMap 
Consortium., 2003) and SNPbrowser™ Software v4.0, ABI Life Technologies). The 
criteria for inclusion in the study were:  1:MAF was not lower than 4-10%, 2: 
SNPs were in an area of high LD and 3: SNP genotyping assays were commercially 
available. SNP loci and LD plot for FXYD6 can be observed in Figure 2.1 and SNP 
allele information in Table 2.3. TaqMan® SNP genotyping assays for each selected 
tagSNP were purchased from ABI Life Technologies. 
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Figure 2.1 Tagging SNP positions on a) FXYD6 locus and b) FXYD6 linkage disequilibrium plot 
.  
a) Six tag SNPs were selected for their ability to represent the polymorphic loci across the 
FXYD6 gene. They are located within introns and exons 
b) FXYD6 linkage disequilibrium plot (The International HapMap Consortium, 2003). Red 
squares indicate high linkage disequilibrium between two loci (LOD≥ 2, D’=1), followed by 
pink (LOD≥ 2, D’<1), blue < 2, D’=1) and white <1, D’<1. Large areas of red squares indicate 
haplotype blocks of loci likely to be inherited together. SNPs were chosen by their ability to 
represent different haplotypes.  
 
 
 
 
 
 
a. 
b. 
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SNP ID Assay ID Location Alleles Ancestral allele MAF
Allele x 
(SNP_VIC)
Allele y 
(SNP_FAM) Polymorphism 
rs30087563 2120467_10 Chr.11: 117707937 C:T T 0.465 C T Transition Substitution
rs3168238 32368298_10 Chr.11:117709645 G:T T 0.047 G T Transversion substitution
rs3885041 27877757_10 Chr.11: 117722742 C:T C 0.221 C T Transition Substitution
rs1815774 11910811_10 Chr.11: 117731439 G:C C 0.393 C G Transversion substitution
rs4938445 3236508_10 Chr.11:117745003 A:G G 0.336 A G Transition substitution
rs497768 1048679_10 Chr.11:117750740 C:G C 0.241 C G Transversion substitution
  
Table 2.3 FXYD6  SNP assay information.  
All SNP assays chosen for genotyping had a Minor Allele Frequency (MAF) higher than 4%. 
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2.2.5 Genotyping quality control 
To confirm that the selected tagSNPs were polymorphic in European populations, 
the Human Random Control DNA panel 1 (HRC1) (Sigma- Aldrich) was genotyped 
using FXYD6 TaqMan® SNP genotyping assays. Genotyping data quality was 
assessed using sample replicates across 96 well plates and not template control 
(NTC) samples were used to detect contamination. Failed and ambiguous 
samples were repeated. 
2.2.6 Genotyping 
Genotyping was done blind to sample diagnosis. Genotyping of the HRC1 gDNA 
sample set was carried out in 96 well plates using TaqMan® SNP Genotyping 
Assay 5' nuclease technology (ABI Life Technologies) according to the 
manufacturer’s protocol. Briefly, a genotyping reaction mix (1x TaqMan® 
Genotyping master mix part no. 4371355, 1x SNP genotyping assay, dH2O in a 
final volume of 15µl) was added to 5ng gDNA from each sample in a 96 well 
plate. Fluorescent amplicons were generated using standard thermal cycling 
conditions (Table 2.5 PCR conditions used for SNP genotyping.) using an ABI 
Prism Sequence Detection 7000 hardware and ABI Prism Sequence Detection 
7000 software. Ambiguous samples were repeated. An end point read of the 
fluorescent signals generated a fluorescent cluster plot (Figure 2.2). 
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SNP ID SNP VIC allele SNP FAM allele
rs3087563 C T
rs3168238 G T
rs3885041 G A
rs1815774 C G
rs4938445 A G
rs497768 C G  
Table 2.4 SNP genotypes 
 
  
 
 
PCR Cycle
Stage Temperature Time Cycles
1 50°C 2 minutes 1
2 95°C 10 minutes 1
3 95°C 15 seconds 40
4 60°C 10 minutes 1
 
Table 2.5 PCR conditions used for SNP genotyping. 
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FAM/FAM (G/G)
FAM/VIC (G/A)
VIC/VIC (A/A)
 
 
Figure 2.2 Example of end point read cluster plot and genotype calling. 
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (alleles A/A),  = 
samples homozygous for SNP_FAM™ (alleles G/G), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (alleles G/A). 
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2.2.7 Haploview 
All genotyping data were uploaded to Haploview v4.2 
(www.broad.mit.edu/mpg/haploview) in Linkage Format as a .txt file. All data 
and statistical analyses were performed using Haploview v4.2.  
2.2.8 Quality Control 
Data quality was assessed using ‘check markers’ in Haploview. Genotyping call 
rate was assessed; this was taken as the percentage of samples which were 
successfully genotyped by each SNP genotyping assay and was used to give 
indication of quality of genotyping and power of the study. Hardy-Weinberg 
equilibrium (HWE) p-value (p<0.001) was determined for controls and cases for 
each SNP genotyping assay. This provided an indication of any deviation from 
genetic equilibrium and is used to primarily detect errors in genotyping. The 
output file also provides the following information for each SNP genotyping 
assay: expected heterozygote genotype numbers, observed heterozygote 
genotype numbers, MAF and alleles detected.  
 
2.2.9 Case/control association test 
Case/ control association tests were performed on allele frequencies for all SNP 
genotyping data. The output file provided information on the dominant allele, 
the allele frequency for case and controls, the Chi Square value and the p value. 
2.2.10 Linkage Disequilibrium blocks  
Linkage disequilibrium was investigated in all data; blocks sharing high levels of 
linkage disequilibrium were defined using Haploview’s ‘solid spine of LD’ method 
using D’ values greater than 0.8. Haplotype blocks were analysed for association. 
Output data provided information on frequency of haplotype associations, 
case/control ratios, chi square value and the derived p value. MAF and LD data 
from this study were compared to published CEU HapMap Data.  
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2.2.11 Epistatic interactions with Map2k7 
Epistatic interactions between FXYD6 and MAP2K7 (MAP2K7 human data 
generated from C. Winchester) were investigated using SNPStats using a co-
dominant model (www.bioinfo.iconologia.net). Data were formatted under the 
following headings: ID, sex (1 male, 2 female), status (Ca (control), Co (case)), 
SNP ID (alleles) and analysis of interaction of covariates was used to indicate 
epistasis.   
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2.3 Mouse lines.  
2.3.1 Fxyd6 Founder Mice  
F1 heterozygote founder mice (Fxyd6+/-) were obtained from (Lexicon 
Pharmaceuticals Incorporated, 2007). The Fxyd6 knockout mice were generated 
via a gene trap mutation disrupting the Fxyd6 gene upstream of the first coding 
exon (Figure 2.3a). The F1 heterozygote founder mice had a mixed genetic 
background of C57BL/6J and 129SvEvBr strain.  
2.3.2 Map2k7 Founder Mice  
Founder Map2k7 mice were a gift from Professor. J. Penninger (Institute of 
Molecular Biology of the Austrian Academy of Science, Vienna, Austria). The 
Map2k7 knockout mouse was generated by replacement of a portion of exon 9 
with a PGK-Neo cassette (Figure 2.3b). Homozygous disruption of Map2k7 
(Map2k7-/-) results in embryonic lethality, thus only wildtype (Map2k7+/+) and 
heterozygous (Map2k7+/-) mice for Map2k7 were used in the following studies. 
The founder Map2k7 Mouse background comprised of at least 87.5% C57BL/6J 
(the rest is 129SvEvBrd (129) strain).  
2.3.3 Backcrosses 
All Fxyd6 and Map2k7 mice used in procedures were backcrossed onto 
C57b6/j_rcchsd strain to eliminate variability which may arise from a mixed 
genetic background. Mice used in chapter 4 were backcrossed for 3 generations, 
whilst mice used in chapter 5 were backcrossed for 4 generations, and mice used 
in chapter 6 were backcrossed for at least 5 generations. Mice used for 
generating backcrosses were aged 6-8 weeks, pair housed in a temperature and 
humidity regulated room with a 12-h dark/light cycle.  Animals were given 
access to food and water ad libitum.  
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Figure 2.3 Schematic diagram representing disruption of 
a) Fxyd6 gene in Fxyd6-/- mice showing the insertion of a trapping cassette up stream of the 
first coding exon. Adapted from (Lexicon Pharmaceuticals Incorporated, 2007)  
b) Disruption of Map2k7 in Map2k7 +/- mice showing the insertion of a PGK neo cassette into 
exon 9. Not drawn to scale. UTR= untranslated region. LTR= long terminal repeat. 
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2.4 Genotyping 
2.4.1 DNA extraction  
Ear clips were taken from all Fxyd6 and Map2k7 mice at 3 weeks of age. 
Genomic DNA was extracted by digesting ear clips in lysis buffer (0.8x cell lysis 
solution (Promega, Cat no A7933),  0.1M EDTA, 140 µg Proteinase K (Sigma-
Aldrich, UK) at a total volume of 200 µl) overnight at 50°C with agitation at 1000 
rpm for a duration of 10 seconds once every minute. The following day 
Proteinase K was deactivated by heating samples to 99°C for 15 minutes. 2x 
volume of 100% ethanol was added to all samples prior to centrifugation at 
13,000 rpm for 5 minutes. Supernatant was discarded and 1 ml of 70% ethanol 
(w/v) was added to all samples prior to centrifugation at 13,000 rpm for 2 
minutes.  Supernatant was discarded and samples were centrifuged at 13,000 
rpm for 5 seconds. Remaining supernatant was discarded and DNA pellet samples 
were air-dried for 30 minutes. DNA was re-suspended in 100 µl dH20 by 
incubation at 50°C for 20 minutes with agitation at 1000 rpm for 10 seconds per 
minute. DNA samples were stored at -20°C until use.     
2.4.2 Quantification of DNA 
The concentration DNA determined using a spectrophotometer (Gene Quant, 
RNA/DNA Calculator, Amersham Pharmcia Biotech) set to measure absorbance at 
wavelength 260 nm and path length 5 mm. Measuring the wavelength at 260 nm 
gives a direct indication of nucleic acid quantity. The following calculation was 
used to derive the exact concentration of DNA in each sample: 
OD260 x dsDNA co-efficient x path length correction = concentration of total DNA (μg/μL) 
2.4.3 Polymerase Chain Reaction (PCR) 
PCR was used to amplify regions of mouse genomic DNA extracted from Fxyd6 
and Map2k7 mice in order to determine their genotype using KOD Hotstart DNA 
polymerase (Merck Millipore, UK). Reaction components used in PCR reaction are 
outlined in Table 2.6 and conditions in Table 2.7. PCR primers specific for Fxyd6 
and Map2k7 were designed using OligoPerfect™ Designer (Invitrogen, UK). 
Proposed forward and reverse primers were ‘blasted’ using Nucleotide Blast 
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(NCBI) to ensure primers were specific to gene of interest. The wildtype forward 
primer for Fxyd6 targets the region upstream of the trapping cassette insert 
(intron 1) and the reverse immediately following the insertion site (intron 1) 
(Figure 2.4). To identify mice with disrupted copies of Fxyd6, a forward primer 
was designed to recognise the trapping cassette. Map2k7 wildtype mice were 
distinguished from Map2k7 heterozygote mice by primers designed to target 
regions either side of the trapping cassette insertion site (exon 9). A primer was 
designed to anneal to the trapping cassette in order to identify heterozygote 
mice (Figure 2.4). Primer sequences are displayed in Table 2.8 and example 
genotype results can be observed in Figure 2.4b and Figure 2.5b. 
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B  
 
Figure 2.4 Fxyd6 Genotyping PCR primer locations  
a) Fxyd6. Wildtype primers (F1, R2) are adjacent to cassette insert site (upstream of the 
first coding exon), the presence of the cassette will inhibit the annealing of the wildtype 
primers. F2 primer has been designed to target the insert, identifying heterozygous and 
knockout mice.  
b) Representative PCR gel used to identify genotypes. Fxyd6+/+ mice (+/+) have a single band at 
366 bp, Fxyd6+/- mice (+/-) have two bands at 288 bp and 366 bp, Fxyd6-/- mice (-/-) have a 
single band at 288 bp. 1 kb= 1 kb pair ladder. 
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Figure 2.5 Map2k7 Genotyping PCR primer locations  
a) Map2k7. Wildtype mice are identified by primers F1 and R1, located in introns flanking 
exon 9, the site of trapping cassette insertion. The disruption of Map2k7 by the insertion of 
the trapping cassette is identified by primers F2 and R2, located along and immediately after 
the trapping cassette.   
b) Representative PCR gel used to identify genotypes. Map2k7+/+ mice (+/+) have a single 
band at 360 bp, Map2k7+/- mice (+/-) have two bands at 261 bp and 360 bp, Map2k7-/- mice 
are embryonically lethal. 1 kb= 1 kb pair ladder. 
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Component Final Concentration
KOD Hot Start DNA Polymerase buffer (Merck Millipore, UK) 1X
MgSO4 1.5 mM
dNTPs 0.2 mM (each)
PCR Grade Water
Primers 0.3 uM each
gDNA 0.1 ug
KOD Hot Start DNA Polymerase 1 µl
DMSO 2%
 
Table 2.6 PCR master mix components and concentrations optimised for use with primers 
designed to genotype Fxyd6 and Map2k7 mice.   
 
 
Step Conditions
1. Polymerase Activation 95 °C for 2 min
2. Denature 95 °C for 20 s
3. Annealing
        Fxyd6 58 °C for 10 s
        Map2k7 66 °C for 10 s
4. Extension 70 °C for 10 s
Repeat steps 2-4 30 Cycles
  
Table 2.7 PCR reaction conditions optimised for primers targeted to Fxyd6 and Map2k7. 
 
 
Gene Primer Sequence 5' → 3'
Fxyd6 Wildtype forward TACCTCACACCTCAGTTCCAAGTGG
Cassette forward AATGGCGTTACTTAAGCTAGCTTGC
Reverse GGGTGGGAGTTCTCGCCTATCACAG
Map2k7 Wildtype Forward GCTCTGTGACTTTGGCATCA
Wildtype Reverse GCCCCAACTAACCAGTGAGA
Cassette Forward GGATGTGGAATGTGTGCGAG
Cassette Reverse TCCCCAGTAGCATGAGGACAC  
Table 2.8 Sequences of forward and reverse primers used to target and amplify regions of 
Fxyd6 (refer to Figure 2.4a)Figure 2.4 Fxyd6 Genotyping PCR primer locations and Map2k7 
(refer to Figure 2.4b).  
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2.5 Na+ K+ ATPase activity in Fxyd6 mice 
2.5.1 Preparation of crude plasma membrane 
Mice (male, 12 weeks old) were killed by cervical dislocation, the brains 
removed rapidly on ice and the prefrontal cortex and hippocampus dissected and 
immediately frozen on dry ice. Brain regions were stored at -80°C until use and 
stored overnight at - 20°C prior to testing. Each frozen brain region was 
homogenised using a plastic Dounce in 300 µl ice cold 0.32 M sucrose solution 
buffer and further homogenised by being passed through a 26g needle 10 times. 
Homogenates were centrifuged at 1000 x g for 10 minutes at 4°C (Sigma 2K15 
rotor Nr. 12148) and supernatants were extracted into a new eppendorf. Crude 
plasma membranes from supernatants were obtained via differential 
centrifugation using sucrose gradients, briefly supernatants were centrifuged at 
1000 x g for 10 minutes at 4°C (Sigma 2K15 rotor Nr. 12148). The resultant 
supernatants were layered over a sucrose gradient of 300 µl 0.32 M ice-cold 
sucrose and 700 µl 1.2 M ice-cold sucrose in Thinwall Polyallomer tubes 
(Beckman Coulter) and centrifuged at 34,000 x g for 50 minutes at 4°C in a 
TLS55 Beckman rotor. The fraction collected between 0.32 M and 1.2 M sucrose 
was diluted 1:3 with ice-cold bi-distilled water, then layered over 500 µl  ice 
cold 0.8 M sucrose and centrifuged at 34,000 x g for 30 minutes. The pellet was 
re-suspended in 300 µl ice cold 5 mM imidazole- HCl buffer (pH 7.4), an aliquot 
was taken for protein quantification, and the rest stored over night at -20°C.  
2.5.2 Protein quantification 
Protein concentration of plasma membrane fractions were determined by an 
adapted version of the method of Bradford (Bradford, 1976). Briefly, a standard 
curve of bovine serum albumin (BSA, Sigma-Aldrich, UK) ranging from 0 µg/ml to 
250 µg/ml was prepared in respective homogenisation buffer.  Samples, 
depending on size of tissue region, were either used neat or diluted in 
homogenisation buffer to ensure protein concentration is within the range of the 
standard curve. 10 µl of each sample or BSA standard was pipetted, in triplicate, 
into a flat-bottomed 96 well plate and 200 µl of 1:4 protein assay dye reagent 
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concentrate (BIO-RAD, Bio-Rad laboratories, UK) (diluted with ddH20) was added 
to each well and incubated at room temperature for 10 minutes to allow colour 
development. Absorbance was read at OD 630nm using Revelation software on a 
DYNEX MRX plate reader. A linear regression of optical density vs. protein 
concentration was calculated from the known standard concentrations and the 
concentration of each sample was calculated from the standard curve.  
2.5.3 Na+ K+ ATPase activity assay 
The day following the preparation of crude plasma membrane, Na+ K+ ATPase 
activity was tested in samples by a method adapted from (Sarkar., 2002). 
20 µg/ml protein suspended in imidazole.HCl buffer (pH 7.4) was added 1:1 to 2x 
ATPase buffer (60 mM imidazole-HCl, 280 mM NaCl, 60 mM histidine, 20 mM 
MgCl2, pH 7.4) and 1:1 to ouabain-ATPase buffer (60 mM imidazole-HCl, 50 mM 
KCl, 20 mM ouabain, 280 mM NaCl, 60 mM L-histidine, 20 mM MgCl2, pH 7.4) 
(total volumes 100 µl). Samples were incubated in the dark, on ice for 60 
minutes. 20 mM Na.ATP was made up in the respective buffer and 100 µl was 
added to all samples to give a final concentration of 10 mM. Samples were 
incubated for 5 minutes at 37°C with agitation at 1000 rpm for a duration of 10 
seconds per minute. Reactions were stopped via the addition of 400 µl BioMol 
Green (Enzo Life Sciences, Inc, Exeter UK) and the optical density was read 25 
minutes later at 630 nm  wavelength on Dynex Technologies MRX plate reader. 
Background was deducted using tissue-free control samples. Na+ K+ ATPase -
specific activity was calculated by deducting the signal from samples incubated 
in ouabain- ATPase buffer from samples incubated in ATPase buffer.  
2.6 Confirmation of protein expression by western 
blotting  
2.6.1 Samples 
Samples used for western blotting were either prepared as crude plasma 
membranes (section 2.5.1) or brain regions were dissected on ice and 
homogenised with a plastic Dounce in 300- 500 µl ice cold 0.32 M sucrose 
solution buffer. The homogenates were further homogenised by being passed 
through a 26g needle 10 times.  
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2.6.2 Sample preparation 
32.5 μg of crude plasma membrane or 16 μg of protein homogenate (determined 
from the protein concentration (see section 2.5.2)) was added to 4x NuPAGE®  
LDS sample buffer (Invitrogen, UK) and 10x NuPAGE® reducing agent (Invitrogen, 
UK), and denatured at 70°C for 10 minutes.   
 
2.6.3 SDS-polyacrylamide gel electrophoresis (-PAGE) 
Proteins were separated by molecular weight using SDS-PAGE gel electrophoresis 
in the XCell SureLock Mini-Cell system (Invitrogen, UK).  10 μl of pre-stained 
Novex® Sharp Protein Standard ladder (Invitrogen, UK) was added to the first 
well of a 10% NuPAGE® Novex® Bis-Tris gel (Invitrogen, UK). 20 μl of prepared 
samples were added to the subsequent wells. The gel was run in 1x NuPAGE® 
MOPs SDS running buffer (Invitrogen, UK) at 200 V for 45 minutes, or until the 
dye had run to the bottom of the gel, with a Gibco BRL PS304 Electrophoresis 
power supply (Gibco BRL Life Technologies). 
2.6.4 Transfer of protein to nitrocellulose 
Following the running of samples, proteins were transferred onto an Invitrolon™ 
Polyvinylidene fluoride (PVDF) membrane (0.45 µm pore size, Invitrogen, UK). 
Membranes were submerged in 100% methanol (>1 minute) prior to being soaked 
in 1x NuPAGE® transfer buffer. All filter papers and sponges were soaked in 1x 
NuPAGE® transfer buffer. The gel was carefully removed from the gel plates and 
the transfer cassette was assembled in the following order: cassette back, 
sponges x3, filter paper, gel, PVDF membrane, filter paper, sponges x4, cassette 
front and inserted into the MiniCell System. The system was filled with 1x 
NuPAGE® transfer buffer and proteins were transferred at 30V for 2 hours using a 
Gibco BRL PS304 Electrophoresis power supply (Gibco BRL Life Technologies).  
 
2.6.5 Protein detection 
Following protein transfer, membranes were rinsed twice in ddH20 and blocked 
with 3% (w/v) milk powder (Marvel) in TBS/Tween (0.05% (w/v) for 2 hours at 
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room temperature with gentle agitation. Membranes were further incubated 
overnight in the relevant blocking buffer and primary antibody (Table 2.9). 
After overnight incubation, the membranes were washed in TBS/Tween (0.05% 
(w/v)) followed by 2hr incubation with the appropriate secondary antibody in 1% 
milk powder in TBS/Tween (0.05%) at room temperature (see Table 2.10). 
 Antibody Species Working dilution Supplier  Antibody
α-Fxyd6 Rabbit 1:1000 Gift from B. Delprat
α-Actin-HRP Rabbit 1:2000 Santa Cruz
α-Actin-HRP Goat 1:5000 Santa Cruz
α-Na
+
 K
+
 ATPase α1 subunit Mouse 1:1000 Abcam
α-Map2k7 Rabbit 1:1000 Calbiochem
α-GluR2 Rabbit 1:1000 Sigma
α-GAD Rabbit 1:500 Sigma
  
Table 2.9 The primary antibodies and their working dilutions used for western blotting  
 
 
 Antibody Working dilution Supplier
α- Mouse HRP 1:5000-1:10,000
α- Mouse HRP 1:5000-1:10,000
                                                                                                       
Santa Cruz
Table 2.10 The secondary antibodies and their working dilutions used for western blotting 
 
2.6.6 Protein Visualisation 
Enhanced chemiluminescence (ECL) used for protein visualisation was dependent 
on primary antibody. FXYD6 required homemade ECL (1:1 solution A (33% (w/v) 
DMSO, 2.5 mM luminol (Fluka analytica, UK), 0.9M coumaric acid (Sigma- Aldrich, 
UK), 0.1M Tris) solution B (0.02% (v/v) H2O2 in 0.1M Tris)) applied for 1 minute. 
All other antibodies required Millipore Immoblin (Fischer Scientific, UK), applied 
for 5 minutes and exposed to X-ray film for 15 seconds- 20 minutes and 
developed using an automatic developer (HyperProcessor, Amersham) 
The film images were scanned to obtain a digital image and the amount of 
protein in samples was estimated using image analysis (Image J).  
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2.7 Gene transcript expression RTq-PCR 
2.7.1 Total RNA isolation 
PFC samples were homogenised in Buffer RLT with (% (v/v) β-mercaptoethanol) 
using Hybaid Ribolyser tubes (Lysing Matrix D, Qbiogene., UK) and total RNA was 
isolated using silica-based membrane spin columns in RNEasy mini Kit (Qiagen., 
UK), according to the manufacturer’s protocol. Total RNA was eluted using 
DNase/RNase free water (Ambion., UK) and contaminating DNA removed by 
treatment with DNaseI (Invitrogen., UK) according to manufacturers protocol. 
The quality of total RNA was analysed using the Nano chip Bioanalyser 2100 
(Agilent Technologies., UK) and quantified using Nanodrop™ 1000 (Thermo 
Scientific., UK).  Samples were stored at -80°C until use. 
 
2.7.2 First Strand CDNA Synthesis  
First strand cDNA was synthesised from 1 µg of total RNA using SuperScript® 
VILO™ cDNA Synthesis Kit (Life Technologies., UK) according to the 
manufacturers protocol. In order to detect contamination, samples with no 
template and no enzyme were included. Samples were stored at -20°C until use.  
2.8 Quantitative real time reverse transcriptase PCR (RTq-
PCR) 
2.8.1 Primers 
Gene expression assays were purchased from Applied Biosystems (refer to Table 
2.11). Β2M, ribosomal 18s and GAPDH were used to create a geometric mean to 
normalise CT values generated from genes of interest (Fxyd6_m1, Fxyd6_g1, 
Map2k7 10/11, Map2k7 1a/1b, PVALB, Grin1). 
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Gene expression assay Gene Amplification region Status Source
β2M β2M Housekeeping gene Applied Biosystems
18s 18s Housekeeping gene Applied Biosystems
GAPDH GAPDH Housekeeping gene Applied Biosystems
Fxyd6_m1 Fxyd6 E xons 1 & 2 Gene of interest Applied Biosystems
Fxyd6_g1 Fxyd6 Exons 3 & 4 Gene of interest Applied Biosystems
Map2k7 10/11 Map2k7 Exons 10 & 11 Gene of interest Applied Biosystems
Map2k7 1a/1b Map2k7 Exons 1a & 1b Gene of interest Applied Biosystems
PVALB PVALB Gene of interest Applied Biosystems
Grin1 Grin1 Gene of interest Applied Biosystems  
Table 2.11 Gene expression assays were purchased from Applied Biosystems. Β2M, ribosomal  
18s (18s) and GAPDH were used to create a geometric mean to normalise CT values 
generated from genes of interest.  
 
2.8.2 RTqPCR 
500 ng of RNA equivalent 1st strand cDNA and mastermix (1x TaqMan®Gene 
Expression Master Mix (Applied Biosystems), 1x Gene Expression Assay (Applied 
Biosystems) and nuclease-free H2O to a final volume of 25 µl) was aliquoted, in 
triplicates, into a 96 well MicroAmp™ optical reaction plate (Applied Biosystems) 
and sealed with MicroAmp™ optical adhesion film (Applied Biosystems). To 
detect contamination, cDNA samples of known genotype were used as controls 
controls (section 2.7.2) and no template controls were included.  PCR thermal 
cycling conditions were ran for 50°C for 2 minutes, 90°C for 10 minutes followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 10 minutes on the ABI SDS7000.  
2.8.3 Gene expression quantification 
CT values (cycle threshold) were exported for each well. The CT value is defined 
as the number of cycles required for the fluorescent signal to exceed reach an 
arbitrary set fluorescent threshold in the linear phase of the amplification level, 
this level is set as a threshold of 0.3. As CT levels are inversely proportional to 
the amount of target nucleic acid in the sample, values can be used to quantify 
gene expression using LinRegPCR. No template controls were checked for non-
amplification. Triplicates were checked for outliers using the Grubbs test 
(GraphPad, http://graphpad.com/quickcalcs/Grubbs1.cfm) and sample averages 
were calculated. REST V2.0.13 (Qiagen., 2009) was used to calculate relative 
expression of each gene of interest, values were normalised by using a geometric 
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mean from the three reference genes using amplification efficiencies obtained 
from LinReg. 2000 iterations were used and a hypothesis test was performed 
with 10,000 random reallocations of samples and controls between the groups, 
significance was set at p<0.05.  
  
2.9 In situ Hybridisation 
 
2.9.1 Labelling Oligonucleotide probes 
A 7 µl mastermix containing 5ng oligonucleotide, 1x TdT buffer, 3.6 µl α33P-dATP 
and 1.5 µl TdT enzyme was incubated at 32 °C for 60 minutes (Amersham 
Biosciences, UK). 50 µl DEPC-treated water was added to the mastermix and 
labelled nucleotide probes were separated from excess radioactivity using 
Biospin 6 Tris Columns (Biorad, 732- 6227, UK), according to manufacturer’s 
instructions. The radioactivity counts of probes were calculated using a liquid 
scintillation analyser (2200CA, Tricarb-Packard). Probes with a radioactivity 
count between 100-500 x 103 dpm/ µl in a total volume of 50 µl were considered 
successfully labelled.  
 
2.9.2 Slide preparation and fixation 
Brains were removed from -80°C and left to equilibrate to -20°C for at least 1 
hour prior to sectioning. 20 µm coronal sections containing the prefrontal 
cortex, striatum/ nucleus accumbens, hippocampus, substantia nigra on the 
cerebellum were collected using a -20°C cryostat (CM1850, Leica). Sections were 
thaw-mounted onto Poly-L-Lysine coated slides (0.01% w/v) and air-dried for 
around one %hour prior to fixation in 4% (w/v) paraformaldehyde (in PBS) for 5 
minutes. Slides were then transferred into a sterile trough containing 1 x PBS 
then dehydrated in 70 % (v/v) ethanol followed by 95% (v/v) ethanol for 5 
minutes each and stored under 100% ethanol at 4°C until use.  
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2.9.3 Hybridisation 
 
Sections were removed from ethanol and air-dried for ~30 minutes. Experimental 
sections were incubated in ‘Hot’ probe buffer (4 µl labelled probe, 200 µl 
hybridisation buffer (4x SSC, 50% deionised formamide, 10% dextran sulphate, 
0.5M sodium phosphate, 0.1M sodium pyrophosphate, 54 mM polyadenylic acid 
and covered with Parafilm® to ensure sections and probes do no dry out. 
Controls sections were incubated in ‘Cold’ probe buffer (4 µl labelled probe, 4.5 
µl unlabelled probe, 200 µl hybridisation buffer) and covered with Parafilm®. All 
sections were placed in petri- dishes containing SSC (150 mM NaCl, 15 mM 
Na.Citrate) -soaked tissue to maintain humidity and incubated overnight at 
42°C. 
 
2.9.4 Hybridisation- washing  
Slides were removed from the oven and submerged in 1x SSC at 55°C. Parafilm® 
covers were carefully removed and slides were transferred into a fresh trough of 
1x SSC at 55°C for 30 minutes with slight agitation.  Slides underwent a 
dehydration step by immersion in 0.1 x SCC, 70% (v/v) ethanol and 95% (v/v) 
ethanol for 20 seconds each with slight agitation. Slides were air-dried for ~ one 
hour and placed under BiomaxTMMR films (Kodak) for 1 to 3 weeks. 
 
2.9.5 Film Development and analysis 
BiomaxTMMR films (Kodak) were developed using an automatic developer 
(HyperProcessor, Amersham, Piscataway, NJ, USA). mRNA levels were analysed 
using Image J software. Non-specific labelling (slides labelled with ‘cold probe’) 
was deducted from total labelling (slides labelled with ‘hot probe’) to quantify 
mRNA levels. 
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2.10 Phenotyping  
2.10.1 Primary phenotype screen 
A primary phenotype screen was carried out on Fxyd6+/+ and Fxyd6-/- mice and 
Map2k7+/+ and Map2k7+/- mice as a first screen for phenotype abnormalities. This 
consisted of a modified version of the Smithkline Beecham, MRC Harwell, 
Imperial College, the Royal London Hospital Phenotype Assessment (SHIRPA) 
assessment. PPS was carried out as outlined in Table 2.12. Weekly weight 
measurements were catalogued and a growth curve for each strain was 
produced. Fxyd6+/+ and Fxyd6-/- mice n=10 per group, aged 7 weeks. Map2k7+/+ 
mice n=9 and Map2k7+/- mice n=7 per group, aged 6 weeks. Data analysed by 
Student’s t-test. 
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Testing location Measure Response score
In arena Body position 0= Inactive, 1= Active, 2= Excessive Activity
Spontaneous activity 0= Absent, 1=Intermittent  rapid darts, 2= Excessive rapid darts
Tremor 0= Absent, 1= Present
Urination Quantity
Defecation Quantity
Bizarre behaviours 0= Absent, 1= Present
Convulsions 0= Absent, 1= Present
Palpebral closure 0= Eyes fully open, 1= Eyes mid closed, 2= Eyes fully closed
Gait 0= Fluid movement, 1=Lack of fluidity in movement
Pelvic Elevation 0= Flattened, 1=Normal (3 mm elevated), 2= Elevated
Coat appearance 0= Tidy and well groomed, 1= Ungroomed 
Piloerection 0= Absent, 1= Present
Tail Elevation 0=Dragging, 1= Horizontal extension, 2= Elevated/ straub tail
Restrained Pinna reflex 0= Present, 1= Absent
Cornea reflex 0= Present, 1= Absent
Lacrimation 0= Absent, 1= Present
Evidence of biting 0= Absent, 1= When handled
Vocalisation 0= Absent, 1= Present
Trunk curl 0= Absent, 1= Present
Other Hanging wire n=3 mean latency to fall from wire (three 120s trials)
Contact righting reflex 0= Present, 1= Absent
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Table 2.12  Primary phenotype screen testing parameters.  
The battery of tests is designed to reveal any basic phenotype abnormalities in a new mouse 
line. Phenotyping is carried out either with a free moving mouse in an arena or by 
restraining the mouse.  
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2.10.2 Rotorod 
The rotorod assesses motor coordination and consisted of a rotating drum set to 
accelerate gradually. Latencies for mice either to fall from the rod or to 
passively rotate with the rod were recorded. The speed was initiated at 4 RPM, 
and incrementally increased until 40 RPM was reached within a 5 minute time 
period. Testing was repeated three times with a 15 minute resting interval 
between tests. Fxyd6+/+ and Fxyd6-/- mice n=10 per group, aged 7 weeks. 
Map2k7+/+ mice n=9 and Map2k7+/- mice n=7 per group, aged 6 weeks. Data 
analysed by Student’s t-test. 
2.10.3 Plus Maze  
Plus maze apparatus consisted of two opposing enclosed, dark arms (30 cm x 6 
cm) and two opposing open light arms (30 cm x 6 cm). The mouse was placed in 
centre of the maze and allowed to freely move for 5 minutes. An overhead infra-
red detecting camera tracked and analysed activity. Data was analysed using 
EthoVision Video Tracking System (Noldus Information Technology, Leesburg, 
VA). Four zones were created in order to analyse behaviour and admittance to 
open and enclosed arms, these zones are out lined in Figure 2.6. Fxyd6+/+ and 
Fxyd6-/- mice n=10 per group, aged 7 weeks. Map2k7+/+ mice n=9 and Map2k7+/- 
mice n=7 per group, aged 6 weeks. Duration and frequency analysed by analysis 
of variance (ANOVA) followed by Tukey’s post hoc for multiple comparisons. 
Distance and mean velocity analysed by Student’s t-test. 
2.10.4 Open field (OF) 
The OF apparatus consisted of four identical plastic arenas (dimensions 40 cm x 
40 cm x 40 cm) situated on an infra-red light box. Movement within the arenas 
was tracked by an overhead infra-red detecting camera using Ethovision XT 
(Noldus) video tracking software. In order to habituate mice to arenas, one 
mouse was placed in each arena for 30 minutes prior to locomotor assessment 
and allowed to move freely.  
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Locomotor activity was assessed immediately following habituation to the 
arenas. Mice were removed from arenas for around five minutes and during this 
time received subcutaneous injections of vehicle (0.9% (w/v) saline) or d-
amphetamine sulphate (Sigma-Aldrich., UK) (3 mg/ kg/ 5 ml) and immediately 
placed back in the arena and allowed to move freely for 1 hour. Mice received 
both treatments over 3 days, with one day washout between drug 
administrations. Treatment groups were fully counterbalanced. Data were 
analysed using Ethovision software. An inner (20 cm X 20 cm) and outer zone 
were created (Figure 2.7) to assess anxiety and exploratory like behaviour. 
Velocity was measured by distance (cm) moved per second. Fxyd6+/+ and Fxyd6-/- 
mice n=12 per group, aged 8 weeks. Map2k7+/+ mice n=9 and Map2k7+/- mice n=7 
per group, aged 7 weeks. Duration and frequency analysed by ANOVA followed 
by Tukey’s post hoc for multiple comparisons. Distance and mean velocity 
analysed by Student’s t-test. 
 
2.10.5 Prepulse inhibition  
Prepulse inhibition (PPI) was assessed following a 7 day washout period after the 
open field amphetamine challenge. PPI apparatus consisted of four identical 
sound-attenuated chambers. Immediately prior to PPI testing, mice received 
intraperitoneal (ip) injections of vehicle (0.9% (w/v) saline) or ketamine (10 mg/ 
kg/ 2 ml and 30 mg/ kg/ 2 ml). Mice was subsequently placed in restrainers and 
secured in the PPI chamber. Mice were exposed to 120 dB noise (pulse), with 
varying levels of prepulse preceding the pulse. Prepulses are of values 4, 8 and 
16 dB above background white noise of 65 dB. Mouse startle response to the 
pulses were recorded. Fxyd6+/+ and Fxyd6-/- mice n=10 per group, aged 9 weeks. 
Map2k7+/+ mice n=9 and Map2k7+/- mice n=7 per group, aged 8 weeks. Duration 
and frequency analysed by ANOVA followed by Tukey’s post hoc for multiple 
comparisons.  
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Figure 2.6 Schematic diagram illustrating plus maze zones and corresponding arms.  
Total activity in closed arms was analysed by collating data from both arms to form zone 1, 
similarly activity from open 2/3rd arms (zone 2) and open 1/3rd arms (zone 3) were collated 
to give indication of anxiety levels.  
 
 
Zone 1
Zone 2
Zone 3
Zone 1: Centre arena             
Zone 2 + zone 3: Outer arena
Zone 3: Thigmotaxis arena     
40 cm
40 cm
 
Figure 2.7 Schematic diagram illustrating open field zones in order to analyse anxiety levels 
and locomotor behaviours.  
Anxious mice would be expected to spend least time in zone 1, centre of the arena, whilst 
mice with high levels of anxiety may spend more time in the very outer arena, zone 3.  
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2.10.6 Working memory in delayed non-match to sample 
Animals 
Mouse littermates were littermate pair housed with free access to water and 
received a restricted diet of 3g feed pellet/ mouse/ day. Weights were recorded 
daily throughout the study to ensure weights did not fall below 85% of expected 
ad libitum feed weight.  
Apparatus 
An elevated cross- maze (elevated off the ground by 1 metre) was adapted to be 
used as a T-Maze using 5 cm by 15.5 cm sliding doors, creating three arms 30 cm 
by 15.5 cm by 5 cm,. The maze was constructed from grey Plexiglas. The arm 
used as the start alley was varied for each trial to prevent the use of visual cues. 
During inter- and intra- trial periods, mice were placed into a holding cage 
located adjacent to the maze.  
Habituation to handler and reward 
In order to reduce handler-mediated anxiety within the mice, all mice were 
handled for 5 minutes each for 3 days prior to habituation to the maze. Each 
day, following handling, mice were introduced to 50% (v/v H20) condensed milk 
by placing a small plastic tray into their home cage containing 8x 70 µl drops. 
The tray was removed following the consumption of all condensed milk drops. 
Habituation to Maze 
Around 1 hour following handling on the 3rd day, mice were exposed to the maze 
in pairs with their cage mate. Mice were placed in the maze for 5 minutes. The 
two ‘goal’ arms were both baited with 140 µl of 50% condensed milk. This 
process was repeated so all mice were exposed to the maze twice on the 3rd day.  
Forced alternations  
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On the 4th day, mice were exposed to 10 forced alternations. Both goal arms 
were baited with a food reward of 70 µl 50% condensed milk. One goal arm of 
the maze (arm A) was blocked off using a sliding door and mice were placed in 
the starting arm. Mice were required to run down the open goal arm (arm B) and 
consume the food reward. This is referred to as a forced-choice run. Following 
the consumption of the reward, or a 2 minute time period, mice were removed 
from maze and placed in the holding cage adjacent to the maze for 10 seconds. 
During this time, access to arm B was blocked using the sliding door and access 
to arm A and its reward was made available. The mouse was placed back on the 
starting arm and was now required to run down arm A and consume the reward. 
This is repeated for 10 trials. Mice have a limit of 2 minutes to find the reward 
for all trials. Forced alternations were continued for 3 days by which point the 
mice were actively running to the goal arm.   
Training 
In the training stage, the mouse performed a (pseudorandom) forced-choice run, 
followed by a 10 seconds intra-trial delay in the holding cage. The mouse was 
placed back into the starting arm of the maze now with access to both goal 
arms; however, the arm which contained the reward for the forced choice run 
was not re-baited and only the previously closed arm remained baited. The aim 
was for the mouse to remember which arm previously contained a reward and to 
avoid this arm, and explore the previously closed off arm. A different pattern of 
randomly chosen forced runs were used each day, with inter-trial delays of 40 
seconds. Training phase was repeated until animals reach a criterion of 7 correct 
trials out of 10 trials in 3 consecutive days. 
Testing 
Mice were tested the day following the completion of training. This consisted of 
the mice performing 3 days of 12 pseudorandom forced choice runs, followed by 
a 5, 15 or 30 second intra-trial delay in the holding cage. Mice were then placed 
back in the starting arm with access to both arms. The mouse had to correctly 
identify the unexplored goal arm to be included as a correct trial. The order of 
the forced choice runs was kept constant for all mice over the three testing 
days. Trials were separated by an inter-trial delay of 40 seconds. Fxyd6+/+ mice 
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n= 7, Fxyd6-/- mice n=6, Map2k7+/+ mice n=5 , Map2k7+/- mice=5. Data analysed 
by ANOVA followed by Tukey’s post hoc for multiple comparisons.  
2.10.7 Sociability  
Sociability was performed on mice one week following the working memory 
assessment.  
Apparatus 
Apparatus consisted of a Plexiglas test box separated by sliding doors into 3 
chambers. The two outer chambers contained a cylindrical wire cage. A clear 
Plexiglas lid was placed on top of the test box. All movement within the arenas 
was tracked Ethovision XT (Noldus).  
Habituation  
To habituate mice to apparatus, mice individually freely explored the test box 
and chambers, including the cylindrical wire cages, for 5 minutes, before being 
placed into a holding cage adjacent to the arena for around 3 minutes.  
Sociability 
Immediately following habituation, an unfamiliar mouse was placed in one of the 
cylindrical wire cages and the test mouse was placed back into the centre 
chamber of the arena and allowed to explore the whole arena, including the 
cylindrical wire cages, freely for 10 minutes, before being placed into a holding 
cage adjacent to the arena for around 3 minutes.  
Social Novelty 
Immediately following from sociability, the ‘unfamiliar’ mouse was kept in the 
wire cage and was termed ‘familiar mouse’. An novel unfamiliar mouse, termed 
‘stranger mouse’ was placed into the empty wire cage. The test mouse was 
placed back into the centre chamber of the arena and allowed to explore the 
whole arena, including the cylindrical wire cages, freely for 10 minutes.  
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Activity analysis 
Activity within the arena was analysed using Ethovison XT (Noldus). Time spent 
and entries into each chamber, and time spent exploring each wire cage were 
analysed. Fxyd6+/+ mice n= 7, Fxyd6-/- mice n=6 , Map2k7+/+ mice n=5 , Map2k7+/- 
mice=5. Data analysed by ANOVA followed by Tukey’s post hoc for multiple 
comparisons. 
2.10.8 Sucrose Preference 
Anhedonia was investigated in mice by sucrose preference testing. Following 
sociability testing, mice were singly housed. Water bottles were removed from 
cages and replaced with 2 bottles containing known volumes of either water or 
1% sucrose solution (dissolved in H20). Bottles were counterbalanced across the 
left and right sides of the feeding compartments and positions were alternated 
daily.  For 5 consecutive days both bottles were weighed every 24 hours and 
preference for sucrose was presented as the percentage of total fluid 
consumption using the following equation: 
Sucrose preference (%) = sucrose solution consumption (mg)/ total fluid intake (mg) 
Fxyd6+/+ mice n= 7, Fxyd6-/- mice n=6 , Map2k7+/+ mice n=5 , Map2k7+/- mice=5. 
Data analysed by ANOVA followed by Tukey’s post hoc for multiple comparisons.  
2.11 Statistical Analysis 
All statistical analyses were carried out in Minitab version 16. Data were 
assessed for normal distribution using the Anderson Darling normality test, data 
which did not follow a normal distribution were transformed using Johnson 
transformation and tested using either Student’s t-test or ANOVA with Tukey’s 
post hoc comparison test. Significance set at p≤0.05. 
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Chapter 3. A genetic association study of the 
FXYD6 gene and epistatic interactions in 
susceptibility to schizophrenia in a British 
population. 
79 
 
 
 
 
3.1 Introduction 
The high heritability rate of schizophrenia (refer to 1.7) has led to a search for 
genes that confer disease susceptibility. The two prevailing ideas behind most 
genetic research on schizophrenia are that schizophrenia is a combination of 
multiple common polymorphisms of modest effect  (The ‘common disease – 
common alleles’ model, refer to 1.8) (Chakravarti., 1999;Gottesman and 
Shields., 1982) and more recently, a common disease caused by multiple rare 
alleles (refer to 1.8, McClellan et al., 2007). 
GWAS and candidate gene genetic association studies have provided evidence 
suggesting a role of common variants in the genetic background of schizophrenia 
in unrelated schizophrenia patients (refer to 1.9.4 (McClellan et al., 
2007;Owen., 2010)). These studies are thought to strengthen the CDCA model of 
schizophrenia, which implies that schizophrenia is the result of the effects of 
multiple inherited genetic mutations (McClellan et al., 2007). However, the 
mode of inheritance is unclear and the genetic architecture of schizophrenia 
remains complex and poorly understood. Recent studies providing contradicting 
results to current literature have led to the re-evaluation of the ‘common 
disease – common alleles’ model as the primary hypothesis of the genetic 
architecture of schizophrenia (reviewed by Mitchell and Porteous., 2011). GWAS 
studies with large sample sizes have only found a few common variants 
associated with the increased risk of schizophrenia (Jia et al., 2010;Purcell et 
al., 2009;Stefansson et al., 2009) challenging the CDCA model which would 
require a larger quantity of common variants to be a valid hypothesis. 
Furthermore, in depth analysis of these studies revealed variance is not due to 
polygenic common variants, and instead the risk of schizophrenia is more likely 
to stem from rare but highly penetrant mutations (Purcell et al., 2009). Several 
features of schizophrenia support the view that it is a ‘common disease caused 
by multiple rare alleles’, such as mutations are often specific to a subset of 
families, or why schizophrenia, an illness associated with reduced fertility, has 
not had reduced frequency over a long period of time (McGrath et al., 
1999;Nimgaonkar et al., 1997). Furthermore, this model may offer an 
explanation to why only a small fraction of genetic risk factors have been 
80 
 
 
 
identified and consistently replicated in association and linkage studies. These 
studies assume unaffected individuals sharing the same SNP-defined haplotypes 
will share common risk variants and present a common phenotype, however rare 
but highly penetrant mutations causing schizophrenia may vary within the same 
haplotype block resulting in a lack, or reduced association which could be 
worsened with high sample numbers (reviewed by McClellan et al., 2007).  
Over a thousand genes and polymorphisms have been implicated in schizophrenia 
as a result of gene discovery strategies, such as GWAS studies, genetic 
association studies and meta-analysis (Allen et al., 2008). However schizophrenia 
is subject to environmental and genetic factors, factors such as pre- and post- 
natal environmental insults and genetic interactions (refer to 1.7), increasing 
the difficulty of identifying rare but highly penetrant susceptibility genes that 
often only confer a fractional. Processes such as gene expression can also be 
mediated by epigenetic mechanisms, which occur without changing the genetic 
code (refer to 1.8) and would therefore go undetected in genetic association 
investigations. A gene’s output can also be modified by the actions of another 
gene (known as epistatic interactions) (refer to 1.8), resulting in differences in 
phenotype between individuals sharing a risk variant (Cloninger., 1997;Moore., 
2003).  
Reduced association can also stem from the variations in the classification and 
diagnoses of disorders. The imprecise nature of the schizophrenic phenotype and 
lack of relevant biological markers lead to variability in the classification of 
schizophrenia. Rare but highly penetrant alleles may be responsible for a small 
range of phenotypes associated with schizophrenia; genetic associations can be 
missed if association studies are performed in a high number sample 
encompassing a wide variety of symptoms.  
Recently a genetic association study has implicated 5 genetic variations from 
FXYD6 in the aetiology of schizophrenia in samples from the United Kingdom 
(Choudhury et al., 2006) with two variants further confirmed in an Aberdeen 
sample (Choudhury et al., 2007). The association between FXYD6 and 
schizophrenia has been investigated in different populations with mixed results. 
Allelic, genotypic or haplotypic associations were not observed in similar studies 
carried out in a Japanese population (Ito et al., 2008;Iwata et al., 2010) or a 
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Chinese Han population (Zhang et al., 2010), however (Zhong et al., 2011) found 
significant associations between a Chinese Han population and schizophrenia 
suggesting FXYD6 gene as a risk factor in schizophrenia across populations is 
subject to other risk factors. 
FXYD6 is located on 11q23.3 (chromosome 11, locus 23.3). 11q22-24 has one of 
the strongest genetic associations with schizophrenia, as revealed by meta-
analysis of 20 genome scans in combination with a number of genome studies 
(Lewis et al., 2003). The FXYD6 protein belongs to the FXYD family, members of 
which are modulators of the Na+ K+ ATPase pump (Garty and Karlish., 
2006;Sweadner and Rael., 2000) (refer to 1.11 and 1.12). As of yet, FXYD6 has 
not been fully characterized, however, it has been revealed to modulate the Na+ 
K+ ATPase pump in the inner ear (Delprat et al., 2007). Several potential links to 
schizophrenia have been found, such as strong mRNA and protein expression in 
the rat brain (Kadowaki et al., 2004, personal correspondance) and in particular 
the forebrain (Kadowaki et al., 2004, personal correspondance); a region that is 
responsible for cognitive, sensory and motor function and is highly associated 
with schizophrenia. In addition FXYD6 protein has been shown to have highest 
levels of expression in the post natal rat brain during development (Kadowaki et 
al., 2004), suggesting it may be involved in neurodevelopment. Furthermore, co-
localisation with the GABAergic interneuron marker parvalbumin in the inner ear 
suggests a potential role of FXYD6 in the GABAergic circuitry (Delprat et al., 
2007) strengthening the argument for a role of FXYD6 in schizophrenia.  
 
3.2 Hypothesis and aim 
FXYD6 has been shown to be associated with schizophrenia in a North European 
population (Scotland and England); however despite molecular evidence further 
supporting a link with schizophrenia, difficulty in replicating this genetic 
association has been encountered. 
The aim of this genetic association study was to genotype alleles of six SNPs in 
FXYD6 and to look for association of single SNPs and haplotypes to determine if 
FXYD6 is a risk factor in schizophrenia in a North European population (the West 
of Scotland and London samples). Epistatic interactions between FXYD6 and 
schizophrenia- associated candidate gene, MAP2K7 (refer to Chapter 6), in the 
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samples were also investigated in order to explore whether the combined effects 
of these genes add to the risk of schizophrenia.  
83 
 
 
 
3.3 Results 
3.3.1 Data Quality 
Six tagging SNPs were selected to analyse genetic association of FXYD6 with 
schizophrenia (refer to 2.2.4) to capture variation across the entire gene. Prior 
to testing for association with schizophrenia, the data were assessed for quality 
(refer to 2.2.5) to eliminate the chance of false data. Ambiguous samples were 
repeated and replication samples that were included throughout the study 
confirmed the accuracy of the data. NTC within the study did not produce a 
signal, confirming samples were contamination free.  The allele frequency (in all 
controls and samples) was used to confirm that genotyping was likely to be 
accurate by being comparable to the expected frequency and with control data 
sets in databases too and a call rate of over 99% of all samples confirmed lack of 
missing data (Table 3.1).  Representative allelic discrimination plots can be 
observed in Figure 3.1-Figure 3.6. 
SNP ID Location Call rate (%) SNP VIC allele SNP FAM allele
rs3087563 Chr.11: 117707937 99.6 C T
rs3168238 Chr.11:117709645 99.8 G T
rs3885041 Chr.11: 117722742 99.8 G A
rs1815774 Chr.11: 117731439 99.8 C G
rs4938445 Chr.11:117745003 99.4 A G
rs497768 Chr.11:117750740 99.6 C G  
Table 3.1 Summary of SNP assays.  
A high percentage of samples were genotyped in all assays (98.5% - 99%). SNPs were 
determined using reporter dyes SNP VIC and SNP FAM to detect the presence of the major 
and minor alleles.  
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Figure 3.1 Representative allelic discrimination plot for rs3087563.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (C/C alleles),  = 
samples homozygous for SNP_FAM™ (T/T alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (C/T alleles). 
 
 
 
Figure 3.2 Representative allelic discrimination plot for rs3168238.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (G/G alleles),  = 
samples homozygous for SNP_FAM™ (T/T alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (G/T alleles).  
 
C/C 
C/T 
T/T 
G/G 
G/T 
T/T 
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Figure 3.3 Representative allelic discrimination plot for rs3885041.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (G/G alleles),  = 
samples homozygous for SNP_FAM™ (A/A alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (G/A alleles). 
 
 
 
Figure 3.4 Representative allelic discrimination plot for rs1815774.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (C/C alleles),  = 
samples homozygous for SNP_FAM™ (G/G alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (C/G alleles). 
G/G 
G/A 
A/A 
C/C 
C/G 
G/G 
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Figure 3.5 Representative allelic discrimination plot for rs4938445.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (A/A alleles),  = 
samples homozygous for SNP_FAM™ (G/G alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (A/G alleles). 
 
 
 
Figure 3.6 Representative allelic discrimination plot for rs497768.  
Genotype of samples are based on arbitrary intensity values for SNP_VIC® (axis x) and 
SNP_FAM™ (axis y). Samples where genotype could not be determined are represented by an 
‘X’,   = no template controls,  = samples homozygous for SNP_VIC® (C/C alleles),  = 
samples homozygous for SNP_FAM™ (G/G alleles), = samples heterozygous for SNP_VIC® and 
SNP_FAM™ (C/G alleles). 
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3.3.2 Allele Frequencies 
The allele frequencies for all SNPs were in Hardy-Weinberg equilibrium (HWE) 
(Table 3.2). However when the data sets were combined, one SNP, rs3885041 
did not follow the expected distribution and therefore deviated from HWE (p= 
8x10-4, Table 3.2).  This is unlikely to be due to genotyping error due to the 
stringent quality control measures (refer to 2.2.8 & 3.3.1) and may be 
representative of disease association in the samples, when these data were 
separated into cases and controls, the allele frequency was in HWE (p<0.001) 
(Table 3.3) confirming rs3885041 follows the expected allelic distribution 
pattern and can therefore be used in this study. 
SNP ID Exp.HET Obs.HET Call rate (%) MAF Alleles HWpval
rs3087563 0.498 0.505 99.6 0.465 C:T 0.6524
rs3168238 0.49 0.482 99.8 0.428 G:T 0.9337
rs3885041 0.449 0.4 99.8 0.341 G:A 8.00E-04
rs1815774 0.48 0.438 99.8 0.399 C:G 0.0124
rs4938445 0.096 0.097 99.4 0.051 A:G 0.6263
rs497768 0.365 0.384 99.6 0.241 C:G 0.1365  
Table 3.2 Summary of genetic frequency in the sample set combining the West of Scotland 
and the London controls and cases samples. Rs3885041 is the only SNP assay in which 
samples are not in HWE (p=8x10-4). Exp.HET= expected heterozygous allele frequencies, 
Obs.HET= observed heterozygous allele frequencies, MAF= minor allele frequency. HWpval= 
Hardy-Weinberg p value (Significance set at p<0.001, refer to 2.2.8).  Case n=498, 
controls=504.  
 
SNP ID Obs.HET %Genotype HWpval Obs.HET %Genotype HWpval
rs3087563 0.499 100 0.652 0.505 98.5 0.9515
rs3168238 0.483 100 0.7837 0.482 99.2 0.9594
rs3885041 0.38 100 0.0655 0.4 99.6 5.20E-03
rs1815774 0.416 100 0.2363 0.438 99.5 0.0244
rs4938445 0.087 100 0.5186 0.097 98.8 1
rs497768 0.394 99.8 0.3833 0.384 99 0.2784
Control samples Case samples
 
Table 3.3 Summary of control and case genetic frequency in the sample set combining the 
West of Scotland and the London samples. Rs3885041 is now in HWE in both control and case 
samples (p>0.001). Exp.HET= expected heterozygous allele frequencies, Obs.HET= observed 
heterozygous allele frequencies, MAF= minor allele frequency. HWpval= Hardy-Weinberg p 
value.  Case n=498, controls=504.  
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3.3.3 Genetic Association  
Association tests were carried out on allele frequencies in control vs. case data 
in the combined West of Scotland and London data set to give indication of 
whether the SNPs in FXYD6 are associated with increased risk to schizophrenia 
(Table 3.4). Chi square values revealed observed results do not significantly 
deviate from expected results, whilst p value confirms there is no significant 
association between the SNPs and schizophrenia cases.  
SNP ID Assoc.allele Case, control ratio Chi Sq. p  value
rs3087563 T 543:467, 521:475 0.425 0.5144
rs3168238 G 587:427, 563:433 0.382 0.5368
rs3885041 G 684:330, 644:352 1.753 0.1854
rs1815774 G 625:389, 584:412 1.89 0.1692
rs4938445 A 959:47, 936:60 1.809 0.1787
rs497768 G 251:761, 232:762 0.587 0.4437  
 
Table 3.4 Allelic association analyses in the combined West of Scotland and London sample 
set. There is no significant association of SNPs rs30087563, rs3168238, rs3885041, 
rs1815774, rs4938445 or rs497768 with schizophrenia in the combined West of Scotland and 
London data set (p>0.05), as observed by no significant difference in case samples 
frequencies compared to  control sample frequencies (as represented by Case, control ratio 
column) chi Sq > 0.05 Case n=498, controls=504 
 
3.3.4 Linkage disequilibrium associate and haplotype association 
Data were explored for haplotype blocks of adjacent SNPs (refer to 2.2.10) to 
investigate association of genetic loci with schizophrenia. Two haplotype blocks 
of associated SNPs were observed in the data set using the solid spine of LD 
method implemented in the Haploview software (refer to 2.2.7), however 
analysis did not reveal any SNP or haplotype associations with schizophrenia. 
Block 1 indicates linkage disequilibrium between rs3885041 and rs1815774 
(region size = 8kb, D’= 91, LOD score>2.0, indicated by red blocks (Figure 3.7) 
whilst block 2 indicates linkage disequilibrium between rs4938845 and rs497768 
(region size= 5 kb, D’=100, LOD score>2.0, indicated by red block, (Figure 3.7), 
(p>0.05) (Table 3.5).  
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Figure 3.7 Linkage disequilibrium (LD) was measured using samples combined from the West 
of Scotland and London sample sets.  
Each box provides D’ values (1-100) with darker shades of red representing stronger LD and 
an LOD score of >2. The haplotype blocks were determined by the solid spine of LD method 
implemented in the Haploview software (refer to 2.2.7). 2 haplotype blocks were 
determined in this sample set. Block 1 show LD between rs3885041 and rs1815774 (region 
size = 8kb, D’ = 91, LOD score >2.0) and block 2 rs4938845 and rs497768 (region size = 5 kb, 
D’ = 100 LOD score >2.0). Case n=498, controls=504  
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Haplotype Case frequency : control frequency P value
Block1
GG 611.9, 402.1 : 562.8, 433.2 0.081
AC 316.9, 697.1 : 330.8, 665.2 0.346
GC 72.1, 941.9 : 81.2, 914.8 0.38
AG 13.1,1000.9 : 21.2, 974.8 0.149
Block 2
AC 715.1, 298.9 : 703.5, 292.5 0.9588
AG 251.5, 762.5 : 232.5, 763.5 0.4442
GC 47.4, 966.6 : 60.0, 936.0 0.177
 
Table 3.5 Haplotypic analyses in the combined sample set. Two haplotype blocks were 
observed in the sample set and are referred to as Block 1 and Block 2. The frequency of 
allele combinations observed in both block 1 and block 2 did not significantly differ between 
case samples (case frequency) and control samples (control frequency) in the sample set 
(p>0.05). Case n=498, controls=504.  
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3.3.5 FXYD6 and MAP2K7 epistasis 
Although there was no association of FXYD variants with schizophrenia, we 
investigated whether there was an epistatic relationship between FXYD6 and 
MAP2K7. MAP2K7 has recently been found to be associated with susceptibility to 
schizophrenia however this study reveals that interactions between these two 
genes do not contribute to the risk of schizophrenia (refer to 2.2.11). Analysis of 
epistatic interactions between MAP2K7 SNPs rs3679 and rs4804833 and FXYD6 
SNPs rs3087563, rs497768, rs4938445, rs1815774, rs3168238, rs3885041 did not 
reveal any significant interactions in case compared to control samples in West 
of Scotland, London and combined data set (Table 3.6).  
Model codominant codominant codominant codominant codominant codominant
rs3087563 0.77 0.77 0.92 0.12 0.98 0.82
rs3168238 0.96 0.9 0.25 0.21 0.39 0.3
rs3885041 0.73 0.92 0.19 0.14 0.92 0.51
rs1815774 0.51 0.74 0.16 0.9 0.34 0.8
rs4938445 0.37 0.31 0.46 0.63 0.65 0.45
rs497768 0.87 0.38 0.7 0.53 0.72 0.19  
Table 3.6 Epistatic interaction p values.  P values representing epistatic interactions 
between MAP2K7 SNPs rs3679 and rs4804833 and FXYD6 SNPs rs3087563, rs497768, 
rs4938445, rs1815774, rs3168238, rs3885041 suggest epistatic interactions between these 
two genes do not contribute a risk to schizophrenia. Case n=498, controls=504. 
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3.4 Discussion 
Genetic association studies investigating whether FXYD6 is a risk factor in the 
susceptibility to schizophrenia have yielded mixed results, with evidence for an 
association (Choudhury et al., 2006; Choudhury et al., 2007; Zhong et al., 2011) 
and against (Ito et al., 2008;Iwata et al., 2010; Zhang et al., 2010).  
This genetic association study genotyped alleles of six SNPs in FXYD6 and 
explored both single SNPs and haplotypes to determine if FXYD6 is a risk factor 
in schizophrenia in a North European population (the West of Scotland and 
London samples). Furthermore, epistatic interactions between FXYD6 and 
MAP2K7, a gene recently shown to be genetically associated with schizophrenia 
(Winchester et al., 2012), were investigated to see if genetic interactions 
between these two genes contribute to the risk of schizophrenia. 
3.4.1 SNP criteria and data quality 
SNPs investigated in this study were selected based upon the following criteria:  
MAF was at least 5-10%, SNPs provided a full coverage of the haplotype diversity 
in FXYD6 and SNP genotyping assays were commercially available. This criterion 
suggests SNPs are polymorphic and span the FXYD6 locus. Five SNPs out of the six 
selected (rs3168238 p=0.009, odds ratio 1.64; rs1815774 p=0.049, odds ratio 
1.21; rs4938445 p=0.010, odds ratio 1.31; rs4938446 p=0.025, odds ratio 1.26 
and rs497768 p=0.023, odds ratio 1.24 (Choudhury et al., 2006) were found to 
have a positive association with Schizophrenia in Choudhury et al’s studies 
(Choudhury et al., 2006;Choudhury et al., 2007). In data samples, no 
contamination was detected and all SNPs were confirmed polymorphic and allele 
frequency followed a similar distribution pattern to those published in HapMap 
(www.hapmap.org). Assay rs3885041 deviated from HWE in London samples. 
HWE is often used as a primary data quality check in association studies (Wittke-
Thompson et al., 2005) and can be investigated through a goodness of fit chi-
squared (X2) test, which assesses the difference between the expected and 
observed allele frequencies. The HWE principle states that in a randomly mating 
population, genetic frequency remains in a state of equilibrium, assuming no 
mutations (Hardy, 1908;Weinberg, 1908), and thus allele frequency is conserved 
from generation to generation. Hardy-Weinberg assumes both alleles are equally 
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selective and so does not take into account evolution. Samples are said to 
deviate from HWE when they exhibit a HWE p value of <0.001 (Guo and 
Thompson., 1992;Wigginton et al., 2005). Deviation may indicate an error in 
genotyping techniques; however it may also be a result of disease-association or 
poor study design (Balding., 2006;Wittke-Thompson et al., 2005). When control 
and case samples tested with rs3885041 were separated, both sample sets were 
in HWE, and so the data were not excluded from the study.   
3.4.2 Allelic and haplotypic association 
Haplotype blocks were determined using Haploview’s ‘Solid spine of LD method’; 
a method which searches for a "spine" of strong LD amongst markers within the 
haplotype block. The first and last markers in the haplotype block are in strong 
LD with the other markers, however adjacent SNPs within the haplotype block 
may not be in strong LD with each other. LD, also known as gamete phase 
equilibrium or allelic association, reflects the relationship between two alleles 
at different loci on the same chromosome, indicating the likeness of these 
alleles being inherited together (Cardon and Bell., 2001). LD association is 
dependent on the association between the causal SNP and the marker SNP 
(Cardon and Bell., 2001;Carlson et al., 2004;Li and Li., 2008). Levels of LD 
between two markers in the data sets were represented by D’ values. D’ gives an 
indication of high levels of association and inheritance between two loci- D’ 
values range from 0 to 100, with D’ = 100 showing complete LD, and 0 no LD 
(Lander et al., 2001;Wall and Pritchard., 2003). A combination of SNPs at the 
same locus likely to be inherited together is regarded as a haplotype block 
(Gabriel et al., 2002). Many haplotype blocks can be transmitted through 
generations with little or no recombination, making it is possible to track a 
mutation (Gabriel et al., 2002).   
Allelic analysis of the six SNPs did not reveal any significant differences in 
variant frequencies between case and control data, suggesting these SNPs do not 
contribute towards the risk of schizophrenia phenotype in this sample set. In the 
data set 2 haplotype blocks were identified with LOD scores of >2. LOD scores 
indicate if the SNPs are linked and are likely to be inherited together or whether 
the association observed is through chance (Lander et al., 2001;Wall and 
Pritchard., 2003). The frequency of allele combinations forming haplotypes did 
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not significantly differ in either block between case and control samples, 
suggesting the inheritance of these sets of loci are not a risk factor in 
schizophrenia.  
The London data sample set from this study was a subset of samples from 
(Choudhury et al., 2007) study in which rs3087563, rs3168238, rs1815774, 
rs4938445, rs497768 were significantly associated with schizophrenia. When 
compared, data reveal a very similar frequency to those observed in Choudhury 
et al’s study, and it is a possibility that despite the study having a high statistical 
power (power level 0.95, refer to 2.2.1), it is not high enough to produce a 
significant association (control n=498, case n=504).  Alternatively, it is possible 
that data from the Choudury et al studies (Choudhury et al., 2006;Choudhury et 
al., 2007), have generated a false- positive association with schizophrenia. 
False-positive associations in genetic association studies may arise for a number 
of reasons including population stratification, which can arise when case-control 
samples are poorly matched for genetic ancestry. Allele frequencies are known 
to vary amongst different populations, these differences in allele frequencies 
between cases and controls can be wrongly interpreted as an association of 
genes with disease.  
Population stratification can be tested by the genotyping of unlinked marker loci 
in both cases and controls (Pritchard & Rosenberg., 1999). However, the power 
to detect population stratification is often inadequate if only a few dozen 
markers are tested or if the markers are not informative of ancestry. The 
samples used in the Choudhury studies have been tested for population 
stratification, making this an unlikely reason behind the generation of false-
positive results. However, other factors such as the wrong use of statistical 
analysis model and human error could have generated false- positive results in 
the Choudhury studies.   
Human error either during the testing procedure or bias during analysis can also 
lead to the production of false results. Efforts can be made in order to detect 
human errors, such as using genotyping repeat samples to ensure the same 
results are reached, including no- template controls in experiments, using 
automated genotype results calling, or having results called by two independent 
researchers. Re-genotyping using a technology different from that originally 
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employed could also provide reassurance that the results are not due to 
genotyping error.  
Given the concern for false-positive findings in studies implicating genes to a 
disease state, replication of results in new patient samples is crucial to 
determining the significance of a reported genetic association. However, lack of 
replication is not always indicative of false-positive results from previous sample 
sets, and can derive from a number of reasons, such as low power or low sample 
numbers, SNPs genotyped, poor study design and incorrect statistical models, 
variations in diagnosis, and assumptions or over interpretation of the data 
(Cardon and Bell., 2001). A number of reasons could be used to explain why this 
study did not replicate the Choudhury study in finding a significant association 
between FXYD6 and schizophrenia. It could be argued that the addition of the 
West of Scotland sample set would be associated with new environmental 
factors (refer to 1.7), differences in epigenetic modification of gene expression 
(refer to 1.8), as well as the possibility of differences in diagnostic criteria used 
to assess Schizophrenic patients. In addition, the following hypotheses of 
schizophrenia offer further explanations as to why positive associations between 
a disease state and genes can be hard to detect. 
 The ‘common disease- common variants’ hypothesis of schizophrenia, which 
states ‘the genetic risk for common diseases will often be due to disease 
producing alleles found at relatively high frequency’ (Pritchard and Cox., 
2002;Becker., 2004)  suggests it would be expected that genetic association 
studies with high enough sample numbers will detect causative alleles. If the 
‘common disease, common variants’ model was applied to this study, where it is 
proposed that schizophrenia is a result of multiple common variants of modest 
effect, the effect of FXYD6 may contribute to schizophrenia phenotype albeit 
with too small an effect size to reach significance. However, recent studies are 
also suggesting schizophrenia is a common disease caused by multiple rare 
alleles. The ‘common disease- rare alleles’ hypothesis proposes mutations are 
highly penetrant and individually rare (Pritchard., 2001;McClellan et al., 2007). 
These types of mutations may be specific to patients/families, thereby making 
them difficult to identify, resulting in many mutations going undetected due to 
low significance. If the ‘rare but highly penetrant allele’ model is applied to this 
study, it could be suggested that statistical significance was not reached due to 
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the large number of non-pedigree samples used. This would introduce a large 
number of different risk mutations, diluting associations of rare but highly 
penetrant variants with schizophrenia. Furthermore, genetic analysis of tagging 
SNPs or haplotypes, rather than analysis of fully sequenced DNA may not provide 
adequate scrutinisation of risk DNA and rare disease-related variants may go 
undetected.  
Due to the lack of clinical data provided with these samples, it is not possible to 
confirm this study is age- matched and sex- matched. As a result of this, 
limitations may occur. Lack of clinical data also limits further analyses of these 
samples, for example, investigating whether FXYD6 acts as a sex-specific risk 
factor, which would be required to evaluate fully whether FXYD6 is a risk factor 
for schizophrenia.  
3.4.3 FXYD6 and MAP2K7 epistasis 
A gene’s phenotype can be modified by the actions of a separate gene; 
association between SNPs which do not share the same chromosome can act as a 
biomarker for schizophrenia and similar disorders. It is possible FXYD6 becomes a 
risk factor for schizophrenia following epistatic interactions. Recently a genetic 
association between MAP2K7 and schizophrenia has been discovered (odds ratio 
~1.9) (Winchester et al., 2012). MAP2K7 is located on chromosome 19 and the 
protein has been associated with the activation of JNK2, which has decreased 
expression in the frontal cortex of patients with schizophrenia (Funk., 2012). 
There are several different inheritance models which can be used to assess 
epistatic interactions to account for the number of copies of alleles required to 
alter the risk for a disease. For example, a polymorphism with two alleles, T and 
a risk allele C, could be tested as a ‘recessive model’, where two copies of C 
would be necessary to cause a risk, or a ‘dominant mode’ where a single copy of 
C could cause a risk, or a ‘co-dominant model’ which is the most generalised 
model and assumes alleles do not present an additive risk (Solé et al., 2006). A 
‘co-dominant model’ was used in this study. Haplotypic analysis did not reveal 
an association between selected markers in FXYD6 and MAP2K7. MAP2K7 SNPs 
rs3679 and rs4804833 and FXYD6 SNPs rs3087563, rs497768, rs4938445, 
rs1815774, rs3168238, rs3885041 did not reveal any significant interactions 
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between MAP2K7 and FXYD6, suggesting interaction of these genes is not a risk 
factor in susceptibility to schizophrenia.  
 
3.4.4 Conclusion 
In conclusion, this study did not find an allelic or haplotypic association between 
FXYD6 and schizophrenia in a north European population. A number of 
influencing factors, such as environmental factors or genetic interactions may 
have contributed to the lack of association with schizophrenia, which has 
previously been observed in a similar genetic study. Epistatic interactions 
between FXYD6 and MAP2K7 are not a risk factor in susceptibility to 
schizophrenia in a North European population.   
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Chapter 4. Molecular characterisation of FXYD6  
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4.1 Introduction 
Despite three recent genetic association studies finding an association between 
FXYD6 and schizophrenia in a Caucasian population (Choudhury et al., 
2006;Choudhury et al., 2007), and a Chinese Han population (Zhong et al., 
2011), subsequent genetic association studies have failed to confirm an 
association in a similar Caucasian population, a Japanese population (Ito et al., 
2008;Iwata et al., 2010) and a further Chinese Han population (Zhang et al., 
2010). Therefore it remains ambiguous as to whether FXYD6 is a risk factor in 
developing schizophrenia and what role it plays.  
FXYD6 is known to be expressed in the brain (Kadowaki et al., 2004;Stansberg et 
al., 2011;Yamaguchi et al., 2001) and several studies suggest a molecular 
association between FXYD6 and schizophrenia may exist. For example, it has 
recently been revealed that Fxyd6 is strongly expressed in the rat forebrain 
(Ferra., 2006); a region that is responsible for cognitive, sensory and motor 
function and is highly associated with schizophrenia. In addition, the protein 
encoded by Fxyd6 (often referred to as phosphohippolin), has been discovered 
by means of  western blot analysis to have highest levels of expression in the 
postnatal rat brain during development (Kadowaki et al., 2004); a finding which 
may correlate with the theory that schizophrenia is a neurodevelopmental 
disorder.  
FXYD6 has been shown to co-localise with the GABAergic interneuron marker 
parvalbumin in the inner ear (Delprat et al., 2007). Loss of parvalbumin cells has 
been associated with GABAergic signalling deficits in schizophrenia (Kadowaki et 
al., 2004;Zhang & Reynolds, 2002;Beasley & Reynolds, 1997;Lewis et al., 2005) 
and it is thought the inhibitory activity of parvalbumin GABAergic signalling can 
be mediated  by the excitatory input derived from NMDA receptors on 
parvalbumin interneurons (Kinney et al., 2006). As deficits in glutamate and 
GABAergic neurotransmitters are leading neurochemical hypotheses of 
schizophrenia (refer to 1.6), it would therefore be interesting to investigate the 
role of Fxyd6 in both GABAergic and glutamatergic circuitry in brain regions 
associated with memory and cognition. This can be explored using markers of 
GABAergic and glutamatergic neurons and neurotransmisson such as parvalbumin 
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protein markers and glutamate receptor markers in regions such as the 
prefrontal cortex and hippocampus. 
FXYD6 has also been shown to co-localise with Na+ K+ ATPase α1 subunit in the 
inner ear and act as a modulator of the inner ear Na+ K+ ATPase pump (Delprat 
et al., 2006;Delprat et al., 2007). It is currently unknown whether FXYD6 also 
acts as a modulator of brain Na+ K
+ ATPase pump activity however if this is the 
case it may provide a further link with schizophrenia. Not only is brain Na+ K+ 
ATPase activity associated with glutamate transport (Rose et al., 2009;Pellerin & 
Magistretti., 1997), but it has also been implicated in several psychiatric 
disorders, with low Na+ K+ ATPase activity reported in schizophrenic and bipolar 
mood disorder patients (Goldstein et al., 2006;Kurup et al., 2001;Petronijevic et 
al., 2003).  
4.2 Aim 
This chapter aims to determine if Fxyd6 acts as a modulator of the Na+ K+ ATPase 
pump and to investigate the molecular association between FXYD6 and 
schizophrenia-associated neurochemical markers. The following aims were 
explored in this chapter:   
 Evaluation of the expression of Fxyd6 and Na+ K+ ATPase were investigated 
in the mouse brain using an in situ hybridisation technique. Mice 
homozygous for disrupted Fxyd6 were utilised to evaluate the impact of 
lack of Fxyd6 on and Na+ K+ ATPase α1 expression. 
 Characterisation of the relationship between FXYD6 and Na+ K+ ATPase 
pump was further explored by investigating the impact of the lack of 
Fxyd6 on Na+ K+ ATPase pump activity in brain regions associated with 
schizophrenia. 
 The impact of the lack of Fxyd6 on glutamatergic and GABAergic pathways 
were investigated to explore whether neurochemical changes associated 
with schizophrenia are present in Fxyd6-/- mice. 
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4.3 Results 
4.3.1 Expression of Fxyd6 in the mouse brain 
Hybridisation of a 33P- labelled probe designed to target Fxyd6 mRNA confirmed 
the expression of Fxyd6 in 20 µm coronal adult mouse brain sections. Non-
specific binding was determined using excess of 50x unlabelled probe (refer to 
2.9.1) and was deducted from total binding to calculate the specific binding. 
Qualitative assessment of specific binding revealed Fxyd6 has higher levels of 
expression in the following brain regions: secondary motor cortex, agranular 
insular cortex and prelimbic (PrL) area of the prefrontal cortex, cingulate cortex 
(Cg), claustrum (Cl), perirhinal cortex (PRh), dentate gyrus and the CA3 region 
of the hippocampus and cerebellar lobules of the cerebellum (Figure 4.1).  
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Nonspecific                      Total                   Reference    
 
Figure 4.1 Autoradiographic film showing Fxyd6 distribution in 20 µm coronal mouse brain 
sections, as detected by in situ hybridisation.   
Qualitative assessment revealed Fxyd6 is expressed in a) the secondary motor cortex (M2) 
and the agranular insular (AI) cortex in the prefrontal cortex (bregma 2.10 mm) b) cingulate 
cortex (Cg) and claustrum (Cl) (bregma 1.18 mm) c) perirhinal cortex (PRh) (bregma -1.22 
mm) d) posterior hypothalamic area (PH) dentate gyrus in the hippocampus (DG) (bregma -
1.82), e) CA3 region of the hippocampus (bregma -2.92 mm) f) cerebellar lobules of the 
cerebellum (bregma -6.00). Non-specific binding= 50x excess of unlabelled probe to indicate 
non-specific binding, total binding= antisense probe only, reference= brain regions according 
to the Allen Mouse Brain Atlas (Lein et al., 2006). Scale bar = 2mm. Arrows indicate relevant 
brain region. 
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4.3.2 Fxyd6 total RNA and protein is significantly reduced in mice 
homozygous for Fxyd6 disruption 
To investigate the potential functional link between FXYD6 and schizophrenia, a 
novel strain of mouse containing two disrupted copies of Fxyd6 was obtained 
from Lexicon Pharmaceuticals Incorporated (refer to 2.3.1).  Prior to molecular 
characterisation of these mice, validation of disruption of Fxyd6 total RNA and 
protein was required.  Quantitative real-time polymerase chain reaction (RTq-
PCR) (refer to 2.7), in situ hybridisation (refer to 2.9) and western blotting 
techniques (refer to 2.6) were employed to confirm that homozygous disruption 
of Fxyd6 in mice results in lack of Fxyd6 total RNA and protein. 500 ng of total 
RNA was extracted from the frontal cortex and converted to cDNA from 3 adult 
mice homozygous for functioning Fxyd6 (referred to as Fxyd6+/+ mice) and 3 age-
matched littermate mice homozygous for disrupted Fxyd6 (referred to as Fxyd6-
/- mice) were studied. RTq-PCR primers were designed to target Fxyd6 at two 
sites in the gene (refer to 2.8.1). Fxyd6 m1 is designed to span the targeting 
vector insertion point across exon 1 and exon 2, and Fxyd6 g1 is designed to 
detect splice variants by targeting exon 3 and 4 (Fxyd6 g1). Using a geometric 
mean from three housekeeping genes (18s ribosomal RNA, B2M and GAPDH) 
analysis of cycle threshold values (CT values) revealed Fxyd6 m1 expression in 
Fxyd6-/- mice is significantly reduced by a ratio of 0.001 (standard error of 0.000 
- 0.003, p<0.001) and Fxyd6 g1 significantly reduced by a ratio of 0.001 
(standard error 0.001- 0.00, p<0.001) in comparison to Fxyd6+/+ mice, a ratio of 1 
shows no effect, thus confirming null expression of Fxyd6 RNA following Fxyd6 
disruption (Figure 4.2). The in situ hybridisation probe used in section 4.3.1 
confirmed Fxyd6 homozygous disruption results in null expression of Fxyd6 RNA 
in the adult brain (Figure 4.3a-d), as observed in the following brain regions; 
prelimbic cortex, agranular insular cortex, cingulate cortex, claustrum, medial 
orbital cortex, primary and secondary motor cortex, striatum, nucleus 
accumbens, CA1, CA2, CA3 and dentate gyrus of the hippocampus and 
cerebellum. White matter in the cerebellum was used to normalise results 
(Genotype (F1, 95 = 31.89, p<0.001). 
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To confirm that FXYD6 protein is disrupted in parallel with Fxyd6 RNA reduction, 
western blotting analysis was utilised to establish Fxyd6-/- mice also lack FXYD6 
protein (refer to 2.6). An antibody designed to target FXYD6 protein specifically 
produced a band of the correct size (15 kDa) in Fxyd6+/+ mice. This band was 
absent in Fxyd6-/- mice, indicating null expression of FXYD6 protein (Figure 
4.5e). 
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Figure 4.2 Fxyd6 cDNA relative expression is significantly reduced in Fxyd6-/- mice.  
Cycle threshold (CT) values for a) Fxyd6 g1 and b) Fxyd6 m1 are significantly reduced in 
Fxyd6-/- mice in comparison to Fxyd6+/+ mice (p< 0.001). Data represent expression ratio ± 
S.E.M. relative to Fxyd6+/+ mice samples. Fxyd6+/+ mice n=3, Fxyd6-/- mice n=3
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Figure 4.3 Fxyd6-/- mice display disrupted Fxyd6 RNA and protein expression.  
In situ hybridisation in 20 µm sections  reveals Fxyd6-/- mice have significantly lower Fxyd6 
RNA expression, in comparison to Fxyd6+/+ mice,  a) prelimbic cortex (F1,7 = 15.47, 
p=0.008), b) motor cortex (F1,7 = 16.37, p=0.007), c) perirhinal cortex (F1,7 = 16.96, 
p<0.006) d) dentate gyrus (F1,7 = 14.54, p<0.009). Data represented as expression ratio of 
Fxyd6+/+ mice ± S.E.M  
e) Western blotting confirms the disruption of Fxyd6, in Fxyd6-/- mice, results in the lack of 
FXYD6 protein expression, in comparison to Fxyd6+/+ mice. Lack of protein observed in 16 µg 
protein prefrontal cortex, striatum, hippocampus, cerebellum and brain stem samples. 
Fxyd6+/+ mice n=3, Fxyd6-/- mice n=3 
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4.3.3 Fxyd6 null expression increases Pvalb but not Map2k7 and 
GRIN1 RNA expression 
To investigate if the disruption of Fxyd6 impacts on the expression of Pvalb and 
also schizophrenia-associated gene Map2k7 and the NMDA receptor gene GRIN1, 
RTqPCR (using probes designed to target these genes) was performed 
simultaneously with Fxyd6 m1 and Fxyd6 g1 probes (refer to 4.3.2).  Using a 
geometric mean from three housekeeping genes (18s ribosomal RNA, B2M and 
GAPDH) analysis of cycle threshold values (CT values) revealed Pvalb expression 
in Fxyd6-/- mice is significantly increased by a ratio of 2.987 (standard error 
1.431 – 5.598, p<0.05) in comparison to Fxyd6+/+ mice (Figure 4.4). Since a ratio 
of 1 shows no effect, thus revealing an interaction between Fxyd6 and Pvalb. 
Analysis of CT values also revealed Map2k7 and Grin1 expression in Fxyd6
-/- mice 
does not significantly deviate from Fxyd6+/+ mice (Map2k7 expression ratio = 
0.901, standard error ranging 0.681- 1.146, Grin1 expression ratio= 0.541, 
standard error ranging 0.184 – 1.111) (Figure 4.4).  
4.3.4 Fxyd6 null expression does not impact on GLUR2, NR2A and 
GAD 65/67 protein expression 
The involvement of FXYD6 in the glutamatergic and GABAergic hypothesis of 
schizophrenia was explored further by western blotting technique. Antibodies 
designed to target glutamatergic receptor subunit proteins; AMPA receptor 
subunit GLUR1 and the NMDA receptor subunit NR2A together with the GABA 
synthesising enzyme glutamate decarboxylase 65/ 67, produced bands of the 
correct size (GluR1 102 kDa, NR2A 170 kDa, GAD 65/67 produced a doublet band 
at 65 kDa and 67 kDa) in both Fxyd6+/+ mice and Fxyd6-/- mice. Disruption of 
Fxyd6 did not have an impact on expression on any of the proteins investigated 
(Figure 4.5). 
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Figure 4.4 Pvalb RNA relative expression is significantly increased in Fxyd6-/- mice.  
The disruption 
n of Fxyd6 in Fxyd6-/- mice, in comparison to Fxyd6+/+ mice a) does not alter Grin1 
expression or b) Map2k7 expression however c) significantly increases Pvalb expression  
(***p< 0.001), data represent CT values as a ratio of Fxyd6
+/+ mouse expression. Fxyd6+/+ 
mice n=3, Fxyd6-/- mice n=3 
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Figure 4.5 Western blotting analysis reveals Fxyd6 disruption in Fxyd6-/- mice does not 
impact on the expression of  
a) GLUR2 (F(1,8) = 0.15), p>0.05.   
b) NR2A (F(1,8) = 0.15), p>0.05.  
c) GAD 65/67. (F(1,8) = 3.76), p>0.05. Data represent mean ± S.E.M. Data analysed using 
Student’s t-test. N=4  
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4.3.5 Impact of Fxyd6 null expression on Na+ K+ ATPase activity in 
the forebrain and hippocampus  
The Na+ K+ ATPase activity in adult mice homozygous for Fxyd6 deletion was 
investigated in 16 µg forebrain and hippocampus plasma membrane using an 
assay optimised to detect Na+ K+ ATPase pump activity via phosphate release 
(refer to 2.5). Crude plasma membrane extraction by sucrose fractionation was 
confirmed using 3 different antibodies by western blot (Figure 4.8a). NR2A 
antibody produces a band of the correct size of 170 kDa and shows highest 
expression in the fraction taken as crude plasma membrane fraction, confirming 
the fraction contains the plasma membrane (Figure 4.8a). H3 antibody is used as 
an indicator of nuclear fractions, and produces a band of the size at 17 kDa in 
fractions pellet2 and supernatant (Figure 4.8a).  FXYD6 and Na+ K+ ATPase α1 
subunit antibodies both show highest expression in the crude plasma membrane 
fraction (Figure 4.8a). In comparison to Fxyd6+/+ mice, Na+ K+ ATPase activity 
was significantly decreased in the forebrain of the Fxyd6-/- mice (F(1,12)= 7.90, p= 
0.017, Figure 4.8b). However, despite a trend towards decreased Na+ K+ ATPase 
activity in the hippocampus, the decrease in activity was not found to be 
significant (F(1,14= 2.61, p= 0.130 Figure 4.8c). Following the finding that Fxyd6 
disruption results in a significant decrease of Na+ K+ ATPase activity, protein 
expression of adult mouse Na+ K+ ATPase α1 subunit was subsequently examined 
in forebrain homogenates. Western blotting results revealed protein expression 
of Na+ K+ ATPase α subunit does not alter with the deletion of Fxyd6 (F(1,9= 2.61, 
p= 0.130 Figure 4.8d, Figure 4.8e). 
 
The impact of lack of Fxyd6 on Na+ K+ ATPase expression was further explored 
using in situ hybridisation technique with a probe designed to target Na+ K+ 
ATPase α1 subunit (refer to 2.9). Quantitative analysis of autoradiogram films 
revealed Na+ K+ ATPase α1 subunit expression is not changed in the following 
brain regions in Fxyd6-/- compared to Fxyd6+/+ mice : prelimbic cortex, medial 
orbital cortex, primary and secondary motor cortex, striatum, nucleus 
accumbens, CA1, CA2, CA3 and dentate gyrus of the hippocampus and 
cerebellum (genotype interaction (F1,82 = 0.09, p> 0.05, (representative 
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autoradiographic films (Figure 4.9), there was also no affect of genotype on 
specific regions (F11,82 = 0.29, p> 0.05).  
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Figure 4.6 Confirmation of Na+ K+ ATPase expression in the plasma membrane and impact  of 
Fxyd6 disruption on Na+ K+ ATPase pump activity and protein  
a) Expression of NR2A confirms the fraction in which FXYD6 and Na+ K+ ATPase are expressed 
in is the plasma membrane (PM), marker histone H3 (H3) confirms pellet 2 (P2) and 
supernatant (SN) contain nuclear components P1= pellet 1 (refer to 2.5.1).  
b) Forebrain Na+ K+ ATPase activity is significantly decreased following the disruption of 
Fxyd6 in Fxyd6-/-  mice compared to Fxyd6
+/+ mice  F(1,12)= 7.90,  * p= 0.017 
c) Hippocampal Na+ K+ ATPase activity in Fxyd6-/- mice does not significantly deviate from 
Fxyd6+/+ mice  F(1,14)=2.61, p=0.130. 
d) Na+ K+ ATPase α1 subunit protein expression is not affected by Fxyd6 disruption in Fxyd6-/- 
mice, compared to Fxyd6+/+ mice. Data are expressed as mean ± S.E.M nMol Pi/min/mg 
protein.  
e) Representative western blot images showing Na+ K+ ATPase α1 subunit protein expression 
is not affected by Fxyd6 disruption in Fxyd6-/- mice, compared to Fxyd6+/+ mice.. Data 
analysed using Student’s t-test.  
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Figure 4.7 Representative autoradiographic film and expression levels of Na+ K
+ ATPase. 
Arrows indicate relevant brain region. Levels do not differ between Fxyd6+/+ (n=3) and 
Fxyd6-/- mice (n=4) in: 
a) The prelimbic cortex (F1,6=0.29, p>0.05)  
b) The CA1 region of the hippocampus (F1,6=0.08, p>0.05) 
c) The CA2 region of the hippocampus (F1,6=0.03, p>0.05) 
d) The dentate gyrus (F1,6=0.03, p>0.05)   
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4.4 Discussion 
 
4.4.1 Fxyd6 mRNA brain expression  
In this present work, I have confirmed Fxyd6 mRNA is expressed in various 
regions of the mouse brain. Two regions which are of particular interest that 
show strong Fxyd6 expression are the prefrontal cortex and the hippocampus. 
These two regions have been repeatedly associated with the symptoms of 
schizophrenia (refer to 4.3.1) and are therefore of significance in mouse models 
of this disorder. Decreased functioning and metabolism in the prefrontal cortex 
(hypofrontality) has been associated with schizophrenia symptoms, furthermore, 
impaired cognitive tasks such as decision making are also attributed to the 
altered functioning of this region. Impairments in the functioning of the 
hippocampus have also been associated with deficits in spatial learning, and 
connectivity networks between the prefrontal cortex and the hippocampus are 
thought to be responsible for many areas of cognition and memory consolidation, 
in particular working memory (Laroche et al., 2000;Yoon et al., 2008). Although 
Fxyd6 mRNA is strongly expressed in these regions, qualitative western blot 
analysis of FXYD6 protein expression would be required to investigate whether 
there is also a potential functional role of FXYD6 in these regions and associated 
pathways. If FXYD6 showed expression in these regions, it would suggest Fxyd6-/- 
mice may exhibit impairments in cognition and related phenotypes. 
4.4.2 Fxyd6 DNA and protein is significantly reduced in mice 
homozygous for Fxyd6 disruption 
In order to further characterise Fxyd6 and evaluate the impact of Fxyd6 in the 
modulation of Na+ K+ ATPase pump activity modulation I utilised a mouse  
homozygous for the disruption of Fxyd6 (Fxyd6-/- mice) (Lexicon Pharmaceuticals 
Incorporated., 2007). In these mice I also investigated the role of FXYD6 in 
pathways associated with schizophrenia, such as the GABAergic and 
glutamatergic pathways.  Fxyd6-/- mice were created via the insertion of a 
trapping cassette upstream of exon1 in Fxyd6 (Lexicon Pharmaceuticals 
Incorporated., 2007). To confirm that insertion of the cassette results in the full 
disruption of Fxyd6 and FXYD6 protein transcripts, two RTqPCR primers were 
designed to target Fxyd6 across exon 1 and 2 and exon 3 and 4. This ensures that 
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if alternative splicing has occurred following the insertion of the trapping vector 
upstream of exon1, short transcripts expressing exons 1 and 2 and longer 
transcripts also expressing exons 3 and 4, will be detected. Fxyd6 expression 
levels were quantified using cDNA converted from Fxyd6-/- mouse- derived RNA. 
Results revealed significant disruption of both splice variants of Fxyd6 in Fxyd6-/- 
mice in comparison to Fxyd6+/+ mice. To ensure results are truly representative 
of physiological RNA expression, a geometric mean of 3 housekeeping genes was 
used as reference to normalise samples. This method is better than using only 
one housekeeping gene as it reduces the risk of genotype-related changes in 
expression of any individual housekeeping gene.   
Fxyd6 expression in Fxyd6-/- mice was examined further using in situ 
hybridisation. Dramatically reduced expression of Fxyd6 was apparent 
throughout the brain. Despite these results in conjunction with RTqPCR results 
clearly indicating Fxyd6 RNA has been reduced in Fxyd6-/- mice, and therefore 
suggesting protein expression will also be disrupted, it is still important to 
evaluate FXYD6 protein expression in the mice, to exclude residual alternative 
splicing, or remaining low levels of RNA transcripts. I have shown that FXYD6 
protein was also knocked out in the mice using western blotting. These results 
confirm Fxyd6-/- mice are suitable to be used as a tool for investigating the 
molecular properties of FXYD6. 
4.4.3 Fxyd6 null expression increases Pvalb but not Map2k7 and 
GRIN1 RNA expression 
In situ hybridisation interestingly revealed an up-regulation of Pvalb expression 
in the frontal cortex of Fxyd6-/- mice in comparison to Fxyd6+/+ mice. Pvalb is a 
marker of a subtype of GABAergic interneurons and reduced parvalbumin-
expressing interneuron density has been previously associated with schizophrenia 
(Kinney et al., 2006;Abekawa et al., 2007);(Korotkova et al., 2010). It would 
therefore be interesting to futher investigate whether the expression in Fxyd6-/- 
mice is due to reduced Pvalb expression in neurons, or a reduction in the 
number of neurons expressing Pvalb. Although this is an interesting avenue to 
explore,  further confirmation of altered parvalbumin expression in these mice is 
required, such as increased sample numbers (n = 3 in this study) and a 
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confirmation of  a functional association between FXYD6 and parvalbumin 
proteins in Fxyd6-/- mice would also be needed. 
Reduced expression of MAP2K7 has recently been reported in post-mortem 
prefrontal cortex brain samples from schizophrenic patients (Winchester et al., 
2012). However change in expression was not observed in Fxyd6-/- mice, 
suggesting there is no interaction between these two genes. Glutamate 
dysfunction is also associated with the pathophysiology of schizophrenia and 
glutamate transport has also been linked to the Na+ K
+ ATPase pump (Nanitsos et 
al., 2004;Nanitsos et al., 2005), and so the role of FXYD6 in this circuitry was 
explored by investigating RNA expression of Grin1, a NMDA glutamate receptor 
subunit reported to be involved in memory and learning (Bannerman., 2008), 
however this was also not affected by Fxyd6 disruption, which may be due to 
small n numbers (n=3).  
4.4.4 FXYD6 disruption does not impact on GLUR2, NR2A and GAD 
65/67 protein expression 
As previously mentioned (refer to 4.4.3), parvalbumin and GABAergic 
neurotransmission is reduced in schizophrenia. In addition, the activity of 
glutamic-acid-decarboxylase (GAD), an enzyme which differentially contributes 
to GABA synthesis, is also dysregulated (Dracheva et al., 2004;Addington et al., 
2004). GAD 65/67 protein expression was investigated in Fxyd6-/- mice, using the 
western blotting technique, to further investigate an interaction between FXYD6 
and GABAergic neurotransmission. However Fxyd6 disruption does not have a 
significant impact on expression in Fxyd6-/- mice.  
Glutamate dysfunction in Fxyd6-/- mice was further explored by investigating 
NR2A and AMPA subunit expressions. The role NMDA glutamate receptor subunit 
NR2A (GluN2A) in the PFC in schizophrenia is not well characterised, however 
decreased expression of NR2A in parvalbumin neurons has been observed in the 
PFC of schizophrenia brains (Bitanihirwe et al., 2009). The key AMPA subunit, 
GLUR2 (GluA2), also has altered expression in schizophrenia brains (Eastwood et 
al., 1995;Eastwood et al., 1997), however both of these receptor subunits do not 
have altered protein expression in Fxyd6-/- mice compared to Fxyd6+/+ mice, 
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suggesting the disruption of Fxyd6 does not impact on these subunits in the 
glutamatergic  system. 
4.4.5 FXYD6 modulates Na+ K+ ATPase pump activity in the 
forebrain 
To investigate whether FXYD6 plays a modulatory role of Na+ K+ ATPase activity, 
plasma membrane was extracted from the frontal cortex and hippocampus of 
mice using a sucrose fractionation method. The fraction containing plasma 
membrane was confirmed using antibodies targeting NR2A and Na+ K+ ATPase α1 
as both are present in the plasma membrane of mammalian cells. 
The Na+ K+ ATPase-specific inhibitor ouabain was used as a means of detecting 
Na+ K+ ATPase specific activity in plasma membrane. The results revealed a 
decrease in activity in the forebrain of Fxyd6-/- mice. This is the first time that 
FXYD6 has been shown to be a modulator of brain Na+ K+ ATPase activity. A non-
significant trend towards decreased Na+ K+ ATPase activity was observed in the 
hippocampus, an increase in n number may be required to reach statistical 
power. Despite the altered activity of forebrain Na+ K+ ATPase pump activity, Na+ 
K+ ATPase α1 RNA and protein expression were not affected by Fxyd6 
homozygous disruption. The mechanism behind how FXYD6 modulates the Na+ K+ 
ATPase pump activity is unclear however it has been suggested that the FXYD 
proteins are non-essential modulators of the α/β complex of the Na+ K
+ ATPase 
pump and act to regulate the kinetics of the pump in a tissue-specific manner 
(refer to 1.12.2). To further investigate the interaction and modulation of the 
Na+ K+ ATPase pump, it would be interesting to use immunocytochemistry 
technique using antibodies targeted to the relevant proteins to investigate the 
cellular expression of these proteins in relation to each other. 
Immunoprecipitation would also be a good technique to employ to investigate 
interactions between these proteins. These methods would allow further insight 
in to whether the Na+ K+ ATPase pump and FXYD6 proteins interact by directly 
associating with one another.  
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4.5 Conclusion 
This chapter has provided an insight in the molecular profile of FXYD6. Fxyd6-/- 
mice have been validated as having Fxyd6 DNA, RNA and protein disruption and 
utilised as a tool to elucidate information on the molecular functioning of 
FXYD6. 
Fxyd6 was shown to be expressed in a number of regions of the brain including 
the forebrain and hippocampus, two regions of interest in schizophrenia. 
Furthermore, although the disruption of Fxyd6 does not appear to have an 
impact on glutamatergic receptor expression, Pvalb was found to have increased 
expression in Fxyd6-/- mice, this suggests a potential interaction between FXYD6 
and GABAergic neuronal activity however this area requires further evidence to 
confirm an interaction exists.  
We have confirmed FXYD6 modulates brain Na+ K
+ ATPase activity in the frontal 
cortex, whilst the interaction between FXYD6 and Na+ K+ ATPase does not 
manifest through alteration of protein expression; further experiments could be 
conducted to elucidate the means of interaction between FXYD6 and Na+ K+ 
ATPase. 
Due to the expression of Fxyd6 in the prefrontal cortex, the impairment of Fxyd6 
in Fxyd6-/- mice could have the potential to disrupt memory and learning. The 
phenotype of these mice would therefore be an interesting area to investigate. 
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Chapter 5. Phenotype of mice containing 
disrupted Fxyd6 and similarities to cognitive 
symptoms of schizophrenia. 
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5.1 Introduction 
The molecular characterisation of FXYD6 (refer to Chapter 4) provides novel 
evidence which further supports a role of FXYD6 in schizophrenia and similar 
disorders associated with impaired cognition. Fxyd6 was shown to be expressed 
in the prefrontal cortex and hippocampus, two brain regions highly implicated in 
schizophrenia. The targeted disruption of a gene in an animal model provides an 
excellent tool to research the role of a desired gene in disease pathology, 
however molecular and behavioural characterisation are both required to 
validate the model as being representative of a disorder. 
The expression pattern of Fxyd6 in the brain (refer to 4.3.1) indicates it may be 
involved in cognition and memory. The prefrontal cortex plays a major role in 
working and executive memory. Dysfunction in associated circuitry are thought 
to underlie many of the cognitive symptoms of schizophrenia such as deficits in 
working and executive memory, task switching and decision making (Kim et al., 
2009;Heerey et al., 2008). Clinical, neuropsychological and neuroimaging studies 
have all implicated dysfunction of the prefrontal cortex in the pathology of 
schizophrenia (Chai et al., 2011;Pomarol-Clotet et al., 2010). The hippocampus 
is also a key structure implicated in the symptoms of schizophrenia. It is 
responsible for memory and spatial learning (Gaffan., 1985;Olton and Paras., 
1979). Furthermore, connectivity networks between the prefrontal cortex and 
the hippocampus are thought to be responsible for many areas of cognition and 
memory consolidation, in particular working memory (Laroche et al., 2000;Yoon 
et al., 2008). The presence of Fxyd6 in these brain regions alone make this an 
interesting mouse model to investigate as a model of schizophrenia. However 
the potential interaction of Fxyd6 in GABAergic neuronal activity (refer to 
4.4.3), as observed by increased Pvalb expression in Fxyd6-/- mice , further 
suggests Fxyd6-/- mice may exhibit a phenotype analogous to symptoms observed 
in schizophrenia.  
Currently not much information is known on the role of Na+ K+ ATPase activity in 
behaviour. Mice homozygous for the genetic disruption of Na+ K+ ATPase subunits 
α1, α2, or α3 are all embryonically lethal, however heterozygous disruption of 
each subunit results in altered locomotor activity in response to amphetamine, 
impaired memory and spatial learning, and increased anxiety (Moseley et al., 
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2007). Furthermore, it has been suggested Na+ K+ ATPase is required for memory 
consolidation (Wyse et al., 2004;Sato et al., 2004). Fxyd6-/- mice exhibit 
decreased Na+ K+ ATPase activity in the prefrontal cortex (refer to 4.3.5) and 
may therefore have deficits in memory, locomotor and/or increased anxiety as a 
result of Na+ K+ ATPase dysfunction. 
5.2 Hypothesis and aim 
FXYD6 has been shown to be expressed in brain regions associated with working 
and executive memory, and consolidation of memory; therefore the targeted 
disruption of Fxyd6 may result in cognitive deficits, a symptom associated with 
schizophrenia. The targeted genetic disruption of Fxyd6 may reveal further 
association with symptoms of schizophrenia as the disruption Na+ K+ ATPase α 
subunit has been shown to induce deficits in locomotor activity and increase 
anxiety-like behaviours. The genetic disruption of Fxyd6 results in decreased Na+ 
K+ ATPase activity and Fxyd6-/- mice may therefore show similar phenotypes.  
The aim of this chapter is to provide a phenotypic characterisation of mice 
homozygous for disrupted Fxyd6 (Fxyd6-/- mice), in order to elucidate the in vivo 
role of Fxyd6 and determine if Fxyd6-/- mice represent a rodent model of 
schizophrenia-related behaviours. The strain’s basic phenotype is investigated 
using a battery of assessments, followed by more challenging behavioural tests 
designed to investigate specific traits such as anxiety, locomotor activity, 
sensorimotor gating and cognitive deficits. 
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5.3 Results 
5.3.1 Fxyd6-/- mice have a normal primary phenotype 
In comparison to Fxyd6+/+ mice (n= 10) the disruption of Fxyd6 in Fxyd6-/- mice 
(n=10) did not induce significant abnormalities in basic behaviours tested by the 
primary phenotype screen (Table.5.1) and motor coordination and balance, as 
tested by rotarod, both appeared unaffected by the disruption of Fxyd6 (Table 
5.1, refer to 2.10.2).     
5.3.2 Fxyd6-/- mice do not differ from Fxyd6+/+ in plus maze 
performance 
In order to investigate the impact of lack of Fxyd6 on anxiety related 
behaviours, Fxyd6-/- mouse performance in the elevated plus maze was analysed 
(refer to 2.10.3). In comparison to Fxyd6+/+ mice (n=10), Fxyd6-/- mice (n=10) did 
not reveal any significant changes in anxiety related behaviours, as detected by 
no significant differences in zone duration (F1,79=0.299), p>0.05), zone entry 
frequency (F1, 79= 0.228, p>0.05), distance travelled (F1,19=0.99, p>0.05) and 
mean velocity (F1,19=0.99, p>0.05,Table 5.2) n=10 per group. 
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Table.5.1 Summary of primary phenotype screen performed on mice homozygous for Fxyd6 
(Fxyd6+/+) and mice homozygous for Fxyd6 deletion (Fxyd6-/-).  
Fxyd6-/- mice do not significantly differ from Fxyd6+/+ mice in any parameters tested in the 
primary phenotype screen. Data are presented as mean ± SEM, n = 10. Data analysed by 
Student’s t-test.  
 
Location Phenotype Significance
Fxyd6+/+ Fxyd6-/-
In Arena Body position 1 ± 0 1 ± 0 p >0.05
Spontaneous activity 0 ± 0 0 ± 0 p >0.05
Tremor 0 ± 0 0 ± 0 p >0.05
Urination 0.4 0.6 p >0.05
Defecation 1.2 1 p >0.05
Bizarre behaviours 0 ± 0 0 ± 0 p >0.05
Convulsions 0 ± 0 0 ± 0 p >0.05
Palebral Closure 0 ± 0 0 ± 0 p >0.05
Piloerection 0 ± 0 0 ± 0 p >0.05
Gait 0 ± 0 0 ± 0 p >0.05
Pelvic elevation 1 ± 0 1 ± 0 p >0.05
Tail elevation 1 ± 0 1 ± 0 p >0.05
Pinna reflex 0 ± 0 0 ± 0 p >0.05
Restrained Cornea reflex 0 ± 0 0 ± 0 p >0.05
Provoked biting 0 ± 0 0.1 ± 0.1 p >0.05
Trunk curl 1 ± 0 1 ± 0 p >0.05
Visual placing 1 ± 0 1 ± 0 p >0.05
Hanging wire 1 55.0 ± 5 56.5 ± 3.5 p >0.05
Hanging wire 2 60.0 ± 0 51.5 ± 5.7 p >0.05
Hanging wire 3 60.0 ± 0 54.9 ± 5.1 p >0.05
Hanging wire average 58.3  ± 1.7 54.3 ± 4.4 p >0.05
Rotarod 1 85.9 ± 15.6 131.2 ± 19.9 p >0.05
Rotarod 2 130.7 ± 21.6 107.7 ± 14.1 p >0.05
Rotarod 3 155.6 ± 25.0 144.4 ± 18.2 p >0.05
Rotarod average 124.1 ± 16.8 127.8 ± 14.9 p >0.05
Genotype
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A
Zone Fxyd6+/+ Fxyd6-/- Significance
Centre 101.1 ± 9.4 93.6 ± 6.3 p =0.99, ns
Zone 1 166.7 ± 14.8 163.7 ±  10.9 p =0.99, ns
Zone 2 26.9 ± 7.7 32.2 ± 7.2 p =0.67, ns
Zone 3 4.9 ± 2.7 10.1 ± 4.5 p =0.89 ns
Duration
 
B
Zone Fxyd6+/+ Fxyd6-/- Significance
Centre 24.8 ± 2.0 25.7 ± 1.8 p =0.99, ns
Zone 1 19.4 ± 1.8 19.3 ± 2.0 p =1.00, ns
Zone 2 7.1 ± 1.8 10.3 ± 1.3 p =0.99, ns
Zone 3 0.8 ± 0.4 2.5 ± 0.9 p =0.84, ns
Frequency
 
C
Parameter Fxyd6+/+ Fxyd6-/- Significance
Distance travelled (cm) 1218.2 ± 57.0 1297.6 ± 45.7 p =0.28, ns
Mean velocity (cm/s) 4.1 ± 0.2 4.3 ± 0.2 p =0.28, ns  
 
Table 5.2 Fxyd6-/- mice do not display abnormal anxiety-related behaviours in the elevated 
plus maze, in comparison to Fxyd6+/+ mice.  
Performance in the elevated plus maze did not differ between Fxyd6+/+ and Fxyd6-/- mice in 
the following parameters  
a) duration (seconds) (F1,79=0.299, p> 0.05) 
 b) frequency of entering zones in the EPM (F1, 79=0.228, p> 0.05 and  
c) Distance travelled (T=0.99, p> 0.05) and mean velocity (T=0.99, p> 0.05)  travelled in all 
zones.  Zone 1= closed arm total, zone 2= 2/3rds open arm, zone 3= 1/3rd open arm (refer to 
2.10.4) Data are presented as mean ± SEM. N=10 per group. Duration and frequency 
analysed using ANOVA followed by Tukey’s post hoc test for multiple comparisons. Distance 
and mean velocity analysed by Student’s t-test.  
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5.3.3 Fxyd6-/- mouse performance in open field with 
pharmacological challenges 
Anxiety-like behaviours in Fxyd6-/- mice were further evaluated using the open 
field behavioural test (refer to 2.10.42.10.5). During analysis of data, the open 
field arena was split into three zones, inner, thigmotaxis and outer (refer to 
2.10.4). In addition, normal functioning of the mesolimbic dopamine pathway 
was investigated by assessing hyperlocomotor activity following administration 
of amphetamine and similarly assessing ability of NMDA neurotransmission 
following the administration of ketamine.   
Amphetamine challenge 
Fxyd6-/- mice did not differ from Fxyd6+/+ mice in the duration of time spent in 
individual zones, and did not show altered sensitivity to amphetamine in 
hyperlocomotor activity, as described below: 
Genotype did not significantly affect the duration of time spent in zones 
(F1,119=0.01, p>0.05) and there was no overall interaction between treatment 
and genotype (F1,119=0.07, p>0.05) (Figure 5.1a).  Administration of 3 mg/kg 
amphetamine had a significant overall interaction with zone (F2,119= 17.63, 
p<0.001). Tukey’s post hoc analysis reveals that amphetamine treated mice 
spend significantly less time in the centre duration compared to mice 
administered saline (p<0.001) and more time in the outer zone (p<0.001). Time 
spent in the thigmotaxis zone does not significantly differ in response to 
amphetamine (p>0.05). n= 10 per group (Figure 5.1a).   
Fxyd6-/- mice do not significantly differ from Fxyd6+/+ mice in velocity 
(F1,479=306, p=0.08). Administration of 3 mg/kg amphetamine significantly 
increases velocity in both genotypes (F1,39=4126, p<0.001), however there is no 
significant interaction between amphetamine and genotype (F1,39=1.59, p>0.05, 
Figure 5.1b).  
Total distance travelled during the testing stage is not affected by genotype 
(F1,39=0.32, p>0.05), however overall amphetamine significantly increases 
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distance travelled (F1,39=43.68, p<0.001) but does not have a significant 
interaction with genotype (F1,39=0.17, p>0.05) Figure 5.2. n= 10 per group.  
Ketamine challenge 
Fxyd6-/- mice did not differ from Fxyd6+/+ mice in the duration of time spent in 
individual zones, despite one group revealing a higher baseline velocity (Fxyd6-/- 
mice prior to receiving 10 mg/kg ketamine in comparison to Fxyd6+/+ mice) no 
significant differences were observed following ketamine treatment, as 
described below: 
Administration of treatment (saline, 10 mg/kg ketamine or 25 mg/kg ketamine) 
does not have an overall significant effect on duration in zones in the open field 
(F2,152= 0.84, p>0.05, Figure 5.3a). There was not an overall effect of genotype 
on duration spent in zones (F1,152=0.14, p>0.05) or interaction between drug and 
genotype (F1,152=0.07, p>0.05). Duration spent in zones significantly differed 
from one another (F2,152=191.20, p<0.001) n= 10 per group.  
Mean velocity of movement of Fxyd6+/+ and Fxyd6-/- mice was analysed during 
the habituation period and following ketamine administration. During the 
habituation period, treatment (saline, ketamine 10mg/kg and 25 mg/kg) did not 
influence velocity (F2,305=0.24, p>0.05), however genotype did have a significant 
effect (F1,305=10.23, p=0.002). Tukey’s post hoc analysis revealed Fxyd6
-/- mice 
in treatment group 10 mg/kg ketamine have a higher basal velocity, prior to 
receiving treatment, compared to Fxyd6+/+ mice (p=0.02), this is not observed 
between any of the other groups (p>0.05).  During the test stage, treatment 
does not have a significant effect on velocity over the 60 minute period 
(F2,566=0.20, p>0.05) however during the 10 minutes succeeding treatment 
administration (time point 35-45 minutes) treatment has an overall significant 
impact (F2,140=26.33, p<0.001), this effect does not differ between Fxyd6
-/- mice 
Fxyd6+/+ mice (F2,140=2.27, p>0.05) (Figure 5.3b). Tukey’s post hoc analysis 
demonstrates 10 mg/kg ketamine and 25 mg/kg both induce an overall 
significant effect in comparison to saline (10 mg/kg p=0.03, 25 mg/kg p<0.001). 
Fxyd6+/+ n=10, Fxyd6-/- n=7. 
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Figure 5.1 Fxyd6-/- mice do not exhibit altered locomotor activity responses to amphetamine 
in comparison to Fxyd6+/+ mice in the open field test. 
a) Analysis of duration spent in centre, inner and outer zones of the open field arena reveal 
Fxyd6-/- mice do not significantly differ from Fxyd6+/+ mice, suggesting the homozygous 
disruption of Fxyd6 does not impact on anxiety-related behaviours (F1,119=1.08, p>0.05). 
Administration of 3mg/kg of amphetamine (amp) overall significantly increases anxiety- 
related behaviours in Fxyd6+/+ and Fxyd6-/- mice, as observed by a decrease in time spent in 
the centre of the arena in both genotypes (F2,119= 17.63, p<0.001). In comparison to Fxyd6
+/+ 
mice, Fxyd6-/- mice do not show hypersensitivity to amphetamine challenge (F1,59= 0.04, 
p>0.05). *** p<0.001 overall amphetamine vs. saline affect on duration  
b) Mean velocity in Fxyd6+/+ mice and Fxyd6-/- are both increased following the 
administration of amphetamine (amp) after a 30 minute habituation period (F1,479=4126, 
p<0.001), Fxyd6-/- mice do not differ from their Fxyd6+/+ littermates in their response to 
amphetamine (F1,479=306, p>0.05). n=10 per group. Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons. n=10 per group. Data analysed by ANOVA 
followed by Tukey’s post hoc test for multiple comparisons.  ↓ represents time of treatment 
administration 
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Figure 5.2 Fxyd6-/- mice do not show altered sensitivity to amphetamine in the open field 
test 
Analysis of distance travelled during the testing stage of open field did not reveal a 
significance difference between Fxyd6+/+ and Fxyd6-/- mice (F1,39=0.32, p>0.05) . 
Administration of 3mg/kg of amphetamine significantly increases the overall distance 
travelled (F1,39=43.68, p<0.001), the effect of amphetamine is not influenced by genotype 
(F1,39=0.17, p>0.05) Data analysed by ANOVA followed by Tukey’s post hoc test for multiple 
comparisons. ***p<0.001. 
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Figure 5.3 Fxyd6-/- do not reveal sensitivity to ketamine in the open field test. 
a) Analysis of duration spent in centre, inner and outer zones of the open field arena reveal 
Fxyd6-/- mice do not significantly differ from Fxyd6+/+ mice (F1,152=0.14, p>0.05). 
Administration of 10 mg/kg and 25 mg/kg ketamine (ket), using a cross-over treatment 
regime, does not significantly affect anxiety- like behaviours in both Fxyd6+/+ and Fxyd6-/- 
mice, as observed by no change in time spent in the arena zones (F2,152= 0.84, p>0.05).   
b) Velocity of Fxyd6+/+ and Fxyd6-/- mice were both significantly increased in response to 
ketamine over time points 35-45 minutes (F2,140=26.33, p<0.001) however there is not a 
drug x genotype interaction (F2,140=2.27, p>0.05). Key: * 10 mg/kg ketamine (ket 10) vs. 
saline p=0.03, # 25 mg/kg ketamine (ket 25) vs. saline p<0.001).   Fxyd6+/+ n=10, Fxyd6-/- 
n=7. Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons. ↓ 
represents time of treatment administration 
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5.3.4 Fxyd6-/- acoustic startle 
Prior to conducting PPI, acoustic startle was examined to ensure PPI results were 
not confounded by alterations in hearing (refer to 2.10.5). Startle responses 
from mice homozygous for Fxyd6 null expression did not significantly differ from 
mice homozygous for Fxyd6 expression (F1,143=0.08, p> 0.05, Figure 6.7) 
suggesting lack of Fxyd6 does not affect hearing. n=10 per group. 
5.3.5 Fxyd6-/- sensorimotor gating 
As predicted ketamine induced overall deficits in sensorimotor gating. Deficits in 
sensorimotor gating in Fxyd6-/- mice compared to Fxyd6+/+ mice are only 
apparent following administration of 10 mg/kg ketamine, but not saline or 25 
mg/kg ketamine, as described below (refer to 2.10.5): 
As expected, prepulse levels also had a significant impact on sensorimotor gating 
(F2,206=45.86, p<0.001). Overall PPI results reveal Fxyd6
-/- mice have significantly 
altered PPI compared to Fxyd6+/+ mice (F1,206=6.15, p=0.01). There is also an 
overall effect of treatment (saline, 10 mg/kg ketamine, 25 mg/kg ketamine) 
(F2,206=8.75, p<0.001) and a significant interaction between genotype and 
treatment (F2,206=4.94, p=0.01). The response to the size of prepulse is not 
affected by genotype (F2,206=0.22, p>0.05), or by treatment (F4,1.12, p>0.05). 
Tukey’s post hoc exposes Fxyd6-/- mice only reveal PPI deficits, in comparison to 
Fxyd6+/+ mice, following treatment with 10 mg/kg ketamine (p=0.03), but not 
saline (p>0.05) or 25 mg/kg ketamine (p>0.05). However, post hoc analysis 
revealed there is no deficits at individual prepulses; at prepulse 4, both 
genotype (F1,68=2.32, p>0.05) and treatment (F2,68=0.341) do not significantly 
impact on  PPI responses.  Similarly, at prepulse 8 both genotype (F1,68=0.78, 
p>0.05) and treatment (F2,68=2.04) also do alter PPI response. At prepulse 16, 
treatment significantly inhibits PPI overall (F1,68=6.54, p=0.003) but not genotype 
does not affect the response (F1,68=6.54, p>0.05).  n=10 per group.  
133 
 
 
    a 
 
Figure 5.4 Fxyd6-/- mice do not display hearing loss but do have prepulse inhibition deficits,   
compared to Fxyd6+/+ mice. 
a) Startle magnitude to auditory stimuli of 65 dB, 69 dB, 73 dB, 77 dB, 85 dB, 90 dB, 100 dB, 
110 dB, 120 dB intensities did not differ between Fxyd6+/+ mice and Fxyd6-/- mice (F1,143 = 
0.08, p> 0.05) suggesting disruption of Fxyd6 does not impact on hearing. n=10 per group. 
Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons.   
b) Effect of ketamine treatment (10 or 25 mg/kg) on PPI in Fxyd6-/- mice compared to 
Fxyd6+/+ mice. Prepulse inhibition of the startle response was overall significantly lowered in 
Fxyd6-/- mice compared to Fxyd6+/+ mice (F1,206=6.15, p=0.01) and 10 mg/kg ketamine had 
less effect on Fxyd6-/- mice overall (F1,206=6.15, p=0.01).  However, genotype and treatment 
individually did not have a significant effect at each prepulse level (p>0.05). n=10 per group. 
Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons.  Data 
shown as mean ±S.E.M. 
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5.3.6 Fxyd6-/- mouse sociability and social novelty.  
Fxyd6+/+ and Fxyd6-/- mice both demonstrated a strong preference for exploring 
the chamber containing a strange mouse, in comparison to the empty chamber 
(F2,29=48.36, p<0.001), demonstrating similar levels of mouse sociability (Figure 
5.5a). The disruption of Fxyd6 in Fxyd6-/- mice did not appear to have an impact 
on levels of sociability, as observed by no differences in the duration of time 
spent exploring the chamber containing a mouse, in comparison to Fxyd6+/+ mice 
(F1,29=0.00, p>0.05), and also there was no genotype*zone interaction 
(F2,29=0.12, p=0.884) (Figure 5.5a). Fxyd6
+/+ n=7, Fxyd6+/+ n=6. 
When a novel mouse was added to the arena in the social novelty aspect of this 
task (refer to 2.10.7), zones had a significant impact on duration (F2,29=22.95, 
p<0.001), Tukey’s post hoc analysis reveals only Fxyd6+/+ mice display 
significantly more time investigating the novel mouse compared to the now 
familiar mouse (Fxyd6+/+ p=0.003, Fxyd6-/- p<0.05) (Figure 5.5b). This suggests 
Fxyd6-/- mice may have deficits in social novelty. Time spent in each zone did 
not significantly differ between Fxyd6+/+ and Fxyd6-/- mice (p>0.05). Fxyd6+/+ 
n=7, Fxyd6+/+ n=6. 
5.3.7 Fxyd6-/- mouse sucrose preference 
A sucrose consumption test was performed as a measure of anhedonia in mice 
(refer to 2.10.8). Genotype did not have an overall impact on % of sucrose 
consumption over 5 days (F1,50=2.40, p>0.05), there was a significant effect of 
day (F4,50=3.31, p=0.02) however this was not affected by genotype (F4,50=0.23, 
p>0.05) (Figure 5.6). The average % sucrose consumed over the 5 day period was 
also not significantly affect by genotype (p>0.05). Fxyd6+/+ n=7, Fxyd6+/+ n=6. 
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Figure 5.5 Fxyd6-/- mice do not have sociability deficits however do not show social novelty.  
a) Fxyd6+/+ and Fxyd6-/- mice both displayed sociability, as observed by significantly more 
time spent interacting with the stranger side of the arena, compared to the empty side 
(F2,29=48.36, p<0.001). Genotype did not have an effect on levels of sociability (F1,29=0.00, 
p>0.05) ***p<0.001. Fxyd6+/+ n=7, Fxyd6-/- n=6. Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons.   
b) Only Fxyd6+/+  mice displayed significant sociability, as observed by significantly more 
time spent interacting with a novel mouse (stranger side), in comparison to the now familiar 
mouse (familiar side).= (Fxyd6+/+ mice p=0.003, Fxyd6-/- mice p>0.05). Fxyd6+/+ n=7, Fxyd6-/- 
n=6. Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons.  ** 
p<0.01 
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Figure 5.6 Fxyd6-/- mice also do not show deficits in a model to detect anhedonia.   
Genotype did not have an overall impact on % of sucrose consumption during single days and 
in total  over a 5 day period, suggesting that Fxyd6-/- mice do not suffer from anhedonia 
(F1,50=2.40, p>0.05), Fxyd6
+/+ n=7, Fxyd6-/- n=6. Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons.   
 
137 
 
 
5.3.8 Fxyd6-/- mouse performance in a delayed non-match to 
sample task 
Results from the delayed non-match to sample task revealed that Fxyd6-/- mice 
have difficulty with working memory following a 5 second delay, as shown by 
significantly fewer correct trials  (F1,12=10.44, p=0.008, Figure 5.7a), inter trial 
delays were kept constant. There were no significant differences at intra-trial 
delays of 15 seconds (p>0.05) and 30 seconds (F1,12=0.65, p>0.05). Fxyd6
+/+ and 
Fxyd6-/- mice do not differ in perseverative responding as measured by two or 
more consecutive incorrect trials (F1,12=2.31, p>0.05, Figure 5.7b)  or the % of 
overall trials correct (F1,12=3.17, p>0.05, Figure 5.7c). Fxyd6
+/+ n=7, Fxyd6-/- n=6. 
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Figure 5.7 Fxyd6-/- mice have deficits in working memory.  
 a) In comparison to Fxyd6+/+ mice, Fxyd6-/- mice have deficits in working memory when 
encountering a delay of 5 seconds (F1,12=10.44, p=0.008) but not 15 (p<0.05) and 30 seconds 
(F1,12=0.65, p=0.438). Fxyd6
+/+ n=7, Fxyd6-/- n=6. Data analysed by Student’s t-test with the 
exception of delay at 15 which was analysed by Mann-Whitney non-parametric test. **p<0.01  
b) Fxyd6-/- do not have significantly increased perseverative response in comparison to 
Fxyd6+/+ mice (F1,12=2.31, p>0.05). **p<0.01  
c) Overall % trials correct does not differ between Fxyd6+/+ and Fxyd6-/- mice. Fxyd6+/+ n=7, 
Fxyd6-/- n=6. Data analysed by Student’s t-test .  **p<0.01 
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5.4 Discussion 
The effect of the homozygous disruption of Fxyd6 on phenotype was investigated 
using a range of tests. These were no gross deficits however there is evidence 
for subtle phenotype alterations in particular tests.    
5.4.1 Primary phenotype screen 
The primary phenotype screen comprising of a battery of tests based on the 
SHIRPA screen (Rogers et al., 1997) was initially performed on Fxyd6-/- mice in 
order to detect manifestation of abnormal behaviours such as spontaneous 
activity, aggressiveness, neuromuscular abnormalities, convulsions general 
condition of coat and eye reflexes. For the full list of criteria refer to (refer to 
2.10.1). The screen is initiated by viewing undisturbed mouse behaviour in a 
clear observation arena. The screening is an imperative process that should be 
carried out as a first line of phenotyping for any novel mouse strain as such 
effects could impact on subsequent behaviours and confound interpretation of 
results in more specific tests. In this study, Fxyd6+/+ and Fxyd6-/- mice undergo 
various behavioural tests where results could be misinterpreted due to deficits in 
motor control or muscle fatigue, or tremors or convulsions. The primary 
phenotyping screen did not indicate abnormal behaviours in Fxyd6-/- mice in 
comparison to Fxyd6+/+ mice, and rotarod and grip strength aimed to detect poor 
motor performance, co-ordination and balance also did not differ between 
mouse genotypes. Therefore deficits in subsequent behavioural tests such as 
locomotor activity, social interaction and working memory are likely to be a true 
indication of a role for Fxyd6 in behaviour and cognition, rather than non-
specific confounds.  
5.4.2 Anxiety-related behaviours in Fxyd6-/- mice 
Mouse performance in the elevated plus maze was analysed in order to assess 
the effect of Fxyd6 disruption on anxiety-related behaviours. The elevated plus 
maze uses anxiety-related conflict that arises between the mouse’s natural 
preference for dark enclosed space, compared to the drive to explore a novel 
environment (Lister., 1987). Mice with high levels of anxiety will avoid the bright 
open arms of the maze. Fxyd6-/- mice did not show altered anxiety-related 
141 
 
 
behaviours when compared to Fxyd6+/+ mice during the 5 minutes allowed to 
explore the elevated plus maze.   
Anxiety levels in Fxyd6-/- mice were further explored, along with locomotor 
activity, using the open field test. In order to analyse anxiety-related behaviours 
in the open field arena further, the arena was split into 3 zones during data 
analysis. The ‘centre zone’ indicates the amount of time the mouse spends in 
the centre of the arena, indicating increased exploratory behaviour in the 
mouse, while the outer zone represents the time spent in the rest of the arena. 
The outer zone was further split to analyse thigmotaxis.  Similarly to the 
elevated plus maze, the open field test assesses anxiety arising from the 
mouse’s urge to explore the open centre of the arena, compared to the anxiety- 
induced preference to stay close to the wall (thigmotaxis). In accordance with 
the plus maze, Fxyd6-/- mice did not reveal an increased anxiety phenotype in 
the open field arena. Mice heterozygous for the deletion of the Na+ K+ ATPase 
α1-subunit also do not display increased anxiety-related behaviours (Moseley et 
al., 2007) Since molecular characterisation of Fxyd6+/+ mice revealed co-
localisation between FXYD6 protein and Na+ K+ ATPase α1-subunit (refer Chapter 
4), and functional studies link FXYD6 with the Na+ K+ ATPase subunit (Delprat et 
al., 2007a, Delprat et al., 2007b) this suggests that Na+ K+ ATPase modulation  in 
the PFC or hippocampus is a key factor controlling anxiety.  
The administration of 3mg/kg amphetamine significantly induced 
hyperlocomotion and as a result, distance travelled in both Fxyd6+/+ and Fxyd6-/- 
mice was also increased. In comparison to Fxyd6+/+ mice, Fxyd6-/- mice did not 
reveal any increased sensitivity to amphetamine. Amphetamine induced 
hyperlocomotion is an expected result and confirms the validity of the 
experiment (Ralph et al., 2001). Amphetamine increased anxiety levels in both 
genotypes; again the effect was not affected by genotype. Amphetamine-
induced hyperlocomotion are a result of increased dopamine in the synapse in 
the mesolimbic system (Costall et al., 1987;Pijnenburg et al., 1976). The 
increase in dopamine results in the increased activation of dopamine D1 and D2 
receptors, inducing hyperlocomotion (Sharp et al., 1987;Tenn et al., 
2003;Mansbach et al., 1988;Pijnenburg et al., 1975 refer to 1.6.1),  
Administration of amphetamine in rodents is used to model hyperlocomotor 
activity in order to represent some of the positive symptoms of schizophrenia 
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(refer to 1.3.1, Knable and Weinberger., 1997;Mansbach et al., 1988;Pijnenburg 
et al., 1976;Thornburg and Moore., 1973).  In mice containing genetic mutations 
or lesions, amphetamine administration can reveal dopamine dysfunction or 
subtle abnormalities in locomotor activity or anxiety which open field test alone 
may not show. Hence this evidence implies that Fxyd6-/- mice do not have 
abnormalities in dopamine network. To my knowledge there is no known 
involvement between FXYD proteins and the dopamine network function, 
however mice heterozygous for deletion of α isoforms of Na+ K+ ATPase show 
abnormally increased anxiety and locomotor activity in response to 
methamphetamine (Moseley et al., 2007).  
Potential dysfunction of glutamatergic circuitry was explored in Fxyd6-/- mice by 
administration of a low dose of ketamine (10 mg/kg) and a higher but sub-
anaesthetic dose (25 mg/kg) (Ralph et al., 2001;Imre et al., 2006;Kamiyama et 
al., 2011). Initial analysis of duration spent in zones and velocity of Fxyd6+/+ and 
Fxyd6-/- mice did not reveal any differences following administration of 10 
mg/kg ketamine and 25 mg/kg ketamine, however due to the short half-life of 
Ketamine (13 minutes, (McLean et al., 1996;Maxwell et al., 2006)) data were 
reanalysed for the first 10 minutes after ketamine administration only. Both 
doses of ketamine were then found to induce hyperlocomotion in both 
genotypes; however the effect was not genotype- dependent. Despite treatment 
order and genotype being pseudorandom and balanced amongst groups, one 
group (Fxyd6-/- mice receiving 10 mg/kg ketamine) displayed increased velocity 
baseline, in comparison to Fxyd6+/+ mice. However, in this study it is unlikely 
this is a physiological response derived from the genetic disruption of Fxyd6, as 
it was not displayed in the Fxyd6-/- mice subsequently treated with 25 mg/kg 
ketamine or amphetamine, or Fxyd6+/+ mice with treated 10 mg/kg ketamine, 
despite all groups being counterbalanced.  
5.4.3 Sensorimotor gating in Fxyd6-/- mice 
Prior to testing sensorimotor gating, hearing in Fxyd6-/- mice was tested to 
ensure the disruption of Fxyd6 does not affect hearing, as FXYD6 is expressed in 
the inner ear (Delprat et al., 2007a;Delprat et al., 2007b). Fxyd6-/- mice do not 
have altered hearing. However they have overall deficits in prepulse inhibition, 
indicating deficits in sensorimotor gating. Sensorimotor gating is a complex 
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process involving multiple interactions with multiple neurotransmitters including 
dopamine, serotonin and glutamate (Ojima et al., 2004;Quednow et al., 
2004;Egerton et al., 2008). Deficits in sensorimotor gating stems from problems 
in inhibition in the CNS and results in the inability to filter important sensory 
information from ‘noise’ and is associated with symptoms of schizophrenia. 
Deficits in PPI are often used as a rodent model of the sensorimotor gating 
deficits associated with schizophrenia (Geyer et al., 2001). Inhibition of Na+ K+ 
ATPase activity by ouabain has been associated with inhibition of dopamine and 
serotonin uptake (Steffens M and Feuerstein TJ., 2004) and glutamate transport 
(Nanitsos et al., 2005;Rose et al., 2009). It is possible impairments in 
neurotransmission as a result of impaired Na+ K+ ATPase activity are responsible 
for the impaired sensorimotor gating observed in Fxyd6-/- mice.  
5.4.4 Social interaction and social novelty in Fxyd6-/- mice 
Social deficits are potentially associated with the negative symptoms of 
schizophrenia, as well as autism and related neurodevelopmental disorders (Lord 
et al., 2000;Aghevli et al., 2003;Wing and Gould., 1979). Mice are highly social 
animals and therefore make an excellent model to study deficits in sociability. 
Sociability testing in mice takes into account social approach of mice to a 
stranger mouse. A cylindrical wire cage containing the stranger mouse permits 
visual, olfactory and tactile interaction. In this study, sociability was defined as 
the tendency to approach and remain in the zone containing the stranger mouse. 
Disruption of Fxyd6 did not cause deficits in sociability. However it appears to 
induce a trend towards reduced levels of social novelty- the preference to 
interact with a new stranger mouse, compared to the now familiar mouse, 
reached significance in Fxyd6+/+ mice but not Fxyd6-/- mice. Despite this 
suggesting that Fxyd6-/- mice have reduced levels of social novelty, the levels 
did not significantly differ from Fxyd6+/+ mice. An increase in ‘n’ numbers could 
determine whether this result is a true biological effect that reflects a lack of 
interest from Fxyd6-/- mice in the new mouse. Reduced social novelty could also 
reflect the inability to distinguish between the familiar and novel mouse which 
could be explored further by using the novel object recognition test, which 
explores recognition memory by assessing time spent exploring familiar and non-
familiar objects. This test may provide further insight into novel object 
preference in Fxyd6-/- mice.    
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5.4.5 Sucrose preference 
Anhedonia, the inability to experience pleasure, has been associated with the 
negative symptoms of schizophrenia (refer to 1.3.2). Mice have a preference for 
sweet sucrose water over standard water. It has been suggested that the 
presence of anhedonia in mice can be detected by attenuated sucrose 
preference over water (Papp et al., 1991).  Fxyd6-/- mice consumed similar 
amounts of sucrose water compared to normal water, not only revealing a lack 
of anhedonia but also showing they do not have deficits in taste, which may have 
existed due to the expression of FXYD6 in taste cells (Shindo et al., 2011).  
5.4.6 Working memory 
Impaired working memory is a well recognised cognitive deficit associated with 
schizophrenia (Chai et al., 2011;Goldman-Rakic., 1994;Kim et al., 
2009;Manoach., 2003;Manoach et al., 2000;Pomarol-Clotet et al., 2010). Working 
memory differs from short term memory and spatial memory because it requires 
the retention and manipulation of short term memory in order to reach an 
internal goal (e.g. food reward). A T maze is used in this task, and mice are 
required to remember which arm they visited following a forced arm run (refer 
to 2.10.6), following an intra-trial delay, mice need to retain and manipulate 
this information to choose to enter the previously unvisited arm in return for a 
reward. Delays of varying times are introduced into the intra-trial delays of the 
working memory tasks and the ability to correctly enter an unvisited arm is used 
as an assessment (Aultman and Moghaddam., 2001). Male mice were solely used 
in ‘working memory’ tasks due to female mice requiring considerably longer 
training to reach testing stage (personal communication, Dr. Thomson). This 
gender difference could be due to behaviour being affected by a number of 
factors such as circadian rhythm, menstrual cycle, environmental factors such as 
stimulating housing toys, littermates etc. It is therefore important that during 
behavioural tasks, such as those designed to test working memory, influencing 
factors are kept constant.  
Fxyd6-/- mice displayed deficits in working memory with delays of 5 seconds, 
however not at long delay periods of 15 and 30 seconds. The working memory 
task showed a non-significant trend to becoming increasingly more difficult for 
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wildtype mice as delays are increased, reducing the average % of trials correct, 
significant time-dependent deficits have been in similar working memory studies 
(Aultman and Moghaddam., 2001;Zoubovsky et al., 2011) and it is possible these 
were not observed in this study due to the low n numbers reducing power and 
adding variability (Fxyd6+/+ mice=7, Fxyd6-/- mice n=6) . Deficits in working 
memory in mice should reach a minimum of a 50% correct score by chance 
alone, it is possible Fxyd6-/- mice have deficits in working memory that are not 
apparent due to the low n numbers and variability in data, especially at the high 
delays of 15 and 30 seconds.  
Hypofrontality (reduced glucose utilisation and blood flow in the prefrontal 
cortex) has been associated with deficits in working memory (Berman K et al., 
1988;Carter et al., 1998;Glahn DC et al., 2005); it would therefore be interesting 
to carry out 2 deoxyglucose experiments in these mice to assess whether there is 
altered metabolism in the prefrontal cortex (Weinberger et al., 1986, Callicott 
et al., 2000., Manoach et al., 2000). The hippocampus has also been associated 
with deficits in working memory and memory consolidation (Lipska et al., 
2002;Sato et al., 2004;Wyse et al., 2004) and it has been suggested that both 
the prefrontal cortex and the hippocampus are required for different 
components of working memory (Yoon et al., 2008;Laroche et al., 2000). Hence, 
since Fxyd6 is prominently expressed in the PFC and hippocampus, impaired 
working memory in these mice is consistent with altered function in these areas.    
5.4.7 Conclusion 
This chapter presents a behavioural characterisation of Fxyd6-/- mice and 
provides evidence that the disruption of Fxyd6 in mice models some of the 
aspects of schizophrenia.  
Fxyd6-/- mice do not exhibit altered sensitivity to ketamine or amphetamine, 
indicating no potential glutamatergic or dopaminergic circuitry dysfunction, 
respectively. However indication of deficits in neurotransmission in Fxyd6-/- mice 
comes from subtle deficits in prepulse inhibition.  
The targeted disruption of Fxyd6 also results in prefrontal cortex and 
hippocampal- related behaviour deficits, such as deficits in working memory.  
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The genetic disruption of Fxyd6 in mice results in phenotypes similar to a range 
of symptoms associated with schizophrenia. This is encouraging to further 
investigate Fxyd6-/- a potential mouse model of schizophrenia and associated 
psychiatric and cognitive disorders. It also provides further evidence for a role of 
FXYD6 dysfunction in the aetiology of schizophrenia.   
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Chapter 6. Molecular and phenotypic 
characterisation of Map2k7, and potential as a 
mouse model of schizophrenia –like deficits 
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6.1 Introduction 
The symptoms of schizophrenia are diverse and do not appear to be the result of 
a single neurobiological factor, instead it is often thought to be a result of 
several subtle anomalies including aberrations in cell signalling.  Various studies 
have implicated impairments in neuronal circuitry and neurotransmission in the 
pathology of schizophrenia (Sumiyoshi et al., 1996;Lisman et al., 2008); 
however, the pathological mechanisms that result in impaired cell signalling and 
the signalling cascades involved remain unclear.  
MAP kinases belong to the family of serine/ threonine kinases and are important 
mediators of signal transduction (refer to 1.13); playing a major role in all 
eukaryotic cells’ response to extracellular stimuli and regulating a wide range of 
cellular processes that may lead to functional and morphological alterations of 
neurons (Kyosseva et al., 1999;Pearson et al., 2001;Kyosseva, 2004). The role of 
MAP kinase signal transduction cascades, and in particular MAP kinase kinase 7 
(MAP2K7), in major psychiatric disorders, including schizophrenia, is not well 
understood (refer to 1.13.3). However due to the abundant expression in the 
CNS and pivotal role in the regulation of signal transduction, synaptic plasticity 
and modification of gene expression in neurons (Kyosseva et al., 1999;Pearson et 
al., 2001;Kyosseva, 2004), it is not surprising various intermediates of MAP 
kinase cascades have been suggested to be involved in neurodevelopmental 
abnormalities of the brain in schizophrenia and psychiatric disorders (Kyosseva 
et al., 1999;Funk et al., 2011). 
Recently, our lab found evidence of a role of MAP2K7 as a susceptibility factor in 
schizophrenia. Not only was MAP2K7 found to have attenuated expression in the 
PFC of post mortem schizophrenia brains, but a genetic association between 
MAP2K7 and schizophrenia was found (Winchester et al., 2012). The MAP2K7 
protein is primarily activated by cytokines in the immune system (e.g. TNF, IL-
1), although it has also been shown to be activated by NMDA receptor activity in 
the CNS, a receptor often showing impaired activity in schizophrenia (Tournier 
et al., 2001;Centeno et al., 2006). Following activation, MAP2K7 is dually 
phosphorylated on a specific threonine and tyrosine residue of the 
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phosphorylation motif (refer to 1.13, (Tournier et al., 2001;Holland et al., 1997) 
prior to acting as an upstream JNK2 activator. JNK2 mediates signal transduction 
and regulates many cellular processes such as cell growth and proliferation, 
transcription and apoptosis (Tournier et al., 2001;Holland et al., 1997;Mayer et 
al., 2005). JNK2 has also been shown to have decreased expression and 
phosphorylation in the anterior cingulate cortex (Funk et al., 2011) 
strengthening the hypothesis for a role of MAP2K7 and related pathways as a risk 
factor in schizophrenia.  
Despite the genetic association implicating MAP2K7 as a risk factor of 
schizophrenia, further biological evidence is required to ascertain a functional 
link between the gene and disease. Genetic association studies provide an 
indication of markers of disease; however they do not elucidate information on 
the causative variation or the exact biological mechanism underlying the risk 
factor. Animal models provide a unique way of analysing and understanding the 
functional role of genetic risk factors in the pathophysiology of schizophrenia 
(refer to 1.10). The heterozygous or homozygous disruption of a gene of interest 
allows investigation into signalling networks, interactions and potential 
regulatory and compensatory mechanisms, as well as the impact on behaviour. 
In addition to providing a model to investigate behaviours similar to those 
associated with schizophrenia, the neurochemical hypotheses of schizophrenia 
can be explored in the mice by investigating the expression of relevant markers 
such as the GABAergic interneuron marker parvalbumin or the expression of 
glutamate receptors.  
A mouse heterozygous for Map2k7 has been established (Wada et al., 2004). 
Heterozygous expression of Map2k7 in these mice was confirmed using northern 
and southern blotting which revealed a clear reduction in Map2k7 genomic mRNA 
and DNA (respectively) (Wada et al., 2004), however as of yet these mice have 
not been investigated for impairments in neural circuitry or behaviours 
associated with schizophrenia, such as cognitive deficits.  
6.2 Aim and hypothesis 
MAP2K7 is a putative risk factor in the susceptibility to schizophrenia; however 
biological evidence is still required to establish this link. Map kinases are 
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associated with the maintenance of signal transduction and it is hypothesised 
the heterozygous deletion of Map2k7 will have implications in neurotransmission 
and memory consolidation. This chapter aims to elucidate information on the 
molecular and functional role of Map2k7 by utilising Map2k7 heterozygous mice 
(Map2k7+/-) and investigating changes in schizophrenia-related proteins and 
behaviours, such as working memory.    
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6.3 Results 
6.3.1 Expression of Map2k7 in the mouse brain 
Expression of Map2k7 in 20 μm coronal adult mouse brain sections was visualised 
using a 33P- labelled probe designed to target Map2k7 RNA (refer to 2.9). 
Qualitative assessment from comparison of total staining to non-specific staining 
revealed Map2k7 is expressed in the following brain regions: the prefrontal cortex, 
the granular cell layer of the olfactory bulb (GrO), the CA1 region of the 
hippocampus and the granule cell layer of the dentate gyrus (GrDG), and the 
cerebellar lobules of the cerebellum (Figure 6.1).  
6.3.2 Evidence for a trend towards reduced Map2k7 RNA 
expression in Map2k7+/- mice 
To investigate the potential functional link between MAP2K7 and schizophrenia, 
mice containing one targeted disruption of Map2k7 were utilised (refer to 2.3.2). 
The in situ probe used to detect mouse brain expression of Map2k7 (section 
6.3.1) was further utilised to investigate the effect of heterozygous targeted 
disruption of Map2k7 on RNA levels. Despite a trend towards reduced expression, 
no significant overall attenuation of Map2k7 mRNA expression was observed in 
Map2k7+/- mice (F1,38= 2.88, p>0.05), neither were there decreases in the 
following regions: CA1 (T1,6=0.04, p>0.05), CA3 (T1,6= 4.25, p>0.05), cerebellum 
(T1,6= 0.55, p>0.05), DG (T1,6= 0.3, p>0.05), or olfactory bulb (GrO) (T1,6= 0.1, 
p>0.05) (Figure 6.2a-i). Map2k7+/+ n=5, Map2k7+/- n=3.  
RTq-PCR primers designed to target Map2k7 transcripts across two sites: exon 1a 
and 1b and exons 10 and 11 (refer to 2.8.1), were employed to investigate the 
impact of heterozygous genetic knockdown of Map2k7 upon Map2k7 mRNA 
expression. Using a geometric mean from three housekeeping genes (18s 
ribosomal RNA, B2M and GAPDH) analysis of CT values revealed Map2k7 
expression in Map2k7+/- mice is reduced across exon 10/11 by 20% (Figure 6.3a) 
however this does not reach significance (ratio 1: 0.80, F1,5=1.09, p>0.05). A 
modest reduction of Map2k7 exon 1a and b mRNA expression of 32% was 
observed (Figure 6.3b). To further investigate Map2k7 mRNA expression in 
Map2k7+/- mice, the effect of genotype on overall Map2k7 expression was 
analysed using ANOVA with multiple comparisons, which showed a near 
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significant effect of genotype of Map2k7 expression (F1,11=5.47, p=0.06)  n=3 per 
group. 
6.3.3 Map2k7+/- mice have increased Grin1 RNA expression  
RTqPCR revealed that the heterozygous targeted disruption of Map2k7 
significantly increased glutamate receptor Grin1 mRNA expression (ratio 1: 4.3, 
(F1,5=15.99, p=0.016, Figure 6.3e). However the disruption does not have a 
significant impact on Pvalb (ratio 1: 0.79, F1,5=0.71, p>0.05, Figure 6.3c) or 
Fxyd6 mRNA expression (ratio 1: 1.09, F1,5=0.25, p>0.05, Figure 6.3d). 
6.3.4 Map2k7 reduced expression does not impact on GLUR2, 
NR2A and GAD 65/67 protein expression 
The involvement of MAP2K7 in the glutamatergic hypothesis of schizophrenia 
was explored by the western blotting technique. Antibodies designed to target 
glutamatergic receptor proteins GluR2 and NR2A and glutamate decarboxylase 
(GAD) 65/ 67 produced bands of correct size (GluR2 102 kDa, NR2A 170 kDa, GAD 
65/67 produces a doublet band at 65 kDa and 67 kDa) in both Map2k7+/+ and 
Map2k7+/- mice. Disruption of Map2k7 did not impact on the expression of any of 
the proteins investigated (Figure 6.4). Despite attempts at the optimisation of 
two different MAP2K7 antibodies, neither was able to produce a clear band of 
correct size to confirm MAP2K7 protein knockdown.  
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       Nonspecific             Total               Reference   
     
Figure 6.1 Autoradiogram images showing Map2k7 mRNA distribution in coronal mouse brain 
sections, as detected by in situ hybridisation.  
Qualitative assessment suggests Map2k7 is expressed in a) the prefrontal cortex and in 
particular the granular cell layer of the olfactory bulb (GrO) (bregma 2.10 mm) b) (bregma 
1.18 mm) c) pyramidal cell layer of the hippocampus (Py), granular layer of the dentate 
gyrus (GrDG)  (bregma -1.22 mm) d) pyramidal cell layer of the hippocampus (Py), granular 
layer of the dentate gyrus (GrDG)  (bregma -1.82), e) pyramidal cell layer of the 
hippocampus (Py), granular layer of the dentate gyrus (GrDG)  (bregma -2.92 mm) f) 
cerebellar lobules of the cerebellum (bregma -6.00). Unlabelled= slides incubated with ‘cold 
probe’, indicates non specific labelling, total = slides incubated with ‘hot probe’ refer to 
2.9.1. Scale bar = 2mm. 
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Figure 6.2 Map2k7 expression in Map2k7+/+ and Map2k7+/- mouse brain  
Autoradiogram images showing Map2k7 distribution in Map2k7+/+ and Map2k7+/- coronal 
mouse brain sections in a) the prefrontal cortex and in particular the granular cell layer of 
the olfactory bulb (GrO) b) pyramidal cell layer (Py) and CA3 of the hippocampus, granular 
layer of the dentate gyrus (GrDG)  c) cerebellar lobules of the cerebellum. Scale bar = 2mm.  
Quantitation of autoradiographic film images reveals that Map2k7 mRNA levels do not differ 
significantly in Map2k7+/+ and Map2k7+/- mice in the following brain sections a) granular cell 
layer of the olfactory bulb (GrO) (T1,7=0.18, p>0.05) b) pyramidal cell layer (Py) (T1,7=0.46, 
p>0.05)  c) CA3 of the hippocampus (T1,7=4.19, p>0.05) d) granular layer of the dentate 
gyrus (GrDG) (F1,7=0.92, p>0.05) e) cerebellar lobules of the cerebellum (T1,7=0.62, p>0.05)  
f) total expression (T1,7=2.32, p>0.05). Map2k7
+/+ n=5, Map2k7+/- n=3. Data analysed by 
Student’s t-test.  
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Figure 6.3 Map2k7+/- mice have increased GRIN1 mRNA expression.  
Analysis of CT values revealed Map2k7 heterozygous deletion results in a) a non-significant 
reduction of Map2k7 exon 10/11 expression (ratio 0.80, F1,5=1.09, p=0.18) b) a modest 
reduction of Map2k7 exon 1a and b mRNA expression (ratio 0.68, T1,5=2.17, p=0.05 c) no 
effect on parvalbumin (Pvalb) mRNA expression (ratio 1.79, T1,5=0.71, p>0.05) and d) Fxyd6 
mRNA expression (ratio 1: 1.09, T1,5=0.25, p>0.05) e) GRIN 1 expression (ratio 1: 4.3, 
F1,5=15.99, p=0.016). *p<0.05. n=3. Data analysed by Student’s t-test. 
157 
 
 
    
       
 
Figure 6.4 Western blotting analysis reveals Map2k7 heterozygous disruption does not 
impact on the protein expression of a) GluR2 (F1,7=2.61, p>0.05) b) NR2A (F1,7=1.82, p>0.05) 
c) FXYD6 (F1,7=0.29, p>0.05) d) ATP1a1 (F1,7=0.09, p>0.05) e)GAD 65/67 (F1,7=1.22, p>0.05). 
n=4 
a b 
a b 
e 
c d 
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6.3.5 Map2k7+/- primary phenotype screen 
Map2k7+/- mice (n=9) were not distinguishable from Map2k7+/+ mice (n=7) in all 
parameters of the primary phenotype screen (Table 6.1). Neuromuscular 
function, as tested by hanging wire and motor coordination and balance, as 
tested by rotarod (refer to 2.10.1 & 2.10.2), were also unaffected by the 
heterozygous disruption of Map2k7 (p>0.05, Table 6.1).  
6.3.6 Map2k7+/- mice do not differ from Map2k7+/+ in plus maze 
performance 
In comparison to Map2k7+/+ mice, Map2k7+/- mice did not appear to have 
increased levels of anxiety in the EPM (refer to 2.10.3). This was detected by no 
significant differences in zone duration (F1,63=0.238 p> 0.05), zone entry 
frequency (F1, 63=0.123, p> 0.05), distance travelled (T=3.84, p> 0.05) and mean 
velocity (T=3.29, p> 0.05) in the plus maze (Table 6.2) Map2k7+/+ n=7, Map2k7+/- 
n=9.  
 
 
159 
 
 
Location Phenotype Significance
Map2k7
+/+
Map2k7
+/-
In Arena Body position 1 ± 0 1 ± 0 p >0.05
Spontaneous activity 0 ± 0 0 ± 0 p >0.05
Tremor 0 ± 0 0 ± 0 p >0.05
Urination 0.5 0.7 p >0.05
Defecation 1.4 1.2 p >0.05
Bizarre behaviours 0 ± 0 0 ± 0 p >0.05
Convulsions 0 ± 0 0 ± 0 p >0.05
Palebral Closure 0 ± 0 0 ± 0 p >0.05
Piloerection 0 ± 0 0 ± 0 p >0.05
Gait 0 ± 0 0 ± 0 p >0.05
Pelvic elevation 1 ± 0 1 ± 0 p >0.05
Tail elevation 1 ± 0 1 ± 0 p >0.05
Pinna reflex 0 ± 0 0 ± 0 p  >0.05
Restrained Cornea reflex 0 ± 0 0 ± 0 p >0.05
Provoked biting 0 ± 0 0 ± 0 p >0.05
Trunk curl 1 ± 0 1 ± 0 p >0.05
Visual placing 1 ± 0 1 ± 0 p >0.05
Hanging wire 1 55.7 ±4. 3 52.5- ± 5.2 p >0.05
Hanging wire 2 49.7 ± 6.7 49.1 ± 5.3 p >0.05
Hanging wire 3 59.4 ± 0.5 54.2 ± 5.7 p >0.05
Hanging wire average 54.9  ± 3.3 52.0 ± 3.7 p >0.05
Rotarod 1 96.7 ± 20.7 136.4 ± 17.6 p >0.05
Rotarod 2 105.7 ± 17.8 122.8 ± 19.6 p >0.05
Rotarod 3 132.1 ± 17.5 104.3 ± 17.2 p >0.05
Rotarod average 111.5 ± 14.7 121.2 ± 12.6 p >0.05
Genotype
 
Table 6.1 Summary of primary phenotype screen performed on mice heterozygous for the 
genetic disruption of Map2k7 (Map2k7+/-) and their wildtype littermates Map2k7+/+ mice. 
 Heterozygous disruption of Map2k7 did not significantly alter mice phenotype in parameters 
tested in the primary phenotype screen. Data is presented at mean ± SEM, Map2k7+/+ n = 7, 
Map2k7+/- n=9. Data analysed by Student’s t-test.  
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a
Genotype Centre Closed arm 2/3
rd 
open arm 1/3
rd 
open arm Significance
Map2k7+/+ 112.2 ± 33.3 132.1.7 ± 37.3 37.9 ± 22.5 17.12  ± 11.8 p >0.05, ns
Map2k7
+/-
118.2 ± 12.3 120.9 ± 15.6 44.8 ± 7.9 15.8 ± 6.2 p >0.05, ns
Duration (seconds)
 
b
Genotype Centre Closed arm 2/3
rd open arm 1/3rd open arm Significance
Map2k7+/+ 14.4 ± 2.2 9.9 ± 3.0 7.6 ± 2.9 1.6 ± 0.9 p >0.05, ns
Map2k7+/- 23.9 ± 1.7 13.9 ± 1.6 12.9 ± 2.0 2.3 ± 0.8 p >0.05, ns
Frequency
 
c
Genotype Distance travelled (cm) Mean velocity (cm/s) Significance
Map2k7+/+ 961.0 ± 166.3 3.6 ± 0.3 p >0.05, ns
Map2k7+/- 1302.6 ± 84.4 4.3 ± 0.3 p >0.05, ns  
 
Table 6.2 Map2k7+/- mice do not display abnormal anxiety-related behaviours in the elevated 
plus maze, as indicated by no differences in performance in the following parameters  
a) duration (seconds) (F1,63=0.238 p> 0.05)  
b) frequency of entering zones in the EPM (F1, 63=0.123, p> 0.05) and c) Distance travelled 
(T=3.84, p> 0.05) and mean velocity (T=3.29, p> 0.05) travelled in all zones. Closed zone 
(non-aversive), 2/3rd open arm (mildly aversive), 1/3rd open arm (aversive) refer to 2.10.3) 
Data is presented as mean ± SEM. Map2k7+/+ n=7, Map2k7+/- n=9. Duration and frequency 
analysed using ANOVA followed by Tukey’s post hoc test for multiple comparisons. Distance 
and mean velocity analysed by Student’s t-test.  
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6.3.7 Map2k7+/- mouse performance in open field with 
amphetamine challenge 
Map2k7+/- mice did not show anxiety-like behaviours or hyperlocomotor activity 
in the open field test in comparison to Map2k7+/+ mice, however slightly altered 
sensitivity to amphetamine was observed as described below. 
Overall, genotype did not significantly affect the duration of time spent in zones 
during the habituation stage (F,1,83=2.8, p>0.05) however it approached 
significance in the test stage (F1,83=2.8, p=0.06). There was an overall effect of 
genotype on duration of time spent in each zone (F1,83=4.07, p=0.02) and on 
further investigation,  Tukey’s post hoc analysis revealed Map2k7+/- mice spent 
significantly decreased duration of time in the thigmotaxis zone under saline 
treatment (p=0.02) Figure 6.5a).  Map2k7+/- mice did not significantly differ from 
Map2k7+/- mice in velocity in both the habituation stage (F1,179 =1.15, p>0.05) or 
testing stage (F1,359=1.46, p>0.05) (Figure 6.5b). Administration of 3 mg/kg 
amphetamine significantly increases velocity in both genotypes (F1,27=1.24, 
p<0.001), however there is no significant interaction between amphetamine and 
genotype (F1,27=0.03, p>0.05, Figure 6.5b). Similar results were observed with 
distance travelled during testing stage, Map2k7+/+ and Map2k7+/- mice did not 
differ from each other (F1,39=0.32, p>0.05, Figure 6.6a), although the 
administration of 3mg/kg of amphetamine significantly increases the overall 
distance travelled for both genotypes (F1,39=43.68, p<0.001 Figure 6.6a), the 
response was not influenced by genotype (F1,39=0.17, p>0.05). 
Comparing velocity to the mean baseline revealed an overall near significance 
effect of genotype (F1,359=3.84, p=0.05), and the effect of amphetamine was 
influenced by genotype (F1,359*=9.33, p=0.002, Figure 6.6b). Tukey’s post hoc 
analysis revealed Map2k7+/+ mice exhibited significantly increased velocity at 
time points 35 (p= 0.003), 40 (p=0.04) and 45 minutes (p=0.02), in comparison to 
Map2k7+/- following amphetamine treatment Figure 6.6b). Map2k7+/+ n=7, 
Map2k7+/- n=9.  
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Figure 6.5 Map2k7+/- mice do not have altered locomotor activity however display decreased 
thigmotaxis in comparison to Map2k7+/+ mice 
a) Analysis of duration spent in centre, inner and outer zones of the open field arena reveal 
a significant interaction between genotype and zone duration (F1,83=2.8, p=0.06) with 
Map2k7+/- mice spending less time in the thigmotaxis zone compared to Map2k7+/+ mice 
during treatment with saline (F1,119=1.08, p=0.02). Administration of 3mg/kg of amphetamine 
did not affect duration spent in zones for both genotypes (F1,83=0.06, p>0.05.) n=10 per 
group. Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons.  
Map2k7+/+ n=7, Map2k7+/- n=9. *p=0.02 Map2k7+/+ vs Map2k7+/- 
b) Mean velocity in Map2k7+/+ mice and Map2k7+/- are both increased following the 
administration of amphetamine after a 30 minute habituation period (F1,27=1.24, p<0.001). 
Map2k7+/- mice do not differ from their Map2k7+/+ littermates in their response to 
amphetamine (F1,27=0.03, p>0.05). n=10 per group. Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons. Map2k7+/+ n=7, Map2k7+/- n=9. ↓ represents 
time of treatment administration 
a 
b 
163 
 
 
 
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
M a p 2 k7
+ / +
(s a lin e )
M a p 2 k7
+ / -
(s a lin e )
M a p 2 k7
+ / +
 (a m p )
M a p 2 k7
+ / -
   (a m p )
D
is
ta
n
c
e
 t
r
a
v
e
ll
e
d
 (
c
m
/s
)
***
***
0
0
1
2
3
4
3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0
M a p 2 k7
+ / +
(s a lin e )
M a p 2 k7
+ / -
(s a lin e )
M a p 2 k7
+ / +
(a m p )
M a p 2 k7
+ / -
(a m p )
T im e  (m in u te s )
M
e
a
n
 v
e
lo
c
it
y
 (
r
a
ti
o
 o
f 
a
v
e
r
a
g
e
 b
a
s
e
li
n
e
)
**
*
*
 
Figure 6.6 Map2k7+/- mice reveal altered sensitivity to amphetamine  
a) Analysis of distance travelled following the administration of amphetamine or saline (time 
point 30 min) did not reveal a significance difference between Map2k7+/+ and Map2k7+/- mice 
(F1,39=0.32, p>0.05). Administration of 3mg/kg of amphetamine significantly increases the 
overall distance travelled (F1,39=43.68, p<0.001), however the effect of amphetamine was 
not influenced by genotype (F1,39=0.17, p>0.05). Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons. Map2k7+/+ n=7, Map2k7+/- n=9. *p<0.001 
amphetamine (amp) vs saline 
b) Mean velocity as a ratio of average baseline in Map2k7+/+ mice and Map2k7+/- are both 
increased following the administration of amphetamine (3 mg/kg) after a 30 minute 
habituation period (F1,39=1.59, p<0.001), there is a near-significant overall effect of 
genotype (F1,359=3.84, p=0.05) and a significant overall interaction between genotype and 
amphetamine (F1,359*=9.33, p=0.002, Tukey’s post hoc analysis revealed Map2k7
+/- mice 
exhibited significantly increased velocity at time points 35 (p= 0.003), 40 (p=0.04) and 45 
minutes (p=0.02), in comparison to Map2k7+/+ following amphetamine treatment.  Map2k7+/+ 
n=7, Map2k7+/- n=9. *p<0.05, **p<0.01 significance observed between Map2k7+/+ vs. 
Map2k7+/- with amphetamine (amp).  
a 
b 
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6.3.8 Map2k7+/- acoustic startle 
Prior to conducting PPI, acoustic startle was examined to ensure Map2k7+/- mice 
do not exhibit deficits in hearing which may affect PPI results (refer to 2.10.5). 
Age-matched Map2k7+/+ and Map2k7+/- mice were tested for their startle 
responses to a range of auditory stimuli (65 dB, 69 dB, 73 dB, 77 dB, 85 dB, 90 
dB, 100 dB, 110 dB, 120 dB). Overall, the heterozygous targeted disruption of 
Map2k7 did not significantly alter startle response in Map2k7+/- mice, compared 
to Map2k7+/+ mice (F[1, 89 = 2.20, p>0.05) suggesting that the lack of Map2k7 does 
not affect hearing (Figure 6.7a). As predicted the size of auditory stimuli 
produces a decibel- dependent increase in startle amplitude (F8,89=12.73, 
p<0.001) however is it not affected by genotype (F8,89=0.76, p>0.05).  N=5 per 
group.  
6.3.9 Map2k7+/- mouse sensorimotor gating  
Overall PPI results reveal Map2k7+/- mice do not significantly differ from 
Map2k7+/+ mice, as described below. 
Map2k7+/- mice do not have deficits in PPI, in comparison to Map2k7+/+ mice 
(F1,95=0.09, p>0.05). Ketamine and prepulse intensity both had an overall 
significant effect (F1,95=6.43, p=0.01 & F2,95=35.98, p<0.001 respectively) 
however effects were not influenced by genotype (genotype x treatment 
F1,95=0.05, p>0.05, genotype x prepulse interaction F2,95=1.16, p>0.05) (Figure 
6.7b). Post hoc analysis did not identify which prepulse level were affected by 
ketamine (pp4 p= 0.54, pp8 p= 0.56, pp16 p=0.89). Map2k7+/+ n=7, Map2k7+/- 
n=9. 
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Figure 6.7 Map2k7+/- mice do not display hearing loss or sensorimotor gating deficits in 
comparison to Map2k7+/+ mice. 
a) Startle magnitude to auditory stimuli of 65 dB, 69 dB, 73 dB, 77 dB, 85 dB, 90 dB, 100 dB, 
110 dB, 120 dB intensities did not differ between Map2k7+/+ mice and Map2k7+/- mice (F[1, 89 
= 2.20, p>0.05) suggesting disruption of Map2k7 does not impact on hearing. n=5 per group. 
Data analysed by ANOVA followed by Tukey’s post hoc test for multiple comparisons.  
b) Overall, prepulse inhibition of the startle response did not significantly differ between 
Map2k7+/+ and Map2k7+/- mice (F1,95=0.09, p>0.05). Ketamine (25 mg/kg) and prepulse both 
had an overall significant effect (F1,95=6.43, p=0.01 & F2,95=35.98, p<0.001 respectively)  
however  there was no significant interaction between genotype and treatment (F1,95=0.05, 
p>0.05) or genotype x prepulse interaction (F2,95=1.16, p>0.05). Map2k7
+/+ n=7, Map2k7+/- 
n=9, data analysed using ANOVA followed by Tukey’s post hoc test for multiple comparisons. 
a 
b 
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6.3.10 Map2k7+/- mouse sociability and social novelty.  
The heterozygous genetic disruption of Map2k7 does not significantly impact on 
levels of sociability. A preference for social novelty was not observed in either 
Map2k7+/+ or Map2k7+/+ mice, as described below. 
Map2k7+/+ and Map2k7+/- mice both exhibit sociability as observed by prolonged 
duration of time spent exploring the chamber containing a strange mouse, in 
comparison to the empty chamber (F2,29=39.13, p<0.001). The heterozygous 
genetic disruption of Map2k7 does not significantly impact on levels of sociability 
(F1,29=0.09, p>0.05) however there is a significant interaction between zone and 
genotype (F2,29=3.33, p=0.05, Figure 6.8a).  
Social novelty was investigated by assessing the duration of time spent 
investigating a novel mouse in this study (refer to 2.10.7), compared to the now 
familiar mouse. Genotype did not have a significant impact on duration 
(F,29=0.23, p>0.05), however zone did have an overall impact (F2,29=12.18, 
p<0.001), and there was an overall interaction between zone and genotype 
(F2,29=4.07, p=0.03, Figure 6.8b). Tukey’s post hoc analysis revealed neither 
Map2k7+/+ or Map2k7+/- mice spend a longer duration of time interacting with the 
stranger mouse, compared to the now familiar mouse, suggesting social novelty 
is not present in these mice (p>0.05, Figure 6.8b). Map2k7+/+ n=5, Map2k7+/- n=5, 
data analysed using ANOVA followed by Tukey’s post hoc test for multiple 
comparisons.   
6.3.11 Map2k7+/- mouse sucrose preference 
Anhedonia in Map2k7+/- mice was investigated using the sucrose preference test 
(refer to 5.3.7), results suggest the heterozygous deletion of Map2k7+/- mice 
does not cause significant levels of anhedonia. One Map2k7+/- mouse was 
removed from testing due to not displaying sucrose preference. Map2k7+/- mice 
were not significantly different from Map2k7+/+ mice in levels of sucrose 
consumption over a 5 day period (F1,44=1.23, p>0.05, Figure 6.9). There was a 
significant effect of day on the % of sucrose consumed (F4,44=1.24, p=0.02) but 
not an impact of genotype on consumption of sucrose on individual days 
(F4,44=0.49, p>0.05). Map2k7
+/+ n=5, Map2k7+/- n=4. 
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The overall average % sucrose consumed over the 5 day period was also not 
significantly affect by genotype (F1,8=0.09, p>0.05, Figure 6.9). Map2k7
+/+ n=5, 
Map2k7+/- n=4.  
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Figure 6.8 Map2k7+/- mice do not have deficits in sociability or suffer from anhedonia.   
a) Levels of sociability; duration spent exploring and interacting with the stranger  mouse in 
comparison to an empty chamber was used as an indication of mouse sociability levels. Both 
Map2k7+/+ and Map2k7+/- mice showed levels of sociability (F2,29=39.13, p<0.001). Genotype 
did not have an overall effect on levels of sociability (F1,29=0.00, p>0.05), however there is a 
near significant interaction between zone and genotype (F2,29=3.33, p=0.05). ***p<0.001 
b) Preference for social novelty; There was an overall interaction between zone and 
genotype (F2,29=4.07, p=0.03) however Tukey’s post hoc analysis revealed that neither 
Map2k7+/+ or Map2k7+/- mice spend a longer duration of time interacting with the stranger 
mouse, compared to the now familiar mouse, suggesting social novelty is not present in 
these mice (p>0.05). Genotype did not have an overall impact (F,29=0.00, p>0.05). Map2k7
+/+ 
n=5, Map2k7+/- n=5.  
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Figure 6.9 Map2k7+/- mice do not suffer from anhedonia.   
Genotype did not have an overall impact on % of sucrose consumption during single days and 
in total  over a 5 day period, revealing Map2k7+/- mice do not suffer from anhedonia 
(F1,44=1.23, p>0.05), Map2k7
+/+ n=5, Map2k7+/- n=4. Data analysed by ANOVA followed by 
Tukey’s post hoc test for multiple comparisons.   
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6.3.12 Map2k7+/- mouse performance in delayed non-match to 
sample 
Results from the delayed non-match to sample T maze task (refer to 2.10.6) 
revealed that there was an overall effect of genotype on working memory 
(F1,32=7.24, p=0.01). However post hoc analysis did not identify which delay the 
deficits occurred (Figure 6.10a) 5 seconds (F1,10=2.31, p=0.22), 15 seconds 
(F1,10=0.82, p=0.96 and 30 seconds (F1,10=1.522, p=0.65). Map2k7
+/+ n=5, 
Map2k7+/- n=6.  
Collapsing of the data in order to evaluate an average response, revealed that 
Map2k7+/- mice exhibit a trend towards reduced working memory overall 
(F1,10=4.73, p=0.05 Figure 6.10b). Map2k7
+/- mice also showed a significant 
increase in perseverative responding, in comparison to Map2k7+/+ mice 
(F1,10=13.29, p=0.005, Figure 6.10c) as measured by the number of 2 or more 
consecutive incorrect trials. Map2k7+/+ n=5, Map2k7+/- n=6. 
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Figure 6.10 Map2k7+/- mice exhibit an overall deficit in working memory and increased 
perseverative errors in delayed non-match to sample test.  
 a) In comparison to Map2k7+/+ mice, Map2k7+/- mice had an overall deficit in working 
memory (F1,32=7.24, p=0.01) however no significant differences were observed at individual 
time delays, 5 seconds (F1,10=2.31, p>0.05), 15 (F1,10=0.82, p>0.05) and 30 seconds 
(F1,10=1.522, p>0.05). Map2k7
+/+ n=5, Map2k7+/- n=6. Data analysed using ANOVA followed by 
Tukey’s post hoc test for multiple comparisons 
b) Overall % trials correct revealed Map2k7+/- mice have a trend towards reduced working 
memory (T1,10=4.73, p=0.05). Map2k7
+/+ n=5, Map2k7+/- n=6, data analysed using Student’s 
t’test. *p=0.05 
c) Map2k7+/- mice had significant increase in perseverative responding, in comparison to 
Map2k7+/+ mice (T1,10=13.29, p=0.005). Map2k7
+/+ n=5, Map2k7+/- n=6, data analysed using 
Student’s t’test. **p<0.01 
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6.4 Discussion 
 
6.4.1 Map2k7 is expressed in brain regions associated with 
schizophrenia 
Qualitative assessment revealed Map2k7 is expressed in regions of the mouse 
brain associated with schizophrenia; the prefrontal cortex, the granular cell 
layer of the olfactory bulb (GrO) and CA1 and dentate gyrus of the hippocampus. 
Altered prefrontal cortical function has been repeatedly implicated in the 
pathophysiology of schizophrenia. Decreased functioning and metabolism of the 
prefrontal cortex (hypofrontality) and dysfunction of prefrontal related tasks, 
such as working memory and decision making are associated with schizophrenia. 
The hippocampus, as part of the medial temporal lobe, is also a central region in 
the pathophysiology of schizophrenia, and is associated with tasks such as spatial 
working memory and learning. Connectivity networks between the prefrontal 
cortex and the hippocampus are thought to be responsible for many areas of 
cognition and memory consolidation, in particular working memory (Laroche et 
al., 2000;Yoon et al., 2008). The expression of Map2k7 in these brain regions 
suggests a potential role in the underlying mechanisms of cognition and memory. 
Animal models of genetic risk factors are likely to aid our understanding of the 
pathogenesis of schizophrenia, for this reason I utilised a mouse model 
containing heterozygous deletion of Map2k7 to elucidate information on the 
functional role of MAP2K7 in schizophrenia. Homozygous deletion of murine 
Map2k7 results in embryonic lethality (Wada et al., 2004), suggesting Map2k7 
has a vital role in neurodevelopment; however the stage of development at 
which lethality occurs is unknown.   
6.4.2 Mice heterozygous for Map2k7 disruption exhibit a trend 
towards reduced Map2k7 mRNA 
RTqPCR detected a modest significant reduction of Map2k7 RNA in Map2k7+/- 
mice, in comparison to Map2k7+/+ mice. Primers designed to target exons 10/11 
revealed a non-significant reduction of 20%, whilst primers designed to 
alternative splice exon 1a and b revealed a significant reduction of 32%. Exon b 
has been shown to have increased expression in subjects homozygous for 
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rs4804833; a Map2k7+/- SNP associated with schizophrenia (Winchester et al., 
2012). It is important to use primers located at different loci to confirm that 
viral insertion disrupts the entire gene of interest and does not result in 
alternative transcripts. 
In order to further investigate Map2k7 expression in Map2k7+/- mice, RNA levels 
were quantified using in situ hybridisation technique. On average, a non-
significant reduction of 12% Map2k7 expression was observed. It is possible 
compensatory up-regulation of transcription from the single Map2k7 allele has 
occurred. However, non-significance could also be due to the low ‘n’ number 
(n=3) used in this study, resulting in increased data variability and decreased 
statistical power. These findings are similar to those observed in other 
heterozygous mouse models that die early in development (Williamson et al., 
2000;Graziotto et al., 2008), which suggest that if the homozygous knockout of a 
gene is embryonically lethal, the gene is likely to have an essential role in 
development and so compensatory up-regulation of related gene expressions will 
occur. The translation into protein was unable to be examined due to failed 
attempts at producing quantifiable protein results using western blotting, 
despite repeated attempts at optimisation of antibodies.  
Wada et al., 2004 confirmed heterozygous expression of Map2k7 in Map2k7+/- 
mice using northern and southern blotting which revealed a clear reduction in 
Map2k7 genomic mRNA and DNA (respectively). These results combined with DNA 
and RNA analysis from this study suggest it is highly likely Map2k7 has reduced 
expression in Map2k7+/- mice and thus are suitable to be used as a tool for 
investigating the functional properties of Map2k7. 
6.4.3 A trend towards Map2k7 reduced expression increases Grin1 
but not Pvalb and Fxyd6 RNA expression 
RTqPCR interestingly revealed that the heterozygous targeted genetic disruption 
of Map2k7 significantly increases Grin1 expression in the frontal cortex of 
Map2k7+/- mice. The Grin1 gene encodes the NR1 (GluN1) subunit for the 
glutamatergic NMDA receptors (Sakurai et al., 2000;Myers et al., 1999). NMDA 
receptors play a crucial role in the glutamatergic excitatory neurotransmitter 
system and hypofunction of receptors are the basis of the glutamate hypothesis 
174 
 
 
of schizophrenia. Emerging evidence suggests a genetic role of GRIN1 in 
schizophrenia. A genetic association has been found between GRIN1 and 
schizophrenia (Georgi et al., 2007;Galehdari, 2009;Qin et al., 2005) and mice 
expressing 5% of normal levels of the Grin1 subunit display behavioural 
abnormalities reflective of those associated with schizophrenia symptoms, such 
as elevated motor activity and stereotypy and deficiencies in social and sexual 
interactions, which were ameliorated by treatment with antipsychotics 
haloperidol or clozapine (Mohn et al., 1999). It is possible that the up-regulation 
of GRIN1 expression is a compensatory mechanism employed to continue the 
normal functioning of synaptic transmission, following reduced expression of 
Map2k7. Interestingly, the NR1 and NR2B subunit of the NMDA receptor have 
been shown to have increased expression in post mortem schizophrenia brains 
(Grimwood et al., 1999;Clinton et al., 2006;Kristiansen et al., 2006;Dracheva et 
al., 2001),  suggesting up-regulation of NMDA receptor subunits may be a feature 
of the neurobiology of schizophrenia.  However, in order to fully confirm an 
association between Map2k7 and Grin1, sample numbers would need to be 
increased as the significant interaction observed in this study was derived from 
an n of 3.  
6.4.4 The modest reduction of Map2k7 does not impact on GLUR2, 
NR2A, GAD 65/67, FXYD6 and Na+ K+ ATPase protein 
expression 
To investigate further the effect of heterozygous knockout of Map2k7 on 
neurotransmission, GLUR2, NR2A and GAD 65/67 protein expression levels were 
investigated using the western blotting technique. The role of the NMDA 
glutamate receptor subunit NR2A (GluN2A) in the PFC in schizophrenia is not 
well characterised, however decreased expression of NR2A in parvalbumin 
neurons has been observed in the PFC of schizophrenia brains (Bitanihirwe et al., 
2009). Nonetheless, NR2A protein expression was not altered in Map2k7+/- mice 
compared to Map2k7+/+ mice, suggesting there is no compensatory regulation of 
the expression of these receptors, despite the increased expression of the NMDA 
receptor subunit Grin1 as observed with RTqPCR (refer to 6.3.3). Furthermore, 
GLUR2 (GluA2), the key subunit of heteromeric glutamate AMPA receptors has 
altered expression in schizophrenia brains (Eastwood et al., 1995;Eastwood et 
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al., 1997), but is not altered in Map2k7+/- mice, suggesting signalling of these 
receptors is not altered by impairments in Map2k7 expression.  
GABAergic neurotransmission is also dysregulated in schizophrenia, glutamic-
acid-decarboxylase (GAD), the enzyme which catalyses the synthesis of GABA 
from glutamate, has been found to be decreased in schizophrenia, however 
Map2k7 disruption does not have a significant impact in expression in Map2k7+/- 
mice. It’d be interesting to carry out further analyses such as studies of 
expression of other related genes to further investigate whether Map2k7 has an 
impact on GABAergic circuitry. 
It is widely accepted that schizophrenia derives from the effects of multiple 
genes. Epistatic static interactions between MAP2K7 and FXYD6 in schizophrenia 
were investigated in a north European population (refer to Chapter 3), however 
interactions were not found be a risk factor. Lack of interaction between Fxyd6 
and Map2k7 was further confirmed by no change in RNA or protein expression of 
FXYD6 and the Na+ K+ ATPase pump, which it co-localises with and modulates in 
Map2k7 mice.  
6.4.5 Primary phenotype screen  
The homozygous knockout of Map2k7 results in embryonic lethality, which would 
suggest a role in neurodevelopment, however no abnormal neurological 
behaviours, such as spontaneous activity, aggressiveness, neuromuscular 
abnormalities, convulsions and general condition of coat and eye reflexes were 
detected in Map2k7+/- mice compared to Map2k7+/- mice.   
From these results it was concluded that any phenotypes generated from 
subsequent behavioural tests designed to detect more complex behaviours, such 
as anxiety and sensorimotor gating, are more likely to be a true reflection of 
phenotype and not a result of poor motor skills or poor health.  
6.4.6 Anxiety-related behaviours in Map2k7+/- mice 
Anxiety-related behaviours can be measured in a mouse model by using the 
innate natural tendency to explore a novel environment, compared to their 
conflicting  preference for dark enclosed space (Lister., 1987). The elevated plus 
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maze and the open field apparatus exploit this conflict to indicate changes in 
levels of anxiety between transgenic or knockout mice and their wildtype 
controls. Mice with high levels of anxiety will avoid the bright open arms of the 
EPM and the centre of the open field arena, and spend more time in the dark 
arms or the corners and walls of the open field arena (thigmotaxis). Map2k7+/- 
mice did not show altered anxiety-related behaviours when compared to 
Map2k7+/+ mice during the 5 minutes allowed to explore the EPM. However, in 
the open field arena, after 30 minutes (during the ‘test stage’), Map2k7+/- mice 
appeared to spend less time in the thigmotaxis zone compared to Map2k7+/+ 
mice. This could possibly indicate disinhibited behaviours, which are thought to 
be a symptom of ‘disorganised schizophrenia’ and are also present following 
drug abuse (Gawin., 1991;Fillmore et al., 2003).  
Impairments to the dopaminergic circuitry were explored in Map2k7+/- mice 
using administration of 3 mg/kg amphetamine. Surprisingly, administration of 3 
mg/kg amphetamine did not produce an overall effect on duration spent in 
zones.  3 zones were introduced during open field analysis to fully assess 
anxiety-related behaviours. Centre zone represents the duration of time the 
mouse spent in the centre of the arena, indicating exploratory behaviour; the 
outer zone represents the time spent in the rest of the arena. The outer zone 
was further split to analyse thigmotaxis. Amphetamine resulted in 
hyperlocomotor activity in both Map2k7+/+ and Map2k7+/- mice, a result 
commonly observed in mice (Ralph et al., 2001), validating the experimental 
approach. Amphetamine increases hyperlocomotor activity by increasing 
synaptic dopamine levels in the mesolimbic system (Costall et al., 
1987;Pijnenburg et al., 1976), this can occur through a number of different 
mechanisms (refer to 1.10.1). The excess levels of dopamine result in the 
increased activation of dopamine D1 and D2 receptors, inducing hyperlocomotion 
(Sharp et al., 1987;Tenn et al., 2003;Mansbach et al., 1988;Pijnenburg et al., 
1975).  
In order to investigate fully the effect of amphetamine on velocity, the mean 
baseline for each individual mouse was taken across time points 5-30 minutes 
and velocity following amphetamine administration (35-90 minutes) was 
calculated. There was a significant overall effect of genotype and Map2k7+/- 
mice exhibited significantly increased velocity at time points 35, 40 and 45 
177 
 
 
minutes, in comparison to Map2k7+/+ mice. Although this could suggest Map2k7+/- 
mice are more sensitive to amphetamine, implying a potential role of Map2k7 in 
the dopaminergic signalling circuitry, further testing such as sensitivity to 
amphetamine in sensorimotor gating (Cilia et al., 2005) or response to 
administration of antipsychotic drugs such as clozapine and haloperidol, which 
are antagonists at the dopamine receptor, would be required to confirm this 
(Swerdlow and Geyer., 1993).  
6.4.7 Sensorimotor gating in Map2k7+/- mice 
Sensorimotor gating is a complex process involving multiple interactions with 
multiple neurotransmitters including dopamine, serotonin and glutamate (Ojima 
et al., 2004;Quednow et al., 2004;Egerton et al., 2008). Deficits in sensorimotor 
gating are a key symptom of schizophrenia and stem from impairments in 
inhibition in a number of regions in CNS. Imaging, electrophysiological 
investigations and animal studies have provided evidence for the role of a 
number of brain regions, such as the hippocampus (Swerdlow et al., 1995;Adler., 
1982;Siegel et al., 1984) nucleus accumbens (Swerdlow et al., 1990;Wan et al., 
1995) and the striatum (Kodsi and Swerdlow., 1994;Kretschmer and Koch., 
1997), in the underlying mechanisms of impaired sensorimotor gating. These 
impairments result in the oversensitivity to sensory information and the inability 
to filter important sensory information from ‘noise’. Map2k7+/- mice did not have 
deficits in hearing or sensorimotor gating, suggesting Map2k7 does not play a 
role in the physiology of hearing or filtering of sensory inputs. The 
administration of ketamine attenuates sensorimotor gating in both Map2k7+/+ 
and Map2k7+/- mice. However ketamine did not induce a significant difference 
between the genotypes. Ketamine exerts its action via inhibition of the NMDA 
receptor and is therefore used to explore impairments in glutamatergic 
signalling despite the up-regulation of the Grin1 subunit in the PFC. These 
results suggests Map2k+/- mice do not have alterations in glutamatergic 
signalling. However it is difficult to conclude whether or not Map2k7 is 
implicated in glutamatergic pathways due to the up-regulation of Grin1 
expression, which may be contributing to normal glutamatergic transmission.  
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6.4.8 Social interaction and social novelty in Map2k7+/- mice 
Testing of mouse social behaviours has become a well-established method to 
study deficits in social interaction and social novelty in models of schizophrenia 
and autism (Lord et al., 2000;Aghevli et al., 2003;Wing and Gould, 1979). 
Various behaviours such as social communication, social novelty (social 
recognition), aggression and juvenile play can be investigated following analysis 
of behaviours between two mice. These mice could be familiar with one 
another, related, strangers or differ in sex.  Social interaction can be assessed 
by the duration of time a mouse will spend investigating and interacting with a 
non-familiar mouse (termed stranger mouse) in an arena containing a cylindrical 
wire cage which permits visual, olfactory and tactile interaction.  
In this study, sociability was defined as the tendency to spend a longer duration 
of time in the zone containing the stranger mouse, in comparison to the empty 
zone. Both Map2k7+/+ and Map2k7+/- mice displayed sociability, however 
disruption of Map2k7 did not induce deficits in sociability. Preference for social 
novelty is interpreted to have occurred when the test mouse spends more time 
investigating a novel mouse, in comparison to a familiar mouse. In this study, 
mice were familiarised to the first stranger mouse during sociability testing, a 
novel mouse was then entered into the ‘empty’ zone to test preference for 
social novelty. Interestingly, neither Map2k7+/+ or Map2k7+/- mice displayed a 
preference for social novelty. The genetic background of the Map2k7+/+ and 
Map2k7+/- mice is C57BL/6 and in our laboratories has been backcrossed onto the 
substrain C57BL/6J rcchsd strain. Studies have shown substrains of C57BL/6 do 
not differ in social interaction levels from one another (Matsuo et al., 2010), 
furthermore both strains have previously shown a preference for social novelty 
(refer to Chapter 5 (Matsuo et al., 2010;Moy et al., 2004). In Moy et al., (2004) 
study, ‘n’ numbers are substantially larger compared to those used in this study 
(n=20, n=5, respectively), and thus statistical power may not be high enough to 
have detected social novelty reliably in the present experiments.  
6.4.9 Anhedonia 
The inability to experience pleasure (anhedonia) is associated with the negative 
symptoms of schizophrenia (refer to 1.3.2, (Strauss and Gold., 2012;Dowd and 
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Barch., 2010;Pizzagalli., 2010). Mice have a natural preference for sweet sucrose 
water over standard water, anhedonia can be detected between wildtype and 
knockout/transgenic mice by a reduction in the ratio of sucrose water to 
standard water consumption (Papp et al., 1991). A heterozygous mouse was 
removed from this study as it did not show any preference for sucrose water 
over standard water during the 5 days. It could be argued that this is a 
phenotype of Map2k7 heterozygous deletion, however the rest of the group (n=4) 
all showed sucrose preference. Analysis of sucrose consumption as a ratio of 
total fluid intake revealed Map2k7+/- mice do not suffer from anhedonia as 
tested in this model.  
6.4.10 Working memory 
Working memory can be assessed using a T maze-based ‘delayed non-match to 
sample’ task (refer to 2.10.6). The task requires the retention and manipulation 
of short term memory in order to perform executive functions (Aultman and 
Moghaddam., 2001). Working memory requires synchrony between the prefrontal 
cortex and hippocampus (Sigurdsson et al., 2010;Yoon et al., 2008) and from the 
expression pattern of Map2k7 in these regions, it was hypothesised Map2k7+/- 
mice may present impairments in working memory. Collapsing the data revealed 
that Map2k7+/- mice have a working memory impairment in comparison to 
Map2k7+/+ mice and on further investigation it was found these impairments 
derived from increased perseverative errors. In this study, perseverative errors 
were defined as a mouse not correcting its behaviour following an incorrect 
trial, leading to at least two consecutive incorrect trials in a row. An increase in 
perseverative errors has been postulated to be a result of impairments in 
dopamine in the PFC (Yawata et al., 2012;Pezze et al., 2006;Zahrt et al., 1997) 
. Moreover, hypofunction of the dopamine D1 receptor has been associated with 
cognitive deficits and working memory impairments in schizophrenia (Castner et 
al., 2000;Abi-Dargham et al., 2002;Granon et al., 2000), effects which are not 
responsive to treatment with typical antipsychotic drugs (Masahiko & Michio., 
1997). However, studies have shown that short term treatment using D1 agonists 
can improve cognitive deficits (Castner et al., 2000;Cai and Arnsten., 1997). It 
may therefore be of interest to investigate the role of D1 receptors in the 
perseverative responding of Map2k+/- mice using D1 agonists, particularly 
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considering the trend towards sensitivity to amphetamine, which suggests a 
potential altered dopaminergic circuitry in these mice.  
Due to the modest impairment in working memory, it is difficult to conclude 
whether Map2k7+/- mice have impairments in the manipulation and retention of 
short term memory and executive functioning. Unusually, during this task there 
was not an overall affect of duration of retention delay during this task. In 
working memory tasks, as retention delays are increased, mice would be 
expected to have decreased correct trials; however this was not observed in 
both genotypes. This could be concealed from variability in performance 
stemming from low ‘n’ numbers. Another possibility for the lack of clear deficits 
associated with increasing delays could be gender, however male mice only were 
used in the ‘working memory’ task due to female mice presenting difficult in 
reaching criteria (personal correspondence), this could be due to a number of 
factors affecting learning behaviour, such as circadian rhythm, menstrual cycle, 
environmental factors such as stimulating housing toys, littermates etc. It is 
therefore important that during working memory testing, and similar tasks, 
environmental factors such as housing conditions and handler are kept constant.  
6.5 Conclusion 
The molecular and phenotypic characterisation of Map2k7+/- mice revealed 
Map2k7 is expressed in brain regions associated with schizophrenia. The 
heterozygous deletion of Map2k7 results in alteration of glutamate receptor 
Grin1 expression, a receptor reported to have altered expression in 
schizophrenia. Similarly, Map2k7+/- mice display some phenotypes similar to 
those reported in schizophrenia, such as working memory deficits, increased 
perseverative responding, and sensitivity to amphetamine.  
As Map2k7+/- mice did not exhibit deficits in PPI, social behaviours or 
neurochemical deficits in GABAergic markers, the functional role of MAP2K7 as a 
risk factor in schizophrenia still remains tenuous, however these results do 
suggest a putative role of MAP2K7 in impairments in glutamatergic 
neurotransmission and a potential rodent model of cognitive impairments.  
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Chapter 7. Discussion. 
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The overall aims of this PhD study were to investigate the genetic and functional 
roles of two genes recently associated with schizophrenia: FXYD6 and MAP2K7. A 
genetic association between FXYD6 and schizophrenia in a Northern European 
population was not confirmed in this study, or a role of epistatic interactions 
between FXYD6 and MAP2K7 in the risk of schizophrenia. Despite this, the 
molecular and phenotypic characterisations of two strains of mice, one 
homozygous for disrupted Fxyd6 and one heterozygous for Map2k7, reveals an 
interesting insight into the roles of these genes in the neuronal circuitry 
associated with schizophrenia and related psychiatric disorders. Furthermore, 
the phenotypes of these mice could provide potential rodent models for looking 
at certain aspects of cognition. 
7.1 FXYD6 as a risk factor in schizophrenia 
This study did not find an allelic or haplotypic association between FXYD6 and 
schizophrenia in a north European population. A proportion of the samples 
analysed derived from a subset of samples from a previous study, in which a 
genetic association between FXYD6 and schizophrenia was found (Choudhury et 
al., 2006; Choudhury et al., 2007). It is well known that difficulty can arise when 
attempting to confirm a positive association between a gene and a disorder and 
the lack of replication could be due to a number of reasons such as the 
generation of false-positive results in the Choudhury studies or factors such as 
low sample size and statistical power, or the potential presence of rare but 
highly penetrant alleles. For these reasons, despite not confirming an association 
between FXYD6 and schizophrenia, a role of FXYD6 in susceptibility to 
schizophrenia was not discarded and instead further explored using a mouse 
model homozygous for disrupted Fxyd6.  
Until now, the molecular role of FXYD6 was unknown. This study not only utilised 
the in situ hybridisation technique to provide further evidence of the expression 
of Fxyd6 in the schizophrenia-related brain regions, the PFC and the 
hippocampus, but also found expression of both Fxyd6 and Na+ K+ ATPase in the 
hippocampus; a region involved in synaptic plasticity and learning and memory. 
In addition, this study confirms for the first time that, like other members of the 
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FXYD family, FXYD6 is a tissue-specific modulator of the Na+ K+ ATPase pump. 
This is particularly interesting as alterations to the Na+ K+ ATPase pump activity 
have been associated with psychiatric disorders whilst mice lacking the Na+ K+ 
ATPase α2 and α3 subunits both exhibit increased anxiety-related behaviour and 
impaired learning and memory where as alpha1 isoform mice showed increased 
locomotor in response to methamphetamine (Moseley et al., 2007).  
The role of FXYD6 in neurochemical pathways associated with schizophrenia was 
also explored, however no evidence of a role of FXYD6 in glutamatergic 
signalling was found at the molecular level, as observed by no change in 
glutamatergic receptor expression. However increased expression of GABAergic 
interneuron marker, and parvalbumin expression in Fxyd6-/- mice suggests that 
FXYD6 might interact with GABAergic neuronal activity. To investigate 
neurotransmission pathways further in Fxyd6-/- mice, amphetamine and 
ketamine were both used to explore impairments in the dopaminergic and 
glutamatergic pathways (respectively) and their effects on locomotor activity. 
Fxyd6-/- mice do not exhibit altered sensitivity to ketamine or amphetamine, 
despite this, subtle deficits observed in prepulse inhibition suggests potential 
deficits in neurotransmission may be present. 
Due to the expression of Fxyd6 in the PFC and the expression of both Fxyd6 and 
Na+ K+ ATPase in the hippocampus, as observed by in situ hybridisation, it was 
hypothesised that memory and learning may be disrupted in Fxyd6-/- mice. This 
was explored by looking at impairments in working memory. Working memory is 
a key symptom associated with the cognitive deficits of schizophrenia (Goldman-
Rakic., 1994;Manoach., 2003), and an important treatment target in 
schizophrenia, as an effective treatment is yet to be discovered. The Fxyd6-/- 
mice displayed deficits in working memory at delays of 5 seconds, this is 
encouraging to further investigate Fxyd6-/- a potential mouse model of cognitive 
disorders and provides further evidence for a role of FXYD6 dysfunction in the 
aetiology of schizophrenia.   
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7.2 MAP2K7 as a risk factor in schizophrenia.   
A recent genetic association study and an expression study have both implicated 
MAP2K7 as a risk factors in the susceptibility to schizophrenia (Winchester et al., 
2012); however this study reveals MAP2K7 does not interact with FXYD6 to 
increase the risk to susceptibility in a north European population.  
The brain expression of Map2k7 was previously unknown, however this study 
utilised the in situ hybridisation technique to show expression in regions 
associated with schizophrenia, including the PFC and the hippocampus. The role 
of MAP2K7 in the susceptibility to schizophrenia was explored using mice 
heterozygous for the disruption of Map2k7. The homozygous disruption of 
Map2k7 is embryonically lethal. RTqPCR and in situ hybridisation techniques 
were used to assess the effect of heterozygous disruption of Map2k7 RNA and 
protein levels. A modest but significant reduction was observed in the RTqPCR 
data; however this was not observed using in situ hybridisation. This could be 
due RTqPCR being a more sensitive technique, compared to in situ hybridisation. 
Wada et al., 2004 have confirmed heterozygous expression of Map2k7 in 
Map2k7+/- mice using northern and southern blotting which revealed a clear 
reduction in Ma2pk7 genomic mRNA and DNA (respectively). These results 
combined with analysis from this study suggest it is highly likely Map2k7 has 
reduced expression in Map2k7+/- mice. 
These mice were also used to confirm the lack of interaction between Fxyd6 and 
Map2k7 which was evidenced by no change in RNA or protein expression of 
FXYD6 and the Na+ K+ ATPase pump in Map2k7+/- mice compared to Mapk7+/+ 
mice. 
The heterozygous deletion of Map2k7 results in alteration of glutamate receptor 
Grin1 RNA expression, a receptor reported to have altered expression in 
schizophrenia. Furthermore, Map2k7+/- mice display increased perseverative 
responding in the working memory task and sensitivity to amphetamine, 
suggesting alterations in dopaminergic circuitry. Despite this, Map2k7+/- mice did 
not exhibit deficits in PPI, social behaviours or neurochemical deficits in 
GABAergic markers, and so the functional role of MAP2K7 as a risk factor in 
schizophrenia still remains unclear.  
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7.3 Future work 
The data generated from this study are very thought-provoking, and if more time 
and funding were available several interesting follow-up studies could be carried 
out. 
Despite this study providing molecular and behaviour characterisations of Fxyd6 
and Map2k7, their roles in susceptibility to schizophrenia still remain ambiguous. 
It would be interesting to investigate hypofrontality in both mouse strains. 
Hypofrontality has been associated with deficits in working memory and is 
observed in schizophrenia brain (Berman et al., 1988;Carter et al., 1998;Glahn  
et al., 2005). As both strains of mice exhibit impairments in components of the 
working memory task it would be interesting to carry out 2 deoxyglucose 
experiments to assess whether there is altered metabolism in the prefrontal 
cortex (Weinberger et al., 1986, Callicott et al., 2000, Manoach et al., 2000). 
Further behaviour tasks aimed to investigate learning and memory in these 
strains would also be interesting in order to investigate fully their roles as 
models of cognition. Executive memory could be investigated using attentional 
set-shifting task, or spatial learning could be assed using the Morris water maze.  
Following the increased expression of Pvalb in Fxyd6-/- mice, it would be 
interesting to investigate the role of FXYD6 in GABAergic neurotransmission 
activity further. Initially, it would also be interesting to investigate further the 
regions where FXYD6 and parvalbumin are both expressed to see if co-
localisation occurs at cellular level. RTqPCR, in situ hybridisation and western 
blot techniques could also be used to investigate the expression of GABA 
receptors in Fxyd6-/- mice. It would also be appealing to investigate serotonin 
and related neurotransmisson pathways in these mice in a similar manner, in 
order to elucidate reason for the subtle alterations observed in PPI. The levels of 
brain-expressed FXYD7 would also be fascinating to investigate to assess if 
expression is up-regulated in order to compensate for reduced modulation of the 
Na+ K+ ATPase pump by FXYD6. 
It would be interesting to investigate further the glutamatergic signalling system 
in the Map2k7+/- mice. This could be done by investigating the expression of 
further NMDA receptor subunits, and by exploring the effects of PCP and/or 
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ketamine on processes such as locomotor activity. Furthermore, using western 
blotting technique, it would be beneficial to investigate the effect of 
heterozygous Map2k7 disruption of the expression of the downstream target, 
JNK2 and related members of the MAPK cascade.    
These studies would further investigate the functional roles of both Fxyd6 and 
Map2k7 genes in the neuropathology of schizophrenia and provide further 
evidence to determine if they would be a suitable model of schizophrenia-
related symptoms 
7.4 Conclusions 
These studies provide an invaluable insight into the molecular functions of 
FXYD6 and MAP2K7, and their potential roles in schizophrenia.  
A genetic association between FXYD6 and schizophrenia in a Northern European 
population was not confirmed in this study, or a role of epistatic interactions 
between FXYD6 and MAP2K7 in the risk of schizophrenia. Despite this, this study 
reveals Fxyd6 is expressed in regions of the brain associated with schizophrenia 
and the targeted disruption of Fxyd6 results in prefrontal cortex and 
hippocampal- related behaviour deficits, such as deficits in working memory. 
FXYD6 may also have a potential role in GABAergic signalling, as observed by 
increased Pvalb expression in Fxyd6-/- mice.  FXYD6 does not appear to have a 
role in glutamatergic signalling as evidenced by the unaltered expression of 
glutamate receptors and normal response to ketamine in the open field task. 
However indication of deficits in neurotransmission in Fxyd6-/- mice comes from 
subtle deficits in prepulse inhibition.  
I have also shown for the first time that FXYD6 modulates brain Na+ K
+ ATPase 
activity in the frontal cortex.  
The molecular and phenotypic characterisation of Map2k7+/- mice revealed 
Map2k7 is also expressed in brain regions associated with schizophrenia and 
display some phenotypes similar to those reported in schizophrenia, such as 
working memory deficits, increased perseverative responding, and sensitivity to 
amphetamine. 
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The heterozygous deletion of Map2k7 also results in alteration of glutamate 
receptor Grin1 expression, suggesting a potential role in glutamatergic signalling 
however a role in GABAergic neurotransmission was not found.  
The functional roles of FXYD6 and MAP2K7 as risk factors in schizophrenia still 
remains equivocal, however these results provide evidence of a putative role for 
both genes in some areas of the underlying neuronal activity associated with 
schizophrenia and associated psychiatric disorders. Furthermore, results from 
this study suggest both strains of mice are potential rodent models of cognitive 
impairments.  
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